

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
15 February 2007 (15.02.2007)

PCT

(10) International Publication Number  
**WO 2007/018508 A1**

(51) International Patent Classification:

**C07D 405/12** (2006.01) **A61K 31/40** (2006.01)  
**C07D 207/50** (2006.01) **A61K 31/4025** (2006.01)

(21) International Application Number:

PCT/US2005/026756

(22) International Filing Date: 28 July 2005 (28.07.2005)

(25) Filing Language: English

(26) Publication Language: English

(71) Applicant (*for all designated States except US*): **GLAXO GROUP LIMITED** [GB/GB]; Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **BUSCH-PE-TERSEN, Jakob** [DK/US]; 709 Swedeland Road, King of Prussia, PA 19406 (US). **FU, Wei** [CN/US]; 709 Swedeland Road, King of Prussia, PA 19406 (US). **JIN, Jian** [CN/US]; 709 Swedeland Road, King of Prussia, PA 19406 (US). **MOORE, Michael, Lee** [US/US]; 1250 South Collegeville Road, Collegeville, PA 19426 (US). **RIVERO, Ralph, A.** [US/US]; 1250 South Collegeville Road, Collegeville, PA 19426 (US). **SHI, Dongchuan** [CN/US]; 709 Swedeland Road, King of Prussia, PA 19406 (US). **WANG, Feng** [CN/US]; 709 Swedeland Road, King of Prussia, PA 19406 (US). **WANG, Yonghui** [CN/US]; 709, Swedeland Road, King of Prussia, PA 19406 (US).

(74) Agents: **SIMON, Soma, G.** et al.; Glaxosmithkline, Corporate Intellectual Property, UW2220, 709 Swedeland Road, P.O. Box 1539, King of Prussia, PA 19406-0939 (US).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(81) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Declarations under Rule 4.17:**

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *of inventorship (Rule 4.17(iv))*

**Published:**

- *with international search report*

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: NOVEL M<sub>3</sub> MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS

(57) Abstract: Muscarinic Acetylcholine receptor antagonists and methods of using them are provided.



WO 2007/018508 A1

## **Novel M<sub>3</sub> Muscarinic Acetylcholine Receptor Antagonists**

### **FIELD OF THE INVENTION**

This invention relates to novel derivatives of cyclic quaternary ammonium salts, pharmaceutical compositions, processes for their preparation, and use thereof in treating M<sub>3</sub> muscarinic acetylcholine receptor mediated diseases.

### **BACKGROUND OF THE INVENTION**

Acetylcholine released from cholinergic neurons in the peripheral and central nervous systems affects many different biological processes through interaction with two major classes of acetylcholine receptors – the nicotinic and the muscarinic acetylcholine receptors. Muscarinic acetylcholine receptors (mAChRs) belong to the superfamily of G-protein coupled receptors that have seven transmembrane domains. There are five subtypes of mAChRs, termed M<sub>1</sub>-M<sub>5</sub>, and each is the product of a distinct gene. Each of these five subtypes displays unique pharmacological properties. Muscarinic acetylcholine receptors are widely distributed in vertebrate organs, and these receptors can mediate both inhibitory and excitatory actions. For example, in smooth muscle found in the airways, bladder and gastrointestinal tract, M<sub>3</sub> mAChRs mediate contractile responses. For review, please see {Brown 1989 247 /id}.

Muscarinic acetylcholine receptor dysfunction has been noted in a variety of different pathophysiological states. For instance, in asthma and chronic obstructive pulmonary disease (COPD), inflammatory conditions lead to loss of inhibitory M<sub>2</sub> muscarinic acetylcholine autoreceptor function on parasympathetic nerves supplying the pulmonary smooth muscle, causing increased acetylcholine release following vagal nerve stimulation. This mAChR dysfunction results in airway hyperreactivity mediated by increased stimulation of M<sub>3</sub> mAChRs {Costello, Evans, et al. 1999 72 /id} {Minette, Lammers, et al. 1989 248 /id}. Similarly, inflammation of the gastrointestinal tract in inflammatory bowel disease (IBD) results in M<sub>3</sub> mAChR-mediated hypermotility {Oprins, Meijer, et al. 2000 245 /id}. Incontinence due to bladder hypercontractility has also been demonstrated to be mediated through increased stimulation of M<sub>3</sub> mAChRs {Hegde & Eglen 1999 251


/id}. Thus the identification of subtype-selective mAChR antagonists may be useful as therapeutics in these mAChR-mediated diseases.

Despite the large body of evidence supporting the use of anti-muscarinic receptor therapy for treatment of a variety of disease states, relatively few anti-muscarinic compounds are in use in the clinic. Thus, there remains a need for

novel compounds that are capable of causing blockade at M<sub>3</sub> mAChRs. Conditions associated with an increase in stimulation of M<sub>3</sub> mAChRs, such as asthma, COPD, IBD and urinary incontinence would benefit by compounds that are inhibitors of mAChR binding.

### **SUMMARY OF THE INVENTION**

This invention relates to compounds of Formula I



wherein

When X is carbon, n is 1, 2, or 3; m is 1, 2, or 3; p is 0, 1, or 2;

When X is oxygen, n is 1; m is 2; p is 1 or 2;

W is O, S, or NH;

U is NR<sub>3</sub>, O, or a bond;

R<sub>3</sub> is selected from the group consisting of hydrogen, C<sub>1</sub>-C<sub>8</sub> branched or unbranched alkyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl lower alkyl, unsubstituted or substituted phenyl, or unsubstituted or substituted phenyl C<sub>1</sub>-C<sub>3</sub> lower alkyl; wherein, when substituted, a group is substituted by one or more radicals selected from the group consisting of C<sub>1</sub>-C<sub>8</sub> alkoxy, halo, hydroxy, amino, cyano, trifluoromethyl, C<sub>1</sub>-C<sub>8</sub> branched or unbranched alkyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl and C<sub>3</sub>-C<sub>8</sub> cycloalkyl lower alkyl;

q is an interger from 0 to 7;

h is 0, 1, or 2;

g is 1, 2, or 3;

Z<sup>-</sup> is selected from the group consisting of I<sup>-</sup>, Br<sup>-</sup>, Cl<sup>-</sup>, F<sup>-</sup>, CF<sub>3</sub>COO<sup>-</sup>, mesylate, tosylate, and any other pharmaceutically acceptable counter ion;

V is selected from the group consisting of phenyl, thiophenyl, furanyl,  
5 pyridinyl, naphthyl, quinolinyl, indolyl, benzothiophenyl and benzofuranyl;

R<sub>4</sub> is selected from the group consisting of hydrogen, hydroxy, amino, halo, cyano, trifluoromethyl, C<sub>1</sub>-C<sub>8</sub> alkoxy, C<sub>1</sub>-C<sub>8</sub> branched or unbranched alkyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl lower alkyl, phenyl, phenyl C<sub>1</sub>-C<sub>3</sub> lower alkyl, COR<sub>6</sub>, COOR<sub>6</sub>, CONHR<sub>6</sub>, CON(R<sub>6</sub>)<sub>2</sub>, NHR<sub>6</sub>, N(R<sub>6</sub>)<sub>2</sub>, and G;

10 k is an integer from 0 to 5;

T is selected from the group consisting of an unsubstituted or substituted following group: phenyl, thiophenyl, furanyl, pyridinyl, naphthyl, quinolinyl, indolyl, benzothiophenyl, and benzofuranyl; wherein, when substituted, a group is substituted by one or more radicals selected from the group consisting of C<sub>1</sub>-C<sub>8</sub>  
15 alkoxy, halo, hydroxy, amino, trifluoromethyl, C<sub>1</sub>-C<sub>8</sub> branched or unbranched alkyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl lower alkyl, phenyl and phenyl C<sub>1</sub>-C<sub>3</sub> lower alkyl;

R<sub>5</sub> is selected from the group consisting of COOR<sub>6</sub>, CONHR<sub>6</sub>, COR<sub>6</sub>, CON(R<sub>6</sub>)<sub>2</sub>, COG, unsubstituted or substituted oxadiazolyl, unsubstituted or  
20 substituted oxazolyl, unsubstituted or substituted imidazolyl, unsubstituted or substituted phenoxy, or cyano; wherein, when substituted, a group is substituted by one or more radicals selected from the group consisting of C<sub>1</sub>-C<sub>8</sub> branched or unbranched alkyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl lower alkyl, phenyl and phenyl C<sub>1</sub>-C<sub>3</sub> lower alkyl, C<sub>1</sub>-C<sub>8</sub> alkoxy, halo, hydroxy, amino, cyano and  
25 trifluoromethyl;

R<sub>6</sub> is selected from the group consisting of C<sub>1</sub>-C<sub>8</sub> branched or unbranched alkyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl lower alkyl, unsubstituted or substituted phenyl, unsubstituted or substituted phenyl C<sub>1</sub>-C<sub>3</sub> lower alkyl, unsubstituted or substituted naphthyl, or unsubstituted or substituted naphthyl C<sub>1</sub>-C<sub>3</sub> lower alkyl;  
30 wherein, when substituted, a group is substituted by one or more radicals selected from the group consisting of C<sub>1</sub>-C<sub>8</sub> alkoxy, halo, hydroxy, amino, cyano,

trifluoromethyl, C<sub>1</sub>-C<sub>8</sub> branched or unbranched alkyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl lower alkyl, phenyl and phenyl C<sub>1</sub>-C<sub>3</sub> lower alkyl;

G is selected from the group consisting of an unsubstituted or substituted following group: pyrrolidinyl, piperdiny, dihydroindolyl, tetrahydroquinoliny, morpholino, azetidiny, hexahydroazepiny, or octahydroazociny; wherein, when substituted, a group is substituted by one or more radicals selected from the group consisting of C<sub>1</sub>-C<sub>8</sub> alkoxy, hydroxy, amino, C<sub>1</sub>-C<sub>8</sub> branched or unbranched alkyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl lower alkyl, phenyl and phenyl C<sub>1</sub>-C<sub>3</sub> lower alkyl;

R<sub>1</sub> is selected from the group consisting of an unsubstituted or substituted following group: phenyl, phenyl C<sub>1</sub>-C<sub>6</sub> lower alkyl, thiophenyl, thiophenyl C<sub>1</sub>-C<sub>6</sub> lower alkyl, furanyl, furanyl C<sub>1</sub>-C<sub>6</sub> lower alkyl, pyridiny, pyridiny C<sub>1</sub>-C<sub>6</sub> lower alkyl, imidazolyl, imidazolyl C<sub>1</sub>-C<sub>6</sub> lower alkyl, naphthyl, naphthyl C<sub>1</sub>-C<sub>6</sub> lower alkyl, quinoliny, quinoliny C<sub>1</sub>-C<sub>6</sub> lower alkyl, indolyl, indolyl C<sub>1</sub>-C<sub>6</sub> lower alkyl, benzothiophenyl, benzothiophenyl C<sub>1</sub>-C<sub>6</sub> lower alkyl, benzofuranyl, benzofuranyl C<sub>1</sub>-C<sub>6</sub> lower alkyl, benzoimidazolyl, benzoimidazolyl C<sub>1</sub>-C<sub>6</sub> lower alkyl, C<sub>1</sub>-C<sub>8</sub> branched or unbranched alkyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl C<sub>1</sub>-C<sub>6</sub> lower alkyl, or C<sub>3</sub>-C<sub>8</sub> alkenyl; wherein, when substituted, a group is substituted by one or more radicals selected from the group consisting of C<sub>1</sub>-C<sub>8</sub> alkoxy, phenoxy, phenyl C<sub>1</sub>-C<sub>3</sub> alkoxy, halo, hydroxy, amino, cyano, trifluoromethyl, methylenedioxy, ethylenedioxy, propylenedioxy, butylenedioxy, C<sub>1</sub>-C<sub>8</sub> branched or unbranched alkyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl lower alkyl, phenyl, phenyl C<sub>1</sub>-C<sub>3</sub> lower alkyl, thiophenyl, thiophenyl C<sub>1</sub>-C<sub>3</sub> lower alkyl, furanyl, furanyl C<sub>1</sub>-C<sub>3</sub> lower alkyl, pyridiny, pyridiny C<sub>1</sub>-C<sub>3</sub> lower alkyl, naphthyl, naphthyl C<sub>1</sub>-C<sub>3</sub> lower alkyl, quinoliny, quinoliny C<sub>1</sub>-C<sub>3</sub> lower alkyl, indolyl, indolyl C<sub>1</sub>-C<sub>3</sub> lower alkyl, benzothiophenyl, benzothiophenyl C<sub>1</sub>-C<sub>3</sub> lower alkyl, benzofuranyl, benzofuranyl C<sub>1</sub>-C<sub>3</sub> lower alkyl, COOH, COR<sub>6</sub>, COOR<sub>6</sub>, CONHR<sub>6</sub>, CON(R<sub>6</sub>)<sub>2</sub>, COG, NHR<sub>6</sub>, N(R<sub>6</sub>)<sub>2</sub>, G, OCOR<sub>6</sub>, OCONHR<sub>6</sub>, NHCOR<sub>6</sub>, N(R<sub>6</sub>)COR<sub>6</sub>, NHCOOR<sub>6</sub> and NHCONHR<sub>6</sub>;

R<sub>2</sub> is selected from the group consisting of C<sub>1</sub>-C<sub>8</sub> branched or unbranched alkyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl lower alkyl, C<sub>3</sub>-C<sub>8</sub> alkenyl, unsubstituted

or substituted phenyl, or unsubstituted or substituted phenyl C1-C3 lower alkyl; wherein, when substituted, a group is substituted by one or more radicals selected from the group consisting of C<sub>1</sub>-C<sub>8</sub> alkoxy, halo, hydroxy, amino, cyano,

trifluoromethyl, C<sub>1</sub>-C<sub>8</sub> branched or unbranched alkyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl lower alkyl, phenyl and phenyl C1-C3 lower alkyl;

or R1 and R2 together is an unsubstituted or substituted following group: –(CH<sub>2</sub>)<sub>j</sub>–, or –(CH<sub>2</sub>)<sub>i</sub>–Phenyl–(CH<sub>2</sub>)<sub>i</sub>–; wherein, j is an interger from 3 to 8; i is an integer from 1 to 3; when substituted, a group is substituted by one or more radicals selected from the group consisting of C<sub>1</sub>-C<sub>8</sub> alkoxy, halo, hydroxy, amino, cyano, trifluoromethyl, C<sub>1</sub>-C<sub>8</sub> branched or unbranched alkyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl lower alkyl, phenyl and phenyl C1-C3 lower alkyl.

### **DETAILED DESCRIPTION**

The present invention includes all hydrates, solvates, complexes and prodrugs of the compounds of this invention. Prodrugs are any covalently bonded compounds that release the active parent drug according to Formula I **in vivo**. If a chiral center or another form of an isomeric center is present in a compound of the present invention, all forms of such isomer or isomers, including enantiomers and diastereomers, are intended to be covered herein. Inventive compounds containing a chiral center may be used as a racemic mixture, an enantiomerically enriched mixture, or the racemic mixture may be separated using well-known techniques and an individual enantiomer may be used alone. In cases in which compounds have unsaturated carbon-carbon double bonds, both the cis (Z) and trans (E) isomers are within the scope of this invention. In cases wherein compounds may exist in tautomeric forms, such as keto-enol tautomers, each tautomeric form is contemplated as being included within this invention whether existing in equilibrium or predominantly in one form.

The meaning of any substituent at any one occurrence in Formula I or any subformula thereof is independent of its meaning, or any other substituent's meaning, at any other occurrence, unless specified otherwise.

Abbreviations and symbols commonly used in the peptide and chemical arts are used herein to describe the compounds of the present invention. In

general, the amino acid abbreviations follow the IUPAC-IUB Joint Commission on Biochemical Nomenclature as described in **Eur. J. Biochem.**, 158, 9 (1984).

Suitable pharmaceutically acceptable salts are well known to those skilled in the art and include basic salts of inorganic and organic acids, such as

5 hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, methane sulphonic acid, ethane sulphonic acid, acetic acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid and mandelic acid.

The term "C<sub>1</sub>-C<sub>8</sub> alkyl" and "C<sub>1</sub>-C<sub>6</sub> alkyl" is used herein includes both  
10 straight or branched chain radicals of 1 to 6 or 8 carbon atoms. By example this term includes, but is not limited to methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, *tert*-butyl, pentyl, hexyl, heptyl, octyl and the like. "Lower alkyl" has the same meaning as C<sub>1</sub>-C<sub>8</sub> alkyl.

The term "C<sub>1</sub>-C<sub>3</sub> lower alkyl" is used herein includes methyl, ethyl, n-  
15 propyl, and isopropyl.

Herein "C<sub>1</sub>-C<sub>8</sub> alkoxy" includes straight and branched chain radicals of the likes of -O-CH<sub>3</sub>, -O-CH<sub>2</sub>CH<sub>3</sub>, and the n-propoxy, isopropoxy, n-butoxy, sec-butoxy, isobutoxy, *tert*-butoxy, pentoxy, and hexoxy, and the like.

"C<sub>3</sub>-C<sub>8</sub>-cycloalkyl" as applied herein is meant to include substituted and  
20 unsubstituted cyclopropane, cyclobutane, cyclopentane and cyclohexane, and the like.

"Alkenyl" is used herein at all occurrences to mean straight or branched chain moiety of 2-10 carbon atoms, unless the chain length is limited thereto, including, but not limited to ethenyl, 1-propenyl, 2-propenyl, 2-methyl-1-propenyl,  
25 1-butenyl, 2-butenyl and the like.

"Halogen" or "halo" means F, Cl, Br, and I.

The preferred compounds of Formula I include those compounds wherein:

When X is carbon, n is 1, 2, or 3; m is 1, 2, or 3; p is 0, or 1;

30 When X is oxygen, n is 1; m is 2; p is 1;

W is O;

U is NR<sub>3</sub>;

R3 is selected from the group consisting of hydrogen, C<sub>1</sub>-C<sub>8</sub> branched or unbranched alkyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl lower alkyl, or phenyl C1-C3 lower alkyl;

q is 0;

5 h is 0;

g is 1;

Z<sup>-</sup> is selected from the group consisting of I<sup>-</sup>, Br<sup>-</sup>, Cl<sup>-</sup>, F<sup>-</sup>, CF<sub>3</sub>COO<sup>-</sup>, mesylate, tosylate, or any other pharmaceutically acceptable counter ion;

10 V is selected from the group consisting of phenyl, thiophenyl, furanyl, naphthyl, benzothiophenyl or benzofuranyl;

R4 is selected from the group consisting of hydrogen, hydroxy, amino, halo, cyano, trifluoromethyl, C<sub>1</sub>-C<sub>8</sub> alkoxy, C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl lower alkyl, phenyl, phenyl C1-C3 lower alkyl, phenylcarbonyl;

k is 1, 2, 3, 4, or 5;

15 T is selected from the group consisting of an unsubstituted or substituted following group: phenyl, thiophenyl, furanyl, naphthyl, benzo-thiophenyl, and benzofuranyl; wherein, when substituted, a group is substituted by one or more radicals selected from the group consisting of C<sub>1</sub>-C<sub>8</sub> alkoxy, halo, hydroxy, amino, trifluoromethyl, C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl lower alkyl,  
20 phenyl and phenyl C1-C3 lower alkyl;

R5 is selected from the group consisting of COOR<sub>6</sub>, CONHR<sub>6</sub>, COR<sub>6</sub>, CON(R<sub>6</sub>)<sub>2</sub>, COG, unsubstituted or substituted oxadiazolyl, unsubstituted or substituted phenoxy, or cyano; wherein, when substituted, a group is substituted by one or more radicals selected from the group consisting of C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>3</sub>-C<sub>8</sub>  
25 cycloalkyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl lower alkyl, phenyl, phenyl C1-C3 lower alkyl and trifluoromethyl;

R6 is selected from the group consisting of C<sub>1</sub>-C<sub>8</sub> branched or unbranched alkyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl lower alkyl, phenyl, phenyl C1-C3 lower alkyl, naphthyl, or naphthyl C1-C3 lower alkyl;



G is selected from the group consisting of pyrrolidinyl, piperdinyl, dihydroindolyl, tetrahydroquinolyl, morpholino, azetidyl, hexahydroazepinyl, or octahydroazocinyl;

R1 is selected from the group consisting of an unsubstituted or substituted  
 5 following group: phenyl C1-C6 lower alkyl, thiophenyl C1-C6 lower alkyl, furanyl C1-C6 lower alkyl, pyridinyl C1-C6 lower alkyl, imidazolyl C1-C6 lower alkyl, naphthyl C1-C6 lower alkyl, quinolyl C1-C6 lower alkyl, indolyl C1-C6 lower alkyl, benzothiophenyl C1-C6 lower alkyl, benzofuranyl C1-C6 lower alkyl, benzoimidazolyl C1-C6 lower alkyl, C<sub>1</sub>-C<sub>8</sub> branched or unbranched alkyl, C<sub>3</sub>-C<sub>8</sub>  
 10 cycloalkyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl C<sub>1</sub>-C<sub>6</sub> lower alkyl, or C<sub>3</sub>-C<sub>8</sub> alkenyl; wherein, when substituted, a group is substituted by one or more radicals selected from the group consisting of C<sub>1</sub>-C<sub>8</sub> alkoxy, phenoxy, phenyl C<sub>1</sub>-C<sub>3</sub> alkoxy, halo, hydroxy, amino, cyano, trifluoromethyl, methylenedioxy, ethylenedioxy, propylenedioxy, butylenedioxy, C<sub>1</sub>-C<sub>8</sub> branched or unbranched alkyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl, C<sub>3</sub>-C<sub>8</sub>  
 15 cycloalkyl lower alkyl, phenyl, phenyl C1-C3 lower alkyl, thiophenyl, thiophenyl C1-C3 lower alkyl, furanyl, furanyl C1-C3 lower alkyl, pyridinyl, pyridinyl C1-C3 lower alkyl, naphthyl, naphthyl C1-C3 lower alkyl, quinolyl, quinolyl C1-C3 lower alkyl, indolyl, indolyl C1-C3 lower alkyl, benzothiophenyl, benzothiophenyl C1-C3 lower alkyl, benzofuranyl, benzofuranyl C1-C3 lower alkyl, COOH, COR<sub>6</sub>,  
 20 COOR<sub>6</sub>, CONHR<sub>6</sub>, CON(R<sub>6</sub>)<sub>2</sub>, COG, NHR<sub>6</sub>, N(R<sub>6</sub>)<sub>2</sub>, G, OCOR<sub>6</sub>, OCONHR<sub>6</sub>, NHCOR<sub>6</sub>, N(R<sub>6</sub>)COR<sub>6</sub>, NHCOOR<sub>6</sub> and NHCONHR<sub>6</sub>;

R2 is selected from the group consisting of C<sub>1</sub>-C<sub>8</sub> branched or unbranched alkyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl lower alkyl, C<sub>3</sub>-C<sub>8</sub> alkenyl, or  
 25 unsubstituted or substituted phenyl C1-C3 lower alkyl; wherein, when substituted, a group is substituted by one or more radicals selected from the group consisting of C<sub>1</sub>-C<sub>8</sub> alkoxy, halo, hydroxy, amino, cyano, trifluoromethyl, C<sub>1</sub>-C<sub>8</sub> branched or unbranched alkyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl lower alkyl, phenyl and phenyl C1-C3 lower alkyl;

or R1 and R2 together is  $-(CH_2)_j-$ , or  $-(CH_2)_i-$ Phenyl $-(CH_2)_j-$ ; wherein, j is  
 30 an interger from 3 to 8; i is an integer from 1 to 3.

Even more preferred are those compounds where:

X is carbon;

n is 1, or 2;

m is 1, 2, or 3;

p is 0, or 1;

5 W is O;

U is NR<sub>3</sub>;

R<sub>3</sub> is hydrogen;

q is 0;

h is 0;

10 g is 1;

Z is selected from the group consisting of I<sup>-</sup>, Br<sup>-</sup>, Cl<sup>-</sup>, F<sup>-</sup>, CF<sub>3</sub>COO<sup>-</sup>, mesylate, tosylate, or any other pharmaceutically acceptable counter ion;

V is selected from the group consisting of phenyl, or naphthyl;

15 R<sub>4</sub> is selected from the group consisting of hydroxy, amino, halo, cyano, trifluoromethyl, C<sub>1</sub>-C<sub>8</sub> alkoxy, C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl lower alkyl, phenyl, phenyl C<sub>1</sub>-C<sub>3</sub> lower alkyl, phenylcarbonyl;

k is 1, 2, or 3;

20 T is selected from the group consisting of unsubstituted or substituted phenyl, and thiophenyl; wherein, when substituted, a group is substituted by one or more radicals selected from the group consisting of C<sub>1</sub>-C<sub>8</sub> alkoxy, halo, hydroxy, amino, trifluoromethyl, C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl lower alkyl, phenyl and phenyl C<sub>1</sub>-C<sub>3</sub> lower alkyl;

25 R<sub>5</sub> is COOR<sub>6</sub>, CONHR<sub>6</sub>, COR<sub>6</sub>, CON(R<sub>6</sub>)<sub>2</sub>, COG, unsubstituted or substituted oxadiazolyl; wherein, when substituted, a group is substituted by one or more radicals selected from the group consisting of C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl lower alkyl, phenyl and phenyl C<sub>1</sub>-C<sub>3</sub> lower alkyl;

R<sub>6</sub> is selected from the group consisting of C<sub>1</sub>-C<sub>8</sub> branched or unbranched alkyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl, or C<sub>3</sub>-C<sub>8</sub> cycloalkyl lower alkyl;

30 G is selected from the group consisting of pyrrolidinyl, piperdiny, dihydroindolyl, tetrahydroquinoliny, morpholino, azetidiny, hexahydroazepiny, or octahydroazociny;

- R1 is selected from the group consisting of an unsubstituted or substituted following group: phenyl C1-C6 lower alkyl, thiophenyl C1-C6 lower alkyl, furanyl C1-C6 lower alkyl, pyridinyl C1-C6 lower alkyl, imidazolyl C1-C6 lower alkyl, naphthyl C1-C6 lower alkyl, quinolinyl C1-C6 lower alkyl, indolyl C1-C6 lower alkyl, benzothiophenyl C1-C6 lower alkyl, benzofuranyl C1-C6 lower alkyl, benzoimidazolyl C1-C6 lower alkyl, C<sub>1</sub>-C<sub>8</sub> branched or unbranched alkyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl C<sub>1</sub>-C<sub>6</sub> lower alkyl, or C<sub>3</sub>-C<sub>8</sub> alkenyl; wherein, when substituted, a group is substituted by one or more radicals selected from the group consisting of C<sub>1</sub>-C<sub>8</sub> alkoxy, phenoxy, phenyl C<sub>1</sub>-C<sub>3</sub> alkoxy, halo, hydroxy, amino, cyano, trifluoromethyl, methylenedioxy, ethylenedioxy, propylenedioxy, butylenedioxy, C<sub>1</sub>-C<sub>8</sub> branched or unbranched alkyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl lower alkyl, phenyl, phenyl C1-C3 lower alkyl, thiophenyl, thiophenyl C1-C3 lower alkyl, furanyl, furanyl C1-C3 lower alkyl, pyridinyl, pyridinyl C1-C3 lower alkyl, naphthyl, naphthyl C1-C3 lower alkyl, quinolinyl, quinolinyl C1-C3 lower alkyl, indolyl, indolyl C1-C3 lower alkyl, benzothiophenyl, benzothiophenyl C1-C3 lower alkyl, benzofuranyl, benzofuranyl C1-C3 lower alkyl, COOH, COR<sub>6</sub>, COOR<sub>6</sub>, CONHR<sub>6</sub>, CON(R<sub>6</sub>)<sub>2</sub>, COG, NHR<sub>6</sub>, N(R<sub>6</sub>)<sub>2</sub>, G, OCOR<sub>6</sub> and NHCOR<sub>6</sub>;
- R2 is selected from the group consisting of C<sub>1</sub>-C<sub>8</sub> branched or unbranched alkyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl lower alkyl, or C<sub>3</sub>-C<sub>8</sub> alkenyl;
- or R1 and R2 together is  $-(CH_2)_j-$ , or  $-(CH_2)_i$ -Phenyl- $(CH_2)_j-$ ; wherein, j is an interger from 3 to 7; i is an integer from 1 to 2.

- The preferred compounds are selected from the group consisting of:
- N*-[({4-[(ethyloxy)carbonyl]phenyl}amino)carbonyl]-*N*-{1-[4-(4-hydroxyphenyl)methyl]-1-methyl-3-pyrrolidiniumyl}-L-tyrosinamide trifluoroacetate;
- N*-[1-(1,3-benzodioxol-5-yl)methyl]-1-methyl-3-pyrrolidiniumyl]-*N*-[({4-[(ethyloxy)carbonyl]phenyl}amino)carbonyl]-L-tyrosinamide trifluoroacetate;
- N*-[({4-[(ethyloxy)carbonyl]phenyl}amino)carbonyl]-*N*-{1-[4-(4-fluorophenyl)methyl]-1-methyl-3-pyrrolidiniumyl}-L-tyrosinamide trifluoroacetate;
- N*-[({4-[(ethyloxy)carbonyl]phenyl}amino)carbonyl]-*N*-{(3*S*)-1-[4-(4-hydroxyphenyl)methyl]-1-methyl-3-pyrrolidiniumyl}-L-tyrosinamide trifluoroacetate;

- N*-[({4-[(ethyloxy)carbonyl]phenyl}amino)carbonyl]-*N*-{(3*S*)-1-[(4-fluorophenyl)methyl]-1-methyl-3-pyrrolidiniumyl}-*L*-tyrosinamide trifluoroacetate;  
*N*-[(3*S*)-1-(1,3-benzodioxol-5-ylmethyl)-1-methyl-3-pyrrolidiniumyl]-*N*-[({4-[(ethyloxy)carbonyl]phenyl}amino)carbonyl]-*L*-tyrosinamide trifluoroacetate;  
5 *N*-[(3*S*)-1-(cyclopropylmethyl)-1-methyl-3-pyrrolidiniumyl]-*N*-[({4-[(ethyloxy)carbonyl]phenyl}amino)carbonyl]-*L*-tyrosinamide trifluoroacetate;  
*N*-{(3*S*)-1-[(3,4-bis(methyloxy)phenyl)methyl]-1-methyl-3-pyrrolidiniumyl}-*N*-[({4-[(ethyloxy)carbonyl]phenyl}amino)carbonyl]-*L*-tyrosinamide trifluoroacetate;  
*N*-[({4-[(ethyloxy)carbonyl]phenyl}amino)carbonyl]-*N*-{1-[(4-fluorophenyl)methyl]-1-  
10 methyl-3-piperidiniumyl}-*L*-tyrosinamide trifluoroacetate;  
*N*-[1-(1,3-benzodioxol-5-ylmethyl)-1-methyl-3-piperidiniumyl]-*N*-[({4-[(ethyloxy)carbonyl]phenyl}amino)carbonyl]-*L*-tyrosinamide trifluoroacetate;  
*N*-(1-[(3,4-bis(methyloxy)phenyl)methyl]-1-methyl-3-piperidiniumyl)-*N*-[({4-[(ethyloxy)carbonyl]phenyl}amino)carbonyl]-*L*-tyrosinamide trifluoroacetate;  
15 *N*-[1-(cyclopropylmethyl)-1-methyl-3-piperidiniumyl]-*N*-[({4-[(ethyloxy)carbonyl]phenyl}amino)carbonyl]-*L*-tyrosinamide trifluoroacetate;  
*N*-{[1-(cyclopropylmethyl)-1-methyl-4-piperidiniumyl]methyl}-*N*-[({4-[(ethyloxy)carbonyl]phenyl}amino)carbonyl]-*L*-tyrosinamide trifluoroacetate;  
*N*-[({4-[(ethyloxy)carbonyl]phenyl}amino)carbonyl]-*N*-{(3*S*)-1-[(3-hydroxyphenyl)methyl]-1-methyl-3-pyrrolidiniumyl}-*L*-tyrosinamide trifluoroacetate;  
20 *N*-[({4-[(ethyloxy)carbonyl]phenyl}amino)carbonyl]-*N*-{(3*S*)-1-[(3-fluorophenyl)methyl]-1-methyl-3-pyrrolidiniumyl}-*L*-tyrosinamide trifluoroacetate;  
*N*-{(3*S*)-1-[(3-cyanophenyl)methyl]-1-methyl-3-pyrrolidiniumyl}-*N*-[({4-[(ethyloxy)carbonyl]phenyl}amino)carbonyl]-*L*-tyrosinamide trifluoroacetate;  
25 *N*-{(3*S*)-1-[(4-(acetylamino)phenyl)methyl]-1-methyl-3-pyrrolidiniumyl}-*N*-[({4-[(ethyloxy)carbonyl]phenyl}amino)carbonyl]-*L*-tyrosinamide trifluoroacetate;  
*N*-[({4-[(ethyloxy)carbonyl]phenyl}amino)carbonyl]-*N*-{(1*R*,3*S*)-1-[(4-fluorophenyl)methyl]-1-methyl-3-pyrrolidiniumyl}-*L*-tyrosinamide trifluoroacetate;  
*N*-[({4-[(ethyloxy)carbonyl]phenyl}amino)carbonyl]-*N*-{(1*S*,3*S*)-1-[(4-fluorophenyl)methyl]-1-methyl-3-pyrrolidiniumyl}-*L*-tyrosinamide trifluoroacetate;  
30 *N*-[(1*R*,3*S*)-1-(1,3-benzodioxol-5-ylmethyl)-1-methyl-3-pyrrolidiniumyl]-*N*-[({4-[(ethyloxy)carbonyl]phenyl}amino)carbonyl]-*L*-tyrosinamide trifluoroacetate;

- N*-[(1*S*,3*S*)-1-(1,3-benzodioxol-5-ylmethyl)-1-methyl-3-pyrrolidiniumyl]-*N*-[{4-[(ethyloxy)carbonyl]phenyl}amino)carbonyl]-L-tyrosinamide trifluoroacetate;  
*N*-[(3*S*)-1-(1,3-benzodioxol-5-ylmethyl)-1-methyl-3-pyrrolidiniumyl]-4-chloro-*N*-[{4-[(ethyloxy)carbonyl]phenyl}amino)carbonyl]-L-phenylalaninamide trifluoroacetate;
- 5 (3*S*)-1-(1,3-benzodioxol-5-ylmethyl)-3-{[*N*-[{4-[(ethyloxy)carbonyl]phenyl}amino)carbonyl]-3-(2-naphthalenyl)-L-alanyl]amino}-1-methylpyrrolidinium trifluoroacetate;
- N*-[(3*S*)-1-(1,3-benzodioxol-5-ylmethyl)-1-methyl-3-pyrrolidiniumyl]-*N*-[{4-[(ethyloxy)carbonyl]phenyl}amino)carbonyl]-4-(phenylcarbonyl)-L-
- 10 phenylalaninamide trifluoroacetate;
- N*-[(3*S*)-1-(1,3-benzodioxol-5-ylmethyl)-1-methyl-3-pyrrolidiniumyl]-*N*-[{4-[(ethyloxy)carbonyl]phenyl}amino)carbonyl]-4-fluoro-L-phenylalaninamide trifluoroacetate;
- (3*S*)-1-(1,3-benzodioxol-5-ylmethyl)-3-[(2*S*)-3-(4-biphenyl)-2-[(4-[(ethyloxy)carbonyl]phenyl}amino)carbonyl]amino}propanoyl]amino]-1-
- 15 methylpyrrolidinium trifluoroacetate;
- N*-[(3*S*)-1-(1,3-benzodioxol-5-ylmethyl)-1-methyl-3-pyrrolidiniumyl]-*N*-[{4-[(ethyloxy)carbonyl]phenyl}amino)carbonyl]-4-methyl-L-phenylalaninamide trifluoroacetate;
- 20 *N*-[(3*S*)-1-(1,3-benzodioxol-5-ylmethyl)-1-methyl-3-pyrrolidiniumyl]-4-bromo-*N*-[{4-[(ethyloxy)carbonyl]phenyl}amino)carbonyl]-L-phenylalaninamide trifluoroacetate;
- N*-[(3*S*)-1-(1,3-benzodioxol-5-ylmethyl)-1-methyl-3-pyrrolidiniumyl]-3-chloro-*N*-[{4-[(ethyloxy)carbonyl]phenyl}amino)carbonyl]-L-phenylalaninamide trifluoroacetate;
- 4-amino-*N*-[(3*S*)-1-(1,3-benzodioxol-5-ylmethyl)-1-methyl-3-pyrrolidiniumyl]-*N*-[{4-[(ethyloxy)carbonyl]phenyl}amino)carbonyl]-L-phenylalaninamide trifluoroacetate;
- 25 *N*-{(3*S*)-1-[(3-chlorophenyl)methyl]-1-methyl-3-pyrrolidiniumyl}-*N*-{[(4-[(1-methylethyl)amino]carbonyl]phenyl)amino]carbonyl]-L-tyrosinamide trifluoroacetate;
- N*-{(3*S*)-1-[(4-chlorophenyl)methyl]-1-methyl-3-pyrrolidiniumyl}-*N*-{[(4-[(1-methylethyl)amino]carbonyl]phenyl)amino]carbonyl]-L-tyrosinamide
- 30 trifluoroacetate;

*N*-((3*S*)-1-[[3,4-bis(methyloxy)phenyl]methyl]-1-methyl-3-pyrrolidiniumyl)-*N*-{[(4-  
 {[(1-methylethyl)amino]carbonyl}phenyl)amino]carbonyl}-L-tyrosinamide  
 trifluoroacetate;

*N*-[(3*S*)-1-(1,3-benzodioxol-5-ylmethyl)-1-methyl-3-pyrrolidiniumyl]-*N*-{[(4-  
 {[(1-methylethyl)amino]carbonyl}phenyl)amino]carbonyl}-L-tyrosinamide  
 trifluoroacetate;

*N*-[(3*S*)-1-[(4-fluorophenyl)methyl]-1-methyl-3-pyrrolidiniumyl]-*N*-{[(4-  
 {[(1-methylethyl)amino]carbonyl}phenyl)amino]carbonyl}-L-tyrosinamide  
 trifluoroacetate;

*N*-[(3*S*)-1-[(4-chlorophenyl)methyl]-1-methyl-3-pyrrolidiniumyl]-*N*-{[(4-  
 [(ethyloxy)carbonyl]phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;

*N*-[(3*S*)-1-[(3-chlorophenyl)methyl]-1-methyl-3-pyrrolidiniumyl]-*N*-{[(4-  
 [(ethyloxy)carbonyl]phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;  
 (2*S*)-2-({*N*-[[(4-[(ethyloxy)carbonyl]phenyl)amino]carbonyl]-L-tyrosyl}amino)-5-

azoniaspiro[4.5]decane trifluoroacetate;

(3'*S*)-3'-({*N*-[[(4-[(ethyloxy)carbonyl]phenyl)amino]carbonyl]-L-tyrosyl}amino)-1,3-  
 dihydrospiro[indole-2,1'-pyrrolidine] trifluoroacetate;

*N*-((3*S*)-1-[[3,4-bis(methyloxy)phenyl]methyl]-1-methyl-3-pyrrolidiniumyl)-*N*-{[(4-  
 [(cyclopropylamino)carbonyl]phenyl)amino]carbonyl}-L-tyrosinamide

trifluoroacetate;

*N*-[(3*S*)-1-ethyl-1-[(4-fluorophenyl)methyl]-3-pyrrolidiniumyl]-*N*-{[(4-  
 [(ethyloxy)carbonyl]phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;

*N*-{[(4-[(ethyloxy)carbonyl]phenyl)amino]carbonyl}-*N*-[(3*S*)-1-[(4-  
 fluorophenyl)methyl]-1-propyl-3-pyrrolidiniumyl]-L-tyrosinamide trifluoroacetate;

*N*-{[(4-[(ethyloxy)carbonyl]phenyl)amino]carbonyl}-*N*-[(3*S*)-1-[(4-  
 fluorophenyl)methyl]-1-(2-propen-1-yl)-3-pyrrolidiniumyl]-L-tyrosinamide  
 trifluoroacetate;

*N*-[(3*S*)-1-(1,3-benzodioxol-5-ylmethyl)-1-methyl-3-pyrrolidiniumyl]-*N*-{[(4-  
 butanoyl]phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;

*N*-[(2*S*)-5-azoniaspiro[4.4]non-2-yl]-*N*-{[(4-  
 [(ethyloxy)carbonyl]phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;  
 (2*S*)-2-({*N*-[[(4-[(ethyloxy)carbonyl]phenyl)amino]carbonyl]-L-tyrosyl}amino)-5-  
 azoniaspiro[4.6]undecane trifluoroacetate;

*N*-[(3*S*)-1-(1,3-benzodioxol-5-ylmethyl)-1-methyl-3-piperidiniumyl]-*N*-{[(4-[(1-methylethyl)amino]carbonyl]phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;

*N*-[(3*S*)-1-(1,3-benzodioxol-5-ylmethyl)-1-methyl-3-piperidiniumyl]-*N*-{[(4-[(methyloxy)carbonyl]phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;

*N*-[(3*S*)-1-(1,3-benzodioxol-5-ylmethyl)-1-methyl-3-piperidiniumyl]-*N*-{[(4-[(ethyloxy)carbonyl]phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;

*N*-[(3*S*)-1-(1,3-benzodioxol-5-ylmethyl)-1-methyl-3-piperidiniumyl]-*N*-{[(4-[(1-methylethyl)oxy]carbonyl]phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;

*N*-[(3*S*)-1-(1,3-benzodioxol-5-ylmethyl)-1-methyl-3-piperidiniumyl]-*N*-{[(4-[(propyloxy)carbonyl]phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;

*N*-[(3*S*)-1-(1,3-benzodioxol-5-ylmethyl)-1-methyl-3-piperidiniumyl]-*N*-{[(4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;

*N*-[(3*S*)-1-(1,3-benzodioxol-5-ylmethyl)-1-methyl-3-piperidiniumyl]-*N*-{[(4-(5-ethyl-1,2,4-oxadiazol-3-yl)phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;

*N*-[(3*S*)-1-(1,3-benzodioxol-5-ylmethyl)-1-methyl-3-piperidiniumyl]-*N*-{[(4-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;

*N*-[(3*S*)-1-(4-fluorophenyl)methyl]-1-methyl-3-piperidiniumyl]-*N*-{[(4-[(1-methylethyl)oxy]carbonyl]phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;

*N*-[(3*S*)-1-(4-hydroxyphenyl)methyl]-1-methyl-3-piperidiniumyl]-*N*-{[(4-[(1-methylethyl)oxy]carbonyl]phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;

*N*-[(3*S*)-1-(3-chlorophenyl)methyl]-1-methyl-3-piperidiniumyl]-*N*-{[(4-[(1-methylethyl)oxy]carbonyl]phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;

*N*-[(3*S*)-1-[(3,4-bis(methyloxy)phenyl)methyl]-1-methyl-3-piperidiniumyl]-*N*-{[(4-[(1-methylethyl)oxy]carbonyl]phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;

*N*-[(3*S*)-1-(3-hydroxyphenyl)methyl]-1-methyl-3-piperidiniumyl]-*N*-{[(4-[(1-methylethyl)oxy]carbonyl]phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;

*N*-[(3*S*)-1-(4-chlorophenyl)methyl]-1-methyl-3-piperidiniumyl]-*N*-{[(4-[(1-methylethyl)oxy]carbonyl]phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;

- N*-[(3*S*)-1-(cyclopropylmethyl)-1-methyl-3-piperidiniumyl]-*N*-{[(4-[(1-methylethyl)oxy]carbonyl}phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;  
*N*-[(3*S*)-1-[(3-hydroxyphenyl)methyl]-1-methyl-3-piperidiniumyl]-*N*-{[(4-[(1-methylethyl)amino]carbonyl}phenyl)amino]carbonyl}-L-tyrosinamide  
5 trifluoroacetate;  
*N*-[(3*S*)-1-[(3-hydroxyphenyl)methyl]-1-methyl-3-pyrrolidiniumyl]-*N*-{[(4-[(1-methylethyl)oxy]carbonyl}phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;  
*N*-[(3*S*)-1-(1,3-benzodioxol-5-ylmethyl)-1-methyl-3-pyrrolidiniumyl]-*N*-{[(4-[(1-methylethyl)oxy]carbonyl}phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;  
10 *N*-[(3*S*)-1-[[3,4-bis(methyloxy)phenyl]methyl]-1-methyl-3-piperidiniumyl)-*N*-{[(4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]amino}carbonyl}-L-tyrosinamide trifluoroacetate;  
*N*-[(3*S*)-1-[[3,4-bis(methyloxy)phenyl]methyl]-1-methyl-3-piperidiniumyl)-*N*-{[(4-(5-ethyl-1,2,4-oxadiazol-3-yl)phenyl]amino}carbonyl}-L-tyrosinamide trifluoroacetate;  
15 *N*-[(3*S*)-1-[[3,4-bis(methyloxy)phenyl]methyl]-1-methyl-3-piperidiniumyl)-*N*-{[(4-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]amino}carbonyl}-L-tyrosinamide trifluoroacetate;  
*N*-[(3*S*)-1-[(3-hydroxyphenyl)methyl]-1-methyl-3-piperidiniumyl]-*N*-{[(4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]amino}carbonyl}-L-tyrosinamide trifluoroacetate;  
20 *N*-[(3*S*)-1-[(3-hydroxyphenyl)methyl]-1-methyl-3-piperidiniumyl]-*N*-{[(4-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]amino}carbonyl}-L-tyrosinamide trifluoroacetate;  
*N*-{[(4-(5-ethyl-1,2,4-oxadiazol-3-yl)phenyl]amino}carbonyl)-*N*-[(3*S*)-1-[(3-hydroxyphenyl)methyl]-1-methyl-3-piperidiniumyl]-L-tyrosinamide trifluoroacetate;  
*N*-[(3*S*)-1,1-bis(cyclopropylmethyl)-3-piperidiniumyl]-*N*-{[(4-[(1-methylethyl)oxy]carbonyl}phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;  
25 *N*-[(3*S*)-1,1-bis(cyclopropylmethyl)-3-piperidiniumyl]-*N*-{[(4-[(1-methylethyl)amino]carbonyl}phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;  
(2*S*)-2-[(*N*-{[(4-[(1-methylethyl)oxy]carbonyl}phenyl)amino]carbonyl)-L-tyrosyl)amino]-6-azoniaspiro[5.6]dodecane trifluoroacetate;  
30 *N*-[(3*S*)-1-[(3-hydroxyphenyl)methyl]-1-propyl-3-piperidiniumyl]-*N*-{[(4-[(1-methylethyl)oxy]carbonyl}phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;



*N*-[(3*S*)-1-(1,3-benzodioxol-5-ylmethyl)-1-propyl-3-piperidiniumyl]-*N*-{[(4-{[(1-methylethyl)oxy]carbonyl}phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;

*N*-[(3*S*)-1-{[3,4-bis(methyloxy)phenyl]methyl}-1-propyl-3-piperidiniumyl]-*N*-{[(4-{[(1-methylethyl)oxy]carbonyl}phenyl)amino]carbonyl}-L-tyrosinamide

5 trifluoroacetate;

*N*-[(3*S*)-1-[(3-hydroxyphenyl)methyl]-1-propyl-3-piperidiniumyl]-*N*-{[(4-{[(1-methylethyl)amino]carbonyl}phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;

10 *N*-[(3*S*)-1-(1,3-benzodioxol-5-ylmethyl)-1-propyl-3-piperidiniumyl]-*N*-{[(4-{[(1-methylethyl)amino]carbonyl}phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;

*N*-[(3*S*)-1-{[3,4-bis(methyloxy)phenyl]methyl}-1-propyl-3-piperidiniumyl]-*N*-{[(4-{[(1-methylethyl)amino]carbonyl}phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;

15 *N*-[(3*S*)-1-[(3-hydroxyphenyl)methyl]-1-(2-propen-1-yl)-3-piperidiniumyl]-*N*-{[(4-{[(1-methylethyl)oxy]carbonyl}phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;

*N*-[(3*S*)-1-(1,3-benzodioxol-5-ylmethyl)-1-(2-propen-1-yl)-3-piperidiniumyl]-*N*-{[(4-{[(1-methylethyl)oxy]carbonyl}phenyl)amino]carbonyl}-L-tyrosinamide

20 trifluoroacetate;

*N*-[(3*S*)-1-{[3,4-bis(methyloxy)phenyl]methyl}-1-(2-propen-1-yl)-3-piperidiniumyl]-*N*-{[(4-{[(1-methylethyl)oxy]carbonyl}phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;

25 *N*-[(3*S*)-1-[(3-hydroxyphenyl)methyl]-1-(2-propen-1-yl)-3-piperidiniumyl]-*N*-{[(4-{[(1-methylethyl)amino]carbonyl}phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;

*N*-[(3*S*)-1-(1,3-benzodioxol-5-ylmethyl)-1-(2-propen-1-yl)-3-piperidiniumyl]-*N*-{[(4-{[(1-methylethyl)amino]carbonyl}phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;

30 *N*-[(3*S*)-1-{[3,4-bis(methyloxy)phenyl]methyl}-1-(2-propen-1-yl)-3-piperidiniumyl]-*N*-{[(4-{[(1-methylethyl)amino]carbonyl}phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;

*N*-{(3*S*)-1-[(4-hydroxyphenyl)methyl]-1-propyl-3-piperidiniumyl}-*N*-{[(4-{[(1-methylethyl)oxy]carbonyl}phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;

*N*-[(3*S*)-1-(cyclopropylmethyl)-1-(2-propen-1-yl)-3-piperidiniumyl]-*N*-{[(4-{[(1-methylethyl)oxy]carbonyl}phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;

5 *N*-[(3*S*)-1-(cyclopropylmethyl)-1-(2-propen-1-yl)-3-piperidiniumyl]-*N*-{[(4-{[(1-methylethyl)amino]carbonyl}phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;

*N*-[(3*S*)-1-(cyclopropylmethyl)-1-propyl-3-piperidiniumyl]-*N*-{[(4-{[(1-methylethyl)amino]carbonyl}phenyl)amino]carbonyl}-L-tyrosinamide

10 trifluoroacetate;

*N*-[(3*S*)-1-(cyclopropylmethyl)-1-propyl-3-piperidiniumyl]-*N*-{[(4-{[(1-methylethyl)oxy]carbonyl}phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;

*N*-[(3*S*)-1-[(3,4-bis(methyloxy)phenyl)methyl]-1-methyl-3-piperidiniumyl]-*N*-{[(4-{[(1-methylethyl)amino]carbonyl}phenyl)amino]carbonyl}-L-tyrosinamide

15 trifluoroacetate;

*N*-{(3*S*)-1-[(3-chlorophenyl)methyl]-1-methyl-3-piperidiniumyl}-*N*-{[(4-{[(1-methylethyl)amino]carbonyl}phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;

*N*-{(3*S*)-1-[(4-hydroxyphenyl)methyl]-1-methyl-3-piperidiniumyl}-*N*-{[(4-{[(1-methylethyl)amino]carbonyl}phenyl)amino]carbonyl}-L-tyrosinamide

20 trifluoroacetate;

*N*-{(3*S*)-1-[(4-fluorophenyl)methyl]-1-methyl-3-piperidiniumyl}-*N*-{[(4-{[(1-methylethyl)amino]carbonyl}phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;

25 *N*-[(3*S*)-1-(1,3-benzodioxol-5-ylmethyl)-1-methyl-3-pyrrolidiniumyl]-*N*-{[(4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;

*N*-[(3*S*)-1-(1,3-benzodioxol-5-ylmethyl)-1-methyl-3-pyrrolidiniumyl]-*N*-{[(4-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl)amino]carbonyl}-L-tyrosinamide

30 trifluoroacetate;

*N*-{(3*S*)-1-[(3-hydroxyphenyl)methyl]-1-methyl-3-pyrrolidiniumyl}-*N*-{[(4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;

- N*-{(3*S*)-1-[(3-hydroxyphenyl)methyl]-1-methyl-3-pyrrolidiniumyl}-*N*-{[4-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]amino}carbonyl)-*L*-tyrosinamide trifluoroacetate;  
*N*-{[4-[(ethyloxy)carbonyl]phenyl]amino}carbonyl)-*N*-{(3*S*)-1-[(4-fluorophenyl)methyl]-1-methyl-3-piperidiniumyl}-*L*-tyrosinamide trifluoroacetate;  
5 *N*-{(3*S*)-1-[(3-chlorophenyl)methyl]-1-methyl-3-piperidiniumyl}-*N*-{[4-[(ethyloxy)carbonyl]phenyl]amino}carbonyl)-*L*-tyrosinamide trifluoroacetate;  
*N*-{(3*S*)-1-[[3,4-bis(methyloxy)phenyl]methyl]-1-methyl-3-piperidiniumyl}-*N*-{[4-[(ethyloxy)carbonyl]phenyl]amino}carbonyl)-*L*-tyrosinamide trifluoroacetate;  
*N*-{[4-[(ethyloxy)carbonyl]phenyl]amino}carbonyl)-*N*-{(3*S*)-1-[(3-hydroxyphenyl)methyl]-1-methyl-3-piperidiniumyl}-*L*-tyrosinamide trifluoroacetate;  
10 *N*-{(3*S*)-1-(cyclopropylmethyl)-1-methyl-3-piperidiniumyl}-*N*-{[4-[(ethyloxy)carbonyl]phenyl]amino}carbonyl)-*L*-tyrosinamide trifluoroacetate;  
*N*-{[3,5-bis[(ethyloxy)carbonyl]-4-methyl-2-thienyl]amino}carbonyl)-*N*-{(3*S*)-1-[(3-hydroxyphenyl)methyl]-1-methyl-3-piperidiniumyl}-*L*-tyrosinamide trifluoroacetate;  
15 *N*-{[3,5-bis[(ethyloxy)carbonyl]-4-methyl-2-thienyl]amino}carbonyl)-*N*-{(3*S*)-1-[(3-chlorophenyl)methyl]-1-methyl-3-piperidiniumyl}-*L*-tyrosinamide trifluoroacetate;  
*N*-{[3,5-bis[(ethyloxy)carbonyl]-4-methyl-2-thienyl]amino}carbonyl)-*N*-{(3*S*)-1-[(4-chlorophenyl)methyl]-1-methyl-3-piperidiniumyl}-*L*-tyrosinamide trifluoroacetate;  
*N*-{[5-[(ethyloxy)carbonyl]-2-thienyl]amino}carbonyl)-*N*-{(3*S*)-1-[(3-hydroxyphenyl)methyl]-1-methyl-3-piperidiniumyl}-*L*-tyrosinamide trifluoroacetate;  
20 *N*-{[5-[(ethyloxy)carbonyl]-2-thienyl]amino}carbonyl)-*N*-{(3*S*)-1-[(3-chlorophenyl)methyl]-1-methyl-3-piperidiniumyl}-*L*-tyrosinamide trifluoroacetate;  
*N*-{[5-[(ethyloxy)carbonyl]-2-thienyl]amino}carbonyl)-*N*-{(3*S*)-1-[(4-chlorophenyl)methyl]-1-methyl-3-piperidiniumyl}-*L*-tyrosinamide trifluoroacetate;  
25 *N*-{(3*S*)-1-[(3-hydroxyphenyl)methyl]-1-methyl-3-piperidiniumyl}-*N*-{[5-[(1-methylethyl)oxy]carbonyl]-2-thienyl]amino}carbonyl)-*L*-tyrosinamide trifluoroacetate;  
*N*-{(3*S*)-1-[(3-chlorophenyl)methyl]-1-methyl-3-piperidiniumyl}-*N*-{[5-[(1-methylethyl)oxy]carbonyl]-2-thienyl]amino}carbonyl)-*L*-tyrosinamide trifluoroacetate;  
30 *N*-{(3*S*)-1-[(4-chlorophenyl)methyl]-1-methyl-3-piperidiniumyl}-*N*-{[5-[(1-methylethyl)oxy]carbonyl]-2-thienyl]amino}carbonyl)-*L*-tyrosinamide trifluoroacetate;

- N*-[({5-[(cyclobutyloxy)carbonyl]-2-thienyl}amino)carbonyl]-*N*-{(3*S*)-1-[(3-hydroxyphenyl)methyl]-1-methyl-3-piperidiniumyl}-*L*-tyrosinamide trifluoroacetate;  
*N*-[({5-[(cyclobutyloxy)carbonyl]-2-thienyl}amino)carbonyl]-*N*-{(3*S*)-1-[(3-chlorophenyl)methyl]-1-methyl-3-piperidiniumyl}-*L*-tyrosinamide trifluoroacetate;
- 5 *N*-[({5-[(cyclobutyloxy)carbonyl]-2-thienyl}amino)carbonyl]-*N*-{(3*S*)-1-[(4-chlorophenyl)methyl]-1-methyl-3-piperidiniumyl}-*L*-tyrosinamide trifluoroacetate;  
*N*-[({5-[(cyclopropylmethyl)oxy]carbonyl}-2-thienyl)amino]carbonyl]-*N*-{(3*S*)-1-[(3-hydroxyphenyl)methyl]-1-methyl-3-piperidiniumyl}-*L*-tyrosinamide trifluoroacetate;  
*N*-{(3*S*)-1-[(3-hydroxyphenyl)methyl]-1-methyl-3-piperidiniumyl}-*N*-[({5-[(phenylmethyl)oxy]carbonyl}-2-thienyl)amino]carbonyl]-*L*-tyrosinamide trifluoroacetate;
- 10 *N*-{(3*S*)-1-[(3-chlorophenyl)methyl]-1-methyl-3-piperidiniumyl}-*N*-[({5-[(phenylmethyl)oxy]carbonyl}-2-thienyl)amino]carbonyl]-*L*-tyrosinamide trifluoroacetate;
- 15 *N*-{(3*S*)-1-[(4-chlorophenyl)methyl]-1-methyl-3-piperidiniumyl}-*N*-[({5-[(phenylmethyl)oxy]carbonyl}-2-thienyl)amino]carbonyl]-*L*-tyrosinamide trifluoroacetate;
- N*-{(3*S*)-1-[(3-hydroxyphenyl)methyl]-1-methyl-3-piperidiniumyl}-*N*-[({5-[(propyloxy)carbonyl]-2-thienyl}amino)carbonyl]-*L*-tyrosinamide trifluoroacetate;
- 20 *N*-{(3*S*)-1-[(3-chlorophenyl)methyl]-1-methyl-3-piperidiniumyl}-*N*-[({5-[(propyloxy)carbonyl]-2-thienyl}amino)carbonyl]-*L*-tyrosinamide trifluoroacetate;
- N*-{(3*S*)-1-[(4-chlorophenyl)methyl]-1-methyl-3-piperidiniumyl}-*N*-[({5-[(propyloxy)carbonyl]-2-thienyl}amino)carbonyl]-*L*-tyrosinamide trifluoroacetate;
- 25 *N*-[({5-[(cyclopentylamino)carbonyl]-2-thienyl}amino)carbonyl]-*N*-{(3*S*)-1-[(3-hydroxyphenyl)methyl]-1-methyl-3-piperidiniumyl}-*L*-tyrosinamide trifluoroacetate;
- N*-[({5-[(cyclopentylamino)carbonyl]-2-thienyl}amino)carbonyl]-*N*-{(3*S*)-1-[(3-chlorophenyl)methyl]-1-methyl-3-piperidiniumyl}-*L*-tyrosinamide trifluoroacetate;
- N*-[({5-[(cyclopentylamino)carbonyl]-2-thienyl}amino)carbonyl]-*N*-{(3*S*)-1-[(4-chlorophenyl)methyl]-1-methyl-3-piperidiniumyl}-*L*-tyrosinamide trifluoroacetate;
- 30 *N*-[({5-[(cycloheptylamino)carbonyl]-2-thienyl}amino)carbonyl]-*N*-{(3*S*)-1-[(3-hydroxyphenyl)methyl]-1-methyl-3-piperidiniumyl}-*L*-tyrosinamide trifluoroacetate;
- N*-[({5-[(cycloheptylamino)carbonyl]-2-thienyl}amino)carbonyl]-*N*-{(3*S*)-1-[(3-chlorophenyl)methyl]-1-methyl-3-piperidiniumyl}-*L*-tyrosinamide trifluoroacetate;

*N*-[({5-[(cycloheptylamino)carbonyl]-2-thienyl}amino)carbonyl]-*N*-{(3*S*)-1-[(4-chlorophenyl)methyl]-1-methyl-3-piperidiniumyl}-*L*-tyrosinamide trifluoroacetate;  
*N*-[({5-[(cyclohexylmethyl)amino]carbonyl}-2-thienyl)amino]carbonyl]-*N*-{(3*S*)-1-[(3-hydroxyphenyl)methyl]-1-methyl-3-piperidiniumyl}-*L*-tyrosinamide

5 trifluoroacetate;

*N*-[({5-[(cyclohexylmethyl)amino]carbonyl}-2-thienyl)amino]carbonyl]-*N*-{(3*S*)-1-[(3-chlorophenyl)methyl]-1-methyl-3-piperidiniumyl}-*L*-tyrosinamide trifluoroacetate;

*N*-{(3*S*)-1,1-bis[(3-chlorophenyl)methyl]-3-piperidiniumyl}-*N*-[({5-[(ethyloxy)carbonyl]-2-thienyl}amino)carbonyl]-*L*-tyrosinamide trifluoroacetate; and  
 10 *N*-[({5-[(ethyloxy)carbonyl]-2-thienyl}amino)carbonyl]-*N*-{(3*S*)-1-[(3-hydroxyphenyl)methyl]-1-methyl-3-piperidiniumyl}-*L*-tyrosinamide trifluoroacetate;  
 or any other pharmaceutically acceptable salt.

15 The most preferred compounds are selected from the group consisting of:

*N*-[(3*S*)-1-(1,3-benzodioxol-5-ylmethyl)-1-methyl-3-piperidiniumyl]-*N*-{[4-[(1-methylethyl)amino]carbonyl]phenyl}amino]carbonyl}-*L*-tyrosinamide trifluoroacetate;

*N*-[(3*S*)-1-(1,3-benzodioxol-5-ylmethyl)-1-methyl-3-piperidiniumyl]-*N*-{[4-[(ethyloxy)carbonyl]phenyl}amino]carbonyl}-*L*-tyrosinamide trifluoroacetate;

*N*-[(3*S*)-1-(1,3-benzodioxol-5-ylmethyl)-1-methyl-3-piperidiniumyl]-*N*-{[4-[(1-methylethyl)oxy]carbonyl]phenyl}amino]carbonyl}-*L*-tyrosinamide trifluoroacetate;

*N*-[(3*S*)-1-(1,3-benzodioxol-5-ylmethyl)-1-methyl-3-piperidiniumyl]-*N*-{[4-[(propyloxy)carbonyl]phenyl}amino]carbonyl}-*L*-tyrosinamide trifluoroacetate;

25 *N*-[(3*S*)-1-(1,3-benzodioxol-5-ylmethyl)-1-methyl-3-piperidiniumyl]-*N*-{[4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]amino}carbonyl}-*L*-tyrosinamide trifluoroacetate;

*N*-[(3*S*)-1-(1,3-benzodioxol-5-ylmethyl)-1-methyl-3-piperidiniumyl]-*N*-{[4-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]amino}carbonyl}-*L*-tyrosinamide

30 trifluoroacetate;

*N*-{(3*S*)-1-[(4-fluorophenyl)methyl]-1-methyl-3-piperidiniumyl}-*N*-{[4-[(1-methylethyl)oxy]carbonyl]phenyl}amino]carbonyl}-*L*-tyrosinamide trifluoroacetate;

- N*-{(3*S*)-1-[(4-hydroxyphenyl)methyl]-1-methyl-3-piperidiniumyl}-*N*-{[(4-{[(1-methylethyl)oxy]carbonyl}phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;  
*N*-{(3*S*)-1-[(3-chlorophenyl)methyl]-1-methyl-3-piperidiniumyl}-*N*-{[(4-{[(1-methylethyl)oxy]carbonyl}phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;
- 5 *N*-{(3*S*)-1-[[3,4-bis(methyloxy)phenyl]methyl]-1-methyl-3-piperidiniumyl}-*N*-{[(4-{[(1-methylethyl)oxy]carbonyl}phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;
- N*-{(3*S*)-1-[(3-hydroxyphenyl)methyl]-1-methyl-3-piperidiniumyl}-*N*-{[(4-{[(1-methylethyl)oxy]carbonyl}phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;
- 10 *N*-{(3*S*)-1-[(4-chlorophenyl)methyl]-1-methyl-3-piperidiniumyl}-*N*-{[(4-{[(1-methylethyl)oxy]carbonyl}phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;
- N*-{(3*S*)-1-(cyclopropylmethyl)-1-methyl-3-piperidiniumyl}-*N*-{[(4-{[(1-methylethyl)oxy]carbonyl}phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;
- N*-{(3*S*)-1-[(3-hydroxyphenyl)methyl]-1-methyl-3-piperidiniumyl}-*N*-{[(4-{[(1-methylethyl)amino]carbonyl}phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;
- 15 *N*-{(3*S*)-1-[(3-hydroxyphenyl)methyl]-1-methyl-3-pyrrolidiniumyl}-*N*-{[(4-{[(1-methylethyl)oxy]carbonyl}phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;
- N*-{(3*S*)-1-(1,3-benzodioxol-5-ylmethyl)-1-methyl-3-pyrrolidiniumyl}-*N*-{[(4-{[(1-methylethyl)oxy]carbonyl}phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;
- 20 *N*-{(3*S*)-1-[[3,4-bis(methyloxy)phenyl]methyl]-1-methyl-3-piperidiniumyl}-*N*-{[(4-{[(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]amino}carbonyl)-L-tyrosinamide trifluoroacetate;
- N*-{(3*S*)-1-[[3,4-bis(methyloxy)phenyl]methyl]-1-methyl-3-piperidiniumyl}-*N*-{[(4-{[(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]amino}carbonyl)-L-tyrosinamide trifluoroacetate;
- 25 *N*-{(3*S*)-1-[(3-hydroxyphenyl)methyl]-1-methyl-3-piperidiniumyl}-*N*-{[(4-{[(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]amino}carbonyl)-L-tyrosinamide trifluoroacetate;
- N*-{(3*S*)-1-[(3-hydroxyphenyl)methyl]-1-methyl-3-piperidiniumyl}-*N*-{[(4-{[(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]amino}carbonyl)-L-tyrosinamide trifluoroacetate;
- 30 *N*-{[(4-{[(5-ethyl-1,2,4-oxadiazol-3-yl)phenyl]amino}carbonyl)-L-tyrosinamide trifluoroacetate;
- N*-{(3*S*)-1-[(3-hydroxyphenyl)methyl]-1-methyl-3-piperidiniumyl}-L-tyrosinamide trifluoroacetate;

- N*-[(3*S*)-1,1-bis(cyclopropylmethyl)-3-piperidiniumyl]-*N*-{[(4-{[(1-methylethyl)oxy]carbonyl}phenyl)amino]carbonyl}-*L*-tyrosinamide trifluoroacetate;  
*N*-[(3*S*)-1,1-bis(cyclopropylmethyl)-3-piperidiniumyl]-*N*-{[(4-{[(1-methylethyl)amino]carbonyl}phenyl)amino]carbonyl}-*L*-tyrosinamide  
5 trifluoroacetate;  
(2*S*)-2-[(*N*-{[(4-{[(1-methylethyl)oxy]carbonyl}phenyl)amino]carbonyl}-*L*-tyrosyl)amino]-6-azoniaspiro[5.6]dodecane trifluoroacetate;  
*N*-{(3*S*)-1-[(3-hydroxyphenyl)methyl]-1-propyl-3-piperidiniumyl}-*N*-{[(4-{[(1-methylethyl)oxy]carbonyl}phenyl)amino]carbonyl}-*L*-tyrosinamide trifluoroacetate;  
10 *N*-[(3*S*)-1-(1,3-benzodioxol-5-ylmethyl)-1-propyl-3-piperidiniumyl]-*N*-{[(4-{[(1-methylethyl)oxy]carbonyl}phenyl)amino]carbonyl}-*L*-tyrosinamide trifluoroacetate;  
*N*-{(3*S*)-1-[[3,4-bis(methyloxy)phenyl]methyl]-1-propyl-3-piperidiniumyl}-*N*-{[(4-{[(1-methylethyl)oxy]carbonyl}phenyl)amino]carbonyl}-*L*-tyrosinamide trifluoroacetate;  
15 *N*-{(3*S*)-1-[(3-hydroxyphenyl)methyl]-1-propyl-3-piperidiniumyl}-*N*-{[(4-{[(1-methylethyl)amino]carbonyl}phenyl)amino]carbonyl}-*L*-tyrosinamide trifluoroacetate;  
*N*-[(3*S*)-1-(1,3-benzodioxol-5-ylmethyl)-1-propyl-3-piperidiniumyl]-*N*-{[(4-{[(1-methylethyl)amino]carbonyl}phenyl)amino]carbonyl}-*L*-tyrosinamide  
20 trifluoroacetate;  
*N*-{(3*S*)-1-[[3,4-bis(methyloxy)phenyl]methyl]-1-propyl-3-piperidiniumyl}-*N*-{[(4-{[(1-methylethyl)amino]carbonyl}phenyl)amino]carbonyl}-*L*-tyrosinamide trifluoroacetate;  
*N*-[(3*S*)-1-[(3-hydroxyphenyl)methyl]-1-(2-propen-1-yl)-3-piperidiniumyl]-*N*-{[(4-{[(1-methylethyl)oxy]carbonyl}phenyl)amino]carbonyl}-*L*-tyrosinamide  
25 trifluoroacetate;  
*N*-[(3*S*)-1-(1,3-benzodioxol-5-ylmethyl)-1-(2-propen-1-yl)-3-piperidiniumyl]-*N*-{[(4-{[(1-methylethyl)oxy]carbonyl}phenyl)amino]carbonyl}-*L*-tyrosinamide trifluoroacetate;  
30 *N*-[(3*S*)-1-[[3,4-bis(methyloxy)phenyl]methyl]-1-(2-propen-1-yl)-3-piperidiniumyl]-*N*-{[(4-{[(1-methylethyl)oxy]carbonyl}phenyl)amino]carbonyl}-*L*-tyrosinamide trifluoroacetate;

*N*-[(3*S*)-1-[(3-hydroxyphenyl)methyl]-1-(2-propen-1-yl)-3-piperidiniumyl]-*N*-{[(4-  
 {[(1-methylethyl)amino]carbonyl}phenyl)amino]carbonyl}-L-tyrosinamide  
 trifluoroacetate;

5 *N*-[(3*S*)-1-(1,3-benzodioxol-5-ylmethyl)-1-(2-propen-1-yl)-3-piperidiniumyl]-*N*-{[(4-  
 {[(1-methylethyl)amino]carbonyl}phenyl)amino]carbonyl}-L-tyrosinamide  
 trifluoroacetate;

*N*-[(3*S*)-1-[[3,4-bis(methyloxy)phenyl]methyl]-1-(2-propen-1-yl)-3-piperidiniumyl]-  
*N*-{[(4-[[[(1-methylethyl)amino]carbonyl]phenyl)amino]carbonyl}-L-tyrosinamide  
 trifluoroacetate;

10 *N*-{(3*S*)-1-[(4-hydroxyphenyl)methyl]-1-propyl-3-piperidiniumyl}-*N*-{[(4-[(1-  
 methylethyl)oxy]carbonyl}phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;  
*N*-{(3*S*)-1-[[3,4-bis(methyloxy)phenyl]methyl]-1-methyl-3-piperidiniumyl}-*N*-{[(4-  
 {[(1-methylethyl)amino]carbonyl}phenyl)amino]carbonyl}-L-tyrosinamide  
 trifluoroacetate;

15 *N*-{(3*S*)-1-[(3-chlorophenyl)methyl]-1-methyl-3-piperidiniumyl}-*N*-{[(4-[(1-  
 methylethyl)amino]carbonyl}phenyl)amino]carbonyl}-L-tyrosinamide  
 trifluoroacetate;

*N*-{(3*S*)-1-[(4-hydroxyphenyl)methyl]-1-methyl-3-piperidiniumyl}-*N*-{[(4-[(1-  
 methylethyl)amino]carbonyl}phenyl)amino]carbonyl}-L-tyrosinamide  
 20 trifluoroacetate;

*N*-{(3*S*)-1-[(4-fluorophenyl)methyl]-1-methyl-3-piperidiniumyl}-*N*-{[(4-[(1-  
 methylethyl)amino]carbonyl}phenyl)amino]carbonyl}-L-tyrosinamide  
 trifluoroacetate;

25 *N*-{[(4-[(ethyloxy)carbonyl]phenyl)amino]carbonyl}-*N*-{(3*S*)-1-[(4-  
 fluorophenyl)methyl]-1-methyl-3-piperidiniumyl}-L-tyrosinamide trifluoroacetate;

*N*-{(3*S*)-1-[(3-chlorophenyl)methyl]-1-methyl-3-piperidiniumyl}-*N*-{[(4-  
 [(ethyloxy)carbonyl]phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;  
*N*-{(3*S*)-1-[[3,4-bis(methyloxy)phenyl]methyl]-1-methyl-3-piperidiniumyl}-*N*-{[(4-  
 [(ethyloxy)carbonyl]phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;

30 *N*-{[(4-[(ethyloxy)carbonyl]phenyl)amino]carbonyl}-*N*-{(3*S*)-1-[(3-  
 hydroxyphenyl)methyl]-1-methyl-3-piperidiniumyl}-L-tyrosinamide trifluoroacetate;  
*N*-[(3*S*)-1-(cyclopropylmethyl)-1-methyl-3-piperidiniumyl]-*N*-{[(4-  
 [(ethyloxy)carbonyl]phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;



*N*-{(3*S*)-1-[(3-hydroxyphenyl)methyl]-1-methyl-3-piperidiniumyl}-*N*-[({5-[(cyclohexyloxy)carbonyl]-2-thienyl}amino)carbonyl]-*L*-tyrosinamide trifluoroacetate;

*N*-{(3*S*)-1-[(3-chlorophenyl)methyl]-1-methyl-3-piperidiniumyl}-*N*-[({5-[(cyclohexyloxy)carbonyl]-2-thienyl}amino)carbonyl]-*L*-tyrosinamide trifluoroacetate;

*N*-{(3*S*)-1-[(4-chlorophenyl)methyl]-1-methyl-3-piperidiniumyl}-*N*-[({5-[(cyclohexyloxy)carbonyl]-2-thienyl}amino)carbonyl]-*L*-tyrosinamide trifluoroacetate;

10 *N*-[({5-[(cyclopentyloxy)carbonyl]-2-thienyl}amino)carbonyl]-*N*-{(3*S*)-1-[(3-hydroxyphenyl)methyl]-1-methyl-3-piperidiniumyl}-*L*-tyrosinamide trifluoroacetate;

*N*-[({5-[(cyclopentyloxy)carbonyl]-2-thienyl}amino)carbonyl]-*N*-{(3*S*)-1-[(3-chlorophenyl)methyl]-1-methyl-3-piperidiniumyl}-*L*-tyrosinamide trifluoroacetate;

15 *N*-[({5-[(cyclopentyloxy)carbonyl]-2-thienyl}amino)carbonyl]-*N*-{(3*S*)-1-[(4-chlorophenyl)methyl]-1-methyl-3-piperidiniumyl}-*L*-tyrosinamide trifluoroacetate;

*N*-[({5-[(cyclohexylmethyl)oxy]carbonyl}-2-thienyl)amino]carbonyl]-*N*-{(3*S*)-1-[(3-hydroxyphenyl)methyl]-1-methyl-3-piperidiniumyl}-*L*-tyrosinamide }-*L*-tyrosinamide trifluoroacetate;

20 *N*-[({5-[(cycloheptyloxy)carbonyl]-2-thienyl}amino)carbonyl]-*N*-{(3*S*)-1-[(3-hydroxyphenyl)methyl]-1-methyl-3-piperidiniumyl}-*L*-tyrosinamide trifluoroacetate;

*N*-[({5-[(cycloheptyloxy)carbonyl]-2-thienyl}amino)carbonyl]-*N*-{(3*S*)-1-[(3-chlorophenyl)methyl]-1-methyl-3-piperidiniumyl}-*L*-tyrosinamide trifluoroacetate; and trifluoroacetate;

25 *N*-[({5-[(cyclohexylmethyl)oxy]carbonyl}-2-thienyl)amino]carbonyl]-*N*-{(3*S*)-1-[(3-chlorophenyl)methyl]-1-methyl-3-piperidiniumyl}-*L*-tyrosinamide trifluoroacetate;

*N*-[({5-[(cyclohexylmethyl)oxy]carbonyl}-2-thienyl)amino]carbonyl]-*N*-{(3*S*)-1-[(4-chlorophenyl)methyl]-1-methyl-3-piperidiniumyl}-*L*-tyrosinamide trifluoroacetate;

*N*-[({5-[(cyclopentylmethyl)oxy]carbonyl}-2-thienyl)amino]carbonyl]-*N*-{(3*S*)-1-[(3-hydroxyphenyl)methyl]-1-methyl-3-piperidiniumyl}-*L*-tyrosinamide trifluoroacetate;

30 *N*-[({5-[(cyclopentylmethyl)oxy]carbonyl}-2-thienyl)amino]carbonyl]-*N*-{(3*S*)-1-[(3-chlorophenyl)methyl]-1-methyl-3-piperidiniumyl}-*L*-tyrosinamide trifluoroacetate;

*N*-{[(5-{[(cyclopentylmethyl)oxy]carbonyl}-2-thienyl)amino]carbonyl}-*N*-{(3*S*)-1-[(4-chlorophenyl)methyl]-1-methyl-3-piperidiniumyl}-L-tyrosinamide trifluoroacetate;  
and

*N*-{[(5-{[(cycloheptyloxy)carbonyl]-2-thienyl)amino}carbonyl]-*N*-{(3*S*)-1-[(4-chlorophenyl)methyl]-1-methyl-3-piperidiniumyl}-L-tyrosinamide trifluoroacetate;  
5 or any other pharmaceutically acceptable salt.

### **Methods of Preparation**


#### **Preparation**

10 The compounds of Formula (I) may be obtained by applying synthetic procedures, some of which are illustrated in the Schemes below. The synthesis provided for these Schemes is applicable for producing compounds of Formula (I) having a variety of different R1, R2, R3, R4, R5 and R6, which are reacted, employing substituents which are suitable protected, to achieve compatibility with  
15 the reactions outlined herein. Subsequent deprotection, in those cases, then affords compounds of the nature generally disclosed. While some Schemes are shown with specific compounds, this is merely for illustration purpose only.

#### **Preparation 1**

20 Resin-bound amines **3** were prepared by reductive alkylation of 2,6-dimethoxy-4-polystyrenebenzyloxy-benzaldehyde (DMHB resin) with *N*-protected diamine HCl salts **2**, which were prepared from Boc-protected diamines **1** (Scheme 1). Reactions of **3** with Fmoc-protected amino acids, followed by removal of the protecting group, provided resin-bound intermediates **4**. Reactions  
25 of **4** with isocyanates afforded the corresponding resin-bound ureas, which were subsequently treated with potassium carbonate and thiophenol to give secondary amines **5**. Reductive alkylation of **5** with aldehydes produced resin-bound tertiary amines **6**. Amines **6** were then reacted with alkyl halides (R3Z) to give the corresponding resin-bound quaternary ammonium salts, which were treated with  
30 50% trifluoroacetic acid in 1,2-dichloroethane to afford targeted compounds **7**.

## Scheme 1



Conditions: a) 2-nitrobenzenesulfonyl chloride (Nosyl-Cl), pyridine, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C – rt; b) 4 M HCl in 1,4-dioxane, MeOH, rt; c) 2,6-dimethoxy-4-polystyrenebenzyloxy-benzaldehyde (DMHB resin), Na(OAc)<sub>3</sub>BH, diisopropylethylamine, 10% acetic acid in 1-methyl-2-pyrrolidinone, rt; d) Fmoc-protected amino acids, 1,3-diisopropylcarbodiimide, 1-hydroxy-7-azabenzotriazole, 1-methyl-2-pyrrolidinone, rt; e) 20% piperidine in 1-methyl-2-pyrrolidinone, rt; f) Ethyl 4-isocyanatobenzoate, 1,2-dichloroethane, rt; g) K<sub>2</sub>CO<sub>3</sub>, PhSH, 1-methyl-2-pyrrolidinone, rt; h) R<sub>2</sub>CHO, Na(OAc)<sub>3</sub>BH, 10% acetic acid in 1-methyl-2-pyrrolidinone, rt; i) R<sub>3</sub>Z, acetonitrile, rt; j) 50% trifluoroacetic acid in 1,2-dichloroethane, rt.

The following examples are provided as illustrative of the present invention but not limiting in any way:

### Example 1

#### Preparation of *N*-[({4-[(ethyloxy)carbonyl]phenyl}amino)carbonyl]-*N*-{(3*S*)-1-[(4-hydroxyphenyl)methyl]-1-methyl-3-pyrrolidiniumyl}-L-tyrosinamide trifluoroacetate

5

##### a) 3(*S*)-amino-*N*-(2-nitrobenzenesulfonyl)pyrrolidine HCl salt

To a solution of 3(*S*)-(-)-(tert-butoxycarbonyl-amino)pyrrolidine (20.12 g, 108 mmol) in 250 mL of anhydrous methylene chloride at 0 °C was added 13.1 mL (162 mmol) of anhydrous pyridine, followed by slow addition of 25.2 g (113.4 mmol) of 2-nitrobenzenesulfonyl chloride. The mixture was warmed to rt over 1 h and stirred at rt for 16 h. The mixture was poured into 300 mL of 1 M aqueous NaHCO<sub>3</sub> solution. After the resulting mixture was stirred at rt for 30 min, the organic layer was separated and washed with 500 mL of 1N aqueous HCl solution twice. The resulting organic layer was dried over MgSO<sub>4</sub> and concentrated *in vacuo*. The residue was used for the the next step without further purification.

To a mixture of the above residue in 140 mL of anhydrous MeOH was added 136 mL (544 mmol) of 4 M HCl in 1,4-dioxane solution. The mixture was stirred at rt for 16 h, concentrated *in vacuo* and further dried in vacuum oven at 35 °C for 24 h to yield 3(*S*)-amino-*N*-(2-nitrobenzenesulfonyl) pyrrolidine HCl salt as a yellow solid (30.5 g, 92% over the two steps): <sup>1</sup>H NMR (400 MHz, d<sub>6</sub>-DMSO) δ 8.63 (s, 3 H), 8.08-7.98 (m, 2 H), 7.96-7.83 (m, 2 H), 3.88-3.77 (m, 1 H), 3.66-3.56 (m, 2 H), 3.46-3.35 (m, 2 H), 2.28-2.16 (m, 1 H), 2.07-1.96 (m, 1 H).

##### b) DMHB resin bound *O*-(1,1-dimethylethyl)-*N*-{(3*S*)-1-[(2-nitrophenyl)sulfonyl]-3-pyrrolidinyl}-L-tyrosinamide

To a mixture of 7.20 g (10.37 mmol, 1.44 mmol/g) of 2,6-dimethoxy-4-polystyrenebenzyloxy-benzaldehyde (DMHB resin) in 156 mL of 10% acetic acid in anhydrous 1-methyl-2-pyrrolidinone was added 9.56 g (31.1 mmol) of example 1a and 9.03 mL (51.84 mmol) of diisopropylethyl amine, followed by addition of 11.0 g (51.84 mmol) of sodium triacetoxymethylborohydride. After the resulting mixture was shaken at rt for 72 h, the resin was washed with DMF (3 x 250 mL),

CH<sub>2</sub>Cl<sub>2</sub>/MeOH (1:1, 3 x 250 mL) and MeOH (3 x 250 mL). The resulting resin was dried in vacuum oven at 35 °C for 24 h. Elemental analysis N: 4.16, S: 3.12.

To a mixture of 800 mg (0.860 mmol, 1.075 mmol/g) of the above resin in 15 mL of anhydrous 1-methyl-2-pyrrolidinone was added 1.98 g (4.30 mmol) of Fmoc-Try(tBu)-OH and 117 mg (0.86 mmol) of 1-hydroxy-7-azabenzotriazole, followed by addition of 0.82 mL (5.16 mmol) of 1,3-diisopropylcarbodiimide. After the resulting mixture was shaken at rt for 24 h, the resin was washed with DMF (3 x 25 mL), CH<sub>2</sub>Cl<sub>2</sub>/MeOH (1:1, 3 x 25 mL) and MeOH (3 x 25 mL). The resulting resin was dried in vacuum oven at 35 °C for 24 h. An analytical amount of resin was cleaved with 50% trifluoroacetic acid in dichloroethane for 2 h at rt. The resulting solution was concentrated *in vacuo*: MS (ESI) 657 [M+H-tBu]<sup>+</sup>.

The above resin (0.860 mmol) was treated with 15 mL of 20% piperidine in anhydrous 1-methyl-2-pyrrolidinone solution. After the mixture was shaken at rt for 15 min, the solution was drained and another 15 mL of 20% piperidine in anhydrous 1-methyl-2-pyrrolidinone solution was added. The mixture was shaken at rt for another 15 min. The solution was drained and the resin was washed with DMF (3 x 25 mL), CH<sub>2</sub>Cl<sub>2</sub>/MeOH (1:1, 3 x 25 mL) and MeOH (3 x 25 mL). The resulting resin was dried in vacuum oven at 35 °C for 24 h to afford DHMB resin bound O-(1,1-dimethylethyl)-N-[(3S)-1-[(2-nitrophenyl)sulfonyl]-3-pyrrolidinyl]-L-tyrosinamide (0.86 mmol). An analytical amount of resin was cleaved with 50% trifluoroacetic acid in dichloroethane for 2 h at rt. The resulting solution was concentrated *in vacuo*: MS (ESI) 435 [M+H-tBu]<sup>+</sup>.

c) DMHB resin-bound ethyl 4-[[[(1S)-1-[(4-[(1,1-dimethylethyl)oxy]phenyl)methyl]-2-oxo-2-[(3S)-3-pyrrolidinylamino]ethyl]amino)carbonyl]amino]benzoate

To a mixture of 200 mg (0.192 mmol, 0.959 mmol/g) of the above dry resin **1b** in 5 mL of anhydrous 1,2-dichloroethane was added 183.4 mg (0.959 mmol) of ethyl 4-isocyanatobenzoate. After the resulting mixture was shaken at rt for 24 h, the resin was washed with DMF (3 x 10 mL), CH<sub>2</sub>Cl<sub>2</sub>/MeOH (1:1, 3 x 10 mL) and MeOH (3 x 10 mL). The resulting resin was dried in vacuum oven at 35 °C for 24 h. An analytical amount of resin was cleaved with 50% trifluoroacetic acid in

dichloroethane for 2 h at rt. The resulting solution was concentrated *in vacuo*: MS (ESI) 626 [M+H-tBu]<sup>+</sup>.

To a mixture of the above dry resin (0.192 mmol) in 6.4 mL of 1-methyl-2-pyrrolidinone was added 265 mg (1.92 mmol) of K<sub>2</sub>CO<sub>3</sub> and 0.0985 mL (0.96 mmol) of PhSH. After the resulting mixture was shaken at rt for 2 h, the resin was washed with DMF (3 x 10 mL), H<sub>2</sub>O (3 x 10 mL), DMF (3 x 10 mL), CH<sub>2</sub>Cl<sub>2</sub>/MeOH (1:1, 3 x 10 mL) and MeOH (3 x 10 mL). The resulting resin was dried in vacuum oven at 35 °C for 24 h to afford DMHB resin-bound ethyl 4-[[[(1*S*)-1-({4-[(1,1-dimethylethyl)oxy]phenyl}methyl)-2-oxo-2-[(3*S*)-3-pyrrolidinylamino]ethyl}amino)carbonyl]amino]benzoate (0.192 mmol). An analytical amount of resin was cleaved with 50% trifluoroacetic acid in dichloroethane for 2 h at rt. The resulting solution was concentrated *in vacuo*: MS (ESI) 441 [M+H-tBu]<sup>+</sup>.

d) *N*-[({4-[(ethyloxy)carbonyl]phenyl}amino)carbonyl]-*N*-{(3*S*)-1-[(4-hydroxyphenyl)methyl]-1-methyl-3-pyrrolidiniumyl}-*L*-tyrosinamide trifluoroacetate

To a mixture of the above dry resin **1c** (0.192 mmol) in 6.4 mL of 10% HOAc in anhydrous 1-methyl-2-pyrrolidinone solution was added 234 mg (1.918 mmol) of 4-hydroxybenzaldehyde and 407 mg (1.92 mmol) of sodium triacetoxyborohydride. After the resulting mixture was shaken at rt for 72 h, the resin was washed with DMF (3 x 10 mL), CH<sub>2</sub>Cl<sub>2</sub>/MeOH (1:1, 3 x 10 mL) and MeOH (3 x 10 mL). The resulting resin was dried in vacuum oven at 35 °C for 24 h. An analytical amount of resin was cleaved with 50% trifluoroacetic acid in dichloroethane for 2 h at rt. The resulting solution was concentrated *in vacuo*: MS (ESI) 547 [M+H-tBu]<sup>+</sup>.

To a mixture of the above dry resin (0.192 mmol) in 6.4 mL of anhydrous acetonitrile was added 120 μL (1.918 mmol) of iodomethane. After the mixture was shaken at rt for 16 h, the resin was washed with DMF (3 x 10 mL), CH<sub>2</sub>Cl<sub>2</sub>/MeOH (1:1, 3 x 10 mL), MeOH (3 x 10 mL) and CH<sub>2</sub>Cl<sub>2</sub> (3x10mL). The resulting resin was dried in vacuum oven at 35 °C for 24 h. The dry resin was treated with 4 mL of 50% trifluoroacetic acid in dichloroethane at rt for 2h. After

the cleavage solution was collected, the resin was treated with another 4 mL of 50% trifluoroacetic acid in dichloroethane at rt for 10min. The combined cleavage solutions were concentrated *in vacuo*. The residue was purified using a Gilson semi-preparative HPLC system with a YMC ODS-A (C-18) column 50 mm by 20 mm ID, eluting with 10% B to 90% B in 3.2 min, hold for 1 min where A = H<sub>2</sub>O (0.1% trifluoroacetic acid) and B = CH<sub>3</sub>CN (0.1% trifluoroacetic acid) pumped at 25 mL/min, to produce *N*-[({4-[(ethyloxy)carbonyl]phenyl}amino)carbonyl]-*N*-{(3*S*)-1-[(4-hydroxyphenyl)methyl]-1-methyl-3-pyrrolidiniumyl}-L-tyrosinamide trifluoroacetate (white powder, 76 mg, 57% over 10 steps): MS (ESI) 561 [M]<sup>+</sup>.

Proceeding in a similar manner, but replacing 3(*S*)-(-)-(tert-butoxycarbonyl-amino)pyrrolidine with the appropriate Boc-protected diamines and/or replacing 4-hydroxybenzaldehyde with the appropriate aldehydes, the compounds listed in Tables 1 - 12 were prepared.




Table 1

Example	R2	MS [M] <sup>+</sup>
2	4-hydroxy phenyl	561
3	4-cyano phenyl	570
4	4-fluoro phenyl	563
5	2-methoxy phenyl	575
6	2-phenylethyl	573
7	3,4-methylenedioxy phenyl	589








Table 2

Example	R <sub>2</sub>	MS [M] <sup>+</sup>
8	4-cyano phenyl	570
9	4-fluoro phenyl	563
10	3,4-dimethoxy phenyl	605
11	3,4-methylenedioxy phenyl	589
12	cyclopropyl	509
13	3-hydroxy phenyl	561
14	3-fluoro phenyl	563
15	3-cyano phenyl	570
16	4-acetyl phenyl	587
17	4-acetamido phenyl	602
18	H	469
19	4-carboxy phenyl	589
20	4-chloro phenyl	579
21	3-chloro phenyl	579



Table 3

Example	Compound	MS [M] <sup>+</sup>
22		563
23		563
24		589
25		589




Table 4

Example	R2	MS [M] <sup>+</sup>
26	4-hydroxy phenyl	561
27	4-cyano phenyl	570
28	4-fluoro phenyl	563
29	3,4-dimethoxy phenyl	605
30	3,4-methylenedioxy phenyl	589
31	cyclopropyl	509




Table 5

Example	R2	MS [M] <sup>+</sup>
32	4-hydroxy phenyl	575
33	4-cyano phenyl	584
34	4-fluoro phenyl	577
35	3,4-dimethoxy phenyl	619
36	3,4-methylenedioxy phenyl	603
37	cyclopropyl	523




Table 6

Example	R2	MS [M] <sup>+</sup>
38	4-fluoro phenyl	577
39	3,4-methylenedioxy phenyl	603
40	4-hydroxy phenyl	575
41	3-chloro phenyl	593
42	3,4-dimethoxy phenyl	619
43	3-hydroxy phenyl	575
44	4-chloro phenyl	593
45	cyclopropyl	523




Table 7

Example	R2	MS [M] <sup>+</sup>
46	4-fluoro phenyl	577
47	3,4-methylenedioxy phenyl	603
48	3-chloro phenyl	593
49	3-hydroxy phenyl	575
50	4-chloro phenyl	593




Table 8

Example	R2	MS [M] <sup>+</sup>
51	4-hydroxy phenyl	575
52	4-cyano phenyl	584
53	4-fluoro phenyl	577
54	3,4-dimethoxy phenyl	619
55	3,4-methylenedioxy phenyl	603
56	cyclopropyl	523





Table 9

Example	R2	MS [M] <sup>+</sup>
57	4-hydroxy phenyl	589
58	4-cyano phenyl	598
59	4-fluoro phenyl	591
60	3,4-dimethoxy phenyl	633
61	3,4-methylenedioxy phenyl	617
62	cyclopropyl	537



5

Table 10

Example	R2	MS [M] <sup>+</sup>
63	4-hydroxy phenyl	589
64	4-cyano phenyl	598
65	4-fluoro phenyl	591
66	3,4-dimethoxy phenyl	633
67	3,4-methylenedioxy phenyl	617
68	cyclopropyl	537




Table 11

Example	R2	MS [M] <sup>+</sup>
69	4-hydroxy phenyl	591
70	4-cyano phenyl	600
71	4-fluoro phenyl	593
72	3,4-dimethoxy phenyl	635
73	3,4-methylenedioxy phenyl	619
74	cyclopropyl	539

5




Table 12

Example	R2	MS [M] <sup>+</sup>
75	4-hydroxy phenyl	589
76	4-cyano phenyl	598
77	4-fluoro phenyl	591
78	3,4-dimethoxy phenyl	633
79	3,4-methylenedioxy phenyl	617
80	cyclopropyl	537

Proceeding in a similar manner as described in example 1, but replacing Fmoc-Try(tBu)-OH with other Fmoc protected amino acids and/or replacing 4-hydroxybenzaldehyde with the appropriate aldehydes, the compounds listed in Tables 13 - 15 were prepared.







Table 13

Example	R1	R2	MS [M] <sup>+</sup>
81	4-chloro	3,4-methylenedioxy phenyl	607
82	4-phenylcarbonyl	3,4-methylenedioxy phenyl	677
83	4-methoxy	3,4-methylenedioxy phenyl	603
84	4-fluoro	3,4-methylenedioxy phenyl	591
85	4-phenyl	3,4-methylenedioxy phenyl	649
86	4-chloro	4-fluoro phenyl	581
87	4-phenylcarbonyl	4-fluoro phenyl	651
88	4-methoxy	4-fluoro phenyl	577
89	4-fluoro	4-fluoro phenyl	565
90	4-phenyl	4-fluoro phenyl	623
91	4-methyl	3,4-methylenedioxy phenyl	587
92	4-bromo	3,4-methylenedioxy phenyl	651
93	3,4-dichloro	3,4-methylenedioxy phenyl	641
94	3-chloro	3,4-methylenedioxy phenyl	607
95	4-cyano	3,4-methylenedioxy phenyl	598
96	2-chloro	3,4-methylenedioxy phenyl	607
97	4-trifluoromethyl	3,4-methylenedioxy phenyl	641
98	3-cyano	3,4-methylenedioxy phenyl	598
99	3,4-dimethoxy	3,4-methylenedioxy phenyl	633
100	4-methyl	4-fluoro phenyl	561
101	4-bromo	4-fluoro phenyl	625
102	3,4-dichloro	4-fluoro phenyl	615
103	3-chloro	4-fluoro phenyl	581
104	4-cyano	4-fluoro phenyl	572
105	2-chloro	4-fluoro phenyl	581

106	4-trifluoromethyl	4-fluoro phenyl	615
107	3-cyano	4-fluoro phenyl	572
108	3,4-dimethoxy	4-fluoro phenyl	607
109	4-amino	3,4-methylenedioxy phenyl	588
110	4-amino	4-fluoro phenyl	562
111	4-carboxyl	4-fluoro phenyl	590

Table 14

Example	Compound	MS [M] <sup>+</sup>
112		561
113		561



5

Table 15

Example	R1	R2	MS [M] <sup>+</sup>
114	2-naphthyl	3,4-methylenedioxy phenyl	623
115	1-naphthyl	3,4-methylenedioxy phenyl	623
116	2-naphthyl	4-fluoro phenyl	597
117	1-naphthyl	4-fluoro phenyl	597

Proceeding in a similar manner as described in example 1, but replacing 4-hydroxybenzaldehyde with the appropriate aldehydes and replacing iodomethane with other alkyl halides, the compounds listed in Table 16 were prepared.

10




Table 16

Example	R2	R3	MS [M] <sup>+</sup>
118	4-fluoro phenyl	ethyl	577
119	4-fluoro phenyl	n-propyl	591
120	4-fluoro phenyl	2-propen-1-yl	589
121	4-fluoro phenyl	4-fluorobenzyl	657
122	4-cyano phenyl	ethyl	584
123	4-cyano phenyl	n-propyl	598
124	4-cyano phenyl	2-propen-1-yl	596
125	4-cyano phenyl	4-cyanobenzyl	671
126	4-chloro phenyl	ethyl	593
127	4-chloro phenyl	n-propyl	607
128	4-chloro phenyl	2-propen-1-yl	605
129	4-chloro phenyl	4-chlorobenzyl	689


## Preparation 2

5

Resin-bound secondary amines **5** were treated with alkyl dihalides to give the corresponding resin-bound quaternary ammonium salts, which were then cleaved with 50% trifluoroacetic acid in 1,2-dichloroethane to afford targeted compounds **8** (Scheme 2).

10

Scheme 2





Conditions: a) alkyl dihalides, acetonitrile, 50 °C; b) 50% trifluoroacetic acid in 1,2-dichloroethane, rt.




### Example 130

5     **Preparation of (2S)-2-({N-[(4-[(ethyloxy)carbonyl]phenyl}amino)carbonyl]-L-tyrosyl}amino)-5-azoniaspiro[4.5]decane trifluoroacetate**

To 200 mg (0.178 mmol) of resin **1c** (DMHB resin-bound ethyl 4-[[[(1S)-1-({4-[(1,1-dimethylethyl)oxy]phenyl}methyl)-2-oxo-2-[(3S)-3-pyrrolidinylamino]ethyl]amino)carbonyl]amino}benzoate) was added 5 mL (36.7 mmol) of 1,5-dibromopentane. The mixture was shaken at 50 °C for overnight. After washing with methylene chloride (5x 6 mL), the resin was dried in vacuum oven at 35 °C for 24 h. The dry resin was treated with 4 mL of 50% trifluoroacetic acid in dichloroethane at rt for 1 h. After the cleavage solution was collected, the resin was treated with another 4 mL of 50% trifluoroacetic acid in dichloroethane at rt for 30 min. The combined cleavage solutions were concentrated *in vacuo*. The residue was purified using a Gilson semi-preparative HPLC system with a YMC ODS-A (C-18) column 50 mm by 20 mm ID, eluting with 10% B to 90% B in 3.2 min, hold for 1 min where A = H<sub>2</sub>O (0.1% trifluoroacetic acid) and B = CH<sub>3</sub>CN (0.1% trifluoroacetic acid) pumped at 25 mL/min, to produce (2S)-2-({N-[(4-[(ethyloxy)carbonyl]phenyl}amino)carbonyl]-L-tyrosyl}amino)-5-azoniaspiro[4.5]decane trifluoroacetate as a white powder (45 mg, 49% over 9 steps): MS (ESI) 509 [M]<sup>+</sup>.

25     Proceeding in a similar manner as described in example 130, but replacing 1,5-dibromopentane with the appropriate alkyl dihalides, the compounds listed in Table 17 were prepared.


Table 17

Example	Compound	MS [M] <sup>+</sup>
131		543
132		495
133		523

### Preparation 3

5 Resin-bound amines **3** were prepared in the same way as described in  
 preparation 1. Reactions of **3** with Fmoc-Try(tBu)-OH, followed by removal of the  
 Fmoc protecting group, provided resin-bound intermediates **9**. A variety of 4-  
 substituted anilines were reacted with 1,1'-carbonyldiimidazole to give the  
 intermediates which in turn were reacted with **9** to afford the corresponding resin-  
 10 bound ureas. The ureas were subsequently treated with potassium carbonate  
 and thiophenol to give secondary amines **10**. Reductive amination of **10** with  
 appropriate aldehydes produced resin-bound tertiary amines **11**. Amines **11** were  
 then reacted with alkyl halides (R3Z) to give the corresponding resin-bound  
 quaternary ammonium salts, which were treated with 50% trifluoroacetic acid in  
 15 1,2-dichloroethane to afford targeted compounds **12** (Scheme 3).

Scheme 3



- 5 Conditions: a) Fmoc-Try(tBu)-OH, 1,3-diisopropylcarbodiimide, 1-hydroxy-7-azabenzotriazole, 1-methyl-2-pyrrolidinone, rt; b) 20% piperidine in 1-methyl-2-pyrrolidinone, rt; c) (R<sub>1</sub>)PhNH<sub>2</sub>, 1,1'-carbonyldiimidazole, diisopropylethylamine, 1,2-dichloroethane, rt; d) K<sub>2</sub>CO<sub>3</sub>, PhSH, 1-methyl-2-pyrrolidinone, rt; e) R<sub>2</sub>CHO,

Na(OAc)<sub>3</sub>BH, 10% acetic acid in 1-methyl-2-pyrrolidinone, rt; f) R3Z, acetonitrile, rt; g) 50% trifluoroacetic acid in 1,2-dichloroethane, rt.

### Example 134

#### Preparation of *N*-{(3*S*)-1-[(3-cyanophenyl)methyl]-1-methyl-3-pyrrolidiniumyl}-*N*-[4-[(cyclopropylamino)carbonyl]phenyl]amino)carbonyl]-L-tyrosinamide trifluoroacetate

To a mixture of 35 mg (0.2 mmol) of 4-amino-cyclopropylbenzamide in 0.5 mL of anhydrous 1,2-dichloroethane was added 32 mg (0.2 mmol) of 1,1'-carbonyldiimidazole, followed by an addition of 35  $\mu$ L (0.2 mmol) of diisopropylethylamine. After the resulting mixture was shaken at rt for 0.5 h, it was pipetted to a mixture of 50 mg (0.04 mmol, 0.8 mmol/g) of example **1b** (DMHB resin bound *O*-(1,1-dimethylethyl)-*N*-{(3*S*)-1-[(2-nitrophenyl)sulfonyl]-3-pyrrolidinyl]-L-tyrosinamide) in 1,2-dichloroethane (0.5 mL). After the resulting mixture was shaken at rt for 24 h, the resin was washed with CH<sub>2</sub>Cl<sub>2</sub> (3 x 1 mL), CH<sub>2</sub>Cl<sub>2</sub>/MeOH (1:1, 3 x 1 mL), MeOH (3 x 1 mL) and CH<sub>2</sub>Cl<sub>2</sub> (3 x 10 mL). The resulting resin was dried in vacuum oven at 35 °C for 24 h. An analytical amount of resin was cleaved with 50% trifluoroacetic acid in dichloroethane for 2 h at rt. The resulting solution was concentrated *in vacuo*: MS (ESI) 637 [M+H-tBu]<sup>+</sup>.

To a mixture of the above dry resin (0.04 mmol) in 1 mL of 1-methyl-2-pyrrolidinone was added 41.5 mg (0.3 mmol) of K<sub>2</sub>CO<sub>3</sub> and 15.4  $\mu$ L (0.15 mmol) of PhSH. After the resulting mixture was shaken at rt for 2 h, the resin was washed with DMF (3 x 10 mL), H<sub>2</sub>O (3 x 10 mL), DMF (3 x 10 mL), CH<sub>2</sub>Cl<sub>2</sub>/MeOH (1:1, 3 x 10 mL) and MeOH (3 x 10 mL). The resulting resin was dried in vacuum oven at 35 °C for 24 h. An analytical amount of resin was cleaved with 50% trifluoroacetic acid in dichloroethane for 2 h at rt. The resulting solution was concentrated *in vacuo*: MS (ESI) 452 [M+H-tBu]<sup>+</sup>.

To a mixture of the above dry resin (0.04 mmol) in 1 mL of 10% HOAc in anhydrous 1-methyl-2-pyrrolidinone solution was added 79 mg (0.6 mmol) of 3-cyanobenzaldehyde and 127.2 mg (0.6 mmol) of sodium triacetoxyborohydride. After the resulting mixture was shaken at rt for 24 h, the resin was washed with

DMF (3 x 10 mL), CH<sub>2</sub>Cl<sub>2</sub>/MeOH (1:1, 3 x 10 mL) and MeOH (3 x 10 mL). The resulting resin was dried in vacuum oven at 35 °C for 24 h. An analytical amount of resin was cleaved with 50% trifluoroacetic acid in dichloroethane for 2 h at rt. The resulting solution was concentrated *in vacuo*: MS (ESI) 567 [M+H-tBu]<sup>+</sup>.

5 To a mixture of the above dry resin (0.04 mmol) in 1 mL of anhydrous acetonitrile was added 18.7 µL 0.3 mmol) of iodomethane. After the mixture was shaken at rt for 16 h, the resin was washed with DMF (3 x 10 mL), CH<sub>2</sub>Cl<sub>2</sub>/MeOH (1:1, 3 x 10 mL), MeOH (3 x 10 mL) and CH<sub>2</sub>Cl<sub>2</sub> (3x10mL). The resulting resin was dried in vacuum oven at 35 °C for 24 h. The dry resin was treated with 2 mL  
10 of 50% trifluoroacetic acid in dichloroethane at rt for 2h. After the cleavage solution was collected, the resin was treated with another 2 mL of 50% trifluoroacetic acid in dichloroethane at rt for 10min. The combined cleavage solutions were concentrated *in vacuo*. The residue was purified using a Gilson semi-preparative HPLC system with a YMC ODS-A (C-18) column 50 mm by 20  
15 mm ID, eluting with 10% B to 90% B in 3.2 min, hold for 1 min where A = H<sub>2</sub>O (0.1% trifluoroacetic acid) and B = CH<sub>3</sub>CN (0.1% trifluoroacetic acid) pumped at 25 mL/min, to produce *N*-{(3*S*)-1-[(3-cyanophenyl)methyl]-1-methyl-3-pyrrolidiniumyl}-*N*-[({4-[(cyclopropylamino)carbonyl]phenyl}amino)carbonyl]-*L*-tyrosinamide trifluoroacetate (white powder, 16 mg, 57% over 10 steps): MS (ESI)  
20 581 [M]<sup>+</sup>.

Proceeding in a similar manner as described in example 134, but replacing 4-amino-cyclopropylbenzamide with the appropriate anilines, and/or replacing 3(*S*)-(-)-(tert-butoxycarbonyl-amino)pyrrolidine with 3(*S*)-(-)-(tert-butoxycarbonyl-amino)piperidine, and/or replacing 3-cyanobenzaldehyde with the appropriate  
25 aldehydes, the compounds listed in Tables 18 - 23 were prepared.




Table 18

Example	R1	R2	MS [M] <sup>+</sup>
135	cyclopropyl	4-hydroxy phenyl	572
136	cyclopropyl	3-chloro phenyl	591
137	cyclopropyl	4-chloro phenyl	591
138	cyclopropyl	3,4-dimethoxy phenyl	616
139	cyclopropyl	3,4-methylenedioxy phenyl	600
140	cyclopropyl	4-fluoro phenyl	574
141	1-methylethyl	3-cyano phenyl	583
142	1-methylethyl	3-chloro phenyl	592
143	1-methylethyl	4-chloro phenyl	592
144	1-methylethyl	3,4-dimethoxy phenyl	618
145	1-methylethyl	3,4-methylenedioxy phenyl	602
146	1-methylethyl	4-fluoro phenyl	576
147	1-methylethyl	4-hydroxy phenyl	575
148	1-methylethyl	3-hydroxy phenyl	575






Table 19

Example	R1	R2	MS [M] <sup>+</sup>
149	(4-methylphenyl)oxy	3,4-methylenedioxy phenyl	623
150	(4-chlorophenyl)oxy	3,4-methylenedioxy phenyl	643
151	(4-methylphenyl)oxy	4-fluoro phenyl	597
152	(4-chlorophenyl)oxy	4-fluoro phenyl	617
153	acetyl	3,4-methylenedioxy phenyl	559
154	propanoyl	3,4-methylenedioxy phenyl	573
155	butanoyl	3,4-methylenedioxy phenyl	587
156	ethyloxy	3,4-methylenedioxy phenyl	561
157	cyano	3,4-methylenedioxy phenyl	542

158	acetyl	4-fluoro phenyl	533
159	propanoyl	4-fluoro phenyl	547
160	butanoyl	4-fluoro phenyl	561
161	ethyloxy	4-fluoro phenyl	535
162	cyano	4-fluoro phenyl	516

Table 20

Example	Compound	MS [M] <sup>+</sup>
163		589



5

Table 21

Example	R1	R2	MS [M] <sup>+</sup>
164	methyl	4-fluoro phenyl	549
165	methyl	3,4-methylenedioxy phenyl	575
166	1-methylethyl	4-fluoro phenyl	577
167	1-methylethyl	3,4-methylenedioxy phenyl	603
168	1-methylethyl	4-hydroxy phenyl	575
169	1-methylethyl	3-chloro phenyl	593
170	1-methylethyl	3,4-dimethoxy phenyl	619
171	1-methylethyl	3-hydroxy phenyl	575
172	1-methylethyl	4-chloro phenyl	593
173	1-methylethyl	cyclopropyl	523
174	n-propyl	4-fluoro phenyl	577
175	n-propyl	3,4-methylenedioxy phenyl	603





Table 22

Example	R2	MS [M] <sup>+</sup>
176	4-fluoro phenyl	590
177	3,4-methylenedioxy phenyl	616
178	4-hydroxy phenyl	588
179	3-chloro phenyl	606
180	3,4-dimethoxy phenyl	632
181	3-hydroxy phenyl	588



5

Table 23

Example	R1	R2	MS [M] <sup>+</sup>
182	methyl	4-fluoro phenyl	563
183	methyl	3,4-methylenedioxy phenyl	589
184	1-methylethyl	4-fluoro phenyl	591
185	1-methylethyl	3,4-methylenedioxy phenyl	617
186	1-methylethyl	4-hydroxy phenyl	589
187	1-methylethyl	3-chloro phenyl	607
188	1-methylethyl	3,4-dimethoxy phenyl	633
189	1-methylethyl	3-hydroxy phenyl	589
190	1-methylethyl	4-chloro phenyl	607
191	1-methylethyl	cyclopropyl	537
192	n-propyl	4-fluoro phenyl	591
193	n-propyl	3,4-methylenedioxy phenyl	617



Proceeding in a similar manner as described in example 134, but replacing 4-amino-cyclopropylbenzamide with the appropriate 1,2,4-oxadiazol anilines, and/or replacing 3(*S*)-(-)-(tert-butoxycarbonyl-amino)pyrrolidine with 3(*S*)-(-)-(tert-butoxycarbonyl-amino)piperidine and/or replacing 3-cyanobenzaldehyde with the appropriate aldehydes, the compounds listed in Tables 24 - 31 were prepared.

1,2,4-Oxadiazol anilines were prepared by reduction of nitrophenyl-1,2,4-oxadiazoles (Lin, Lang, *J. Heterocycl. Chem.* 1980, 17, 1273), which were prepared by cyclizing amidoximes obtained by reaction of nitriles with hydroxylamine (Diana, Volkots, et al. *J. Med.Chem.*1994, 37, 2421).




Table 24

Example	R2	MS [M] <sup>+</sup>
194	4-fluoro phenyl	573
195	3,4-methylenedioxy phenyl	599
196	3-hydroxy phenyl	571




Table 25

Example	R2	MS [M] <sup>+</sup>
197	4-fluoro phenyl	587
198	3,4-methylenedioxy phenyl	613
199	3-hydroxy phenyl	585




Table 26

Example	R2	MS [M] <sup>+</sup>
200	4-fluoro phenyl	603
201	3,4-methylenedioxy phenyl	627
202	3-hydroxy phenyl	599




Table 27

Example	R2	MS [M] <sup>+</sup>
203	4-fluoro phenyl	573
204	3,4-methylenedioxy phenyl	599
205	3-hydroxy phenyl	571




Table 28

Example	R2	MS [M] <sup>+</sup>
206	4-fluoro phenyl	587
207	3,4-methylenedioxy phenyl	613
208	3,4-dimethoxy phenyl	629
209	3-hydroxy phenyl	585





Table 29

Example	R2	MS [M] <sup>+</sup>
210	4-fluoro phenyl	601
211	3,4-methylenedioxy phenyl	627
212	3,4-dimethoxy phenyl	643
213	3-hydroxy phenyl	599



5

Table 30Example	R2	MS [M] <sup>+</sup>
214	4-fluoro phenyl	615
215	3,4-methylenedioxy phenyl	641
216	3,4-dimethoxy phenyl	657
217	3-hydroxy phenyl	613




Table 31

Example	R2	MS [M] <sup>+</sup>
218	4-fluoro phenyl	587
219	3,4-methylenedioxy phenyl	613
220	3,4-dimethoxy phenyl	629
221	3-hydroxy phenyl	585

Proceeding in a similar manner as described in example 134, but replacing 4-amino-cyclopropylbenzamide with the appropriate anilines, and/or replacing 3(*S*)-(-)-(tert-butoxycarbonyl-amino)pyrrolidine with 3(*S*)-(-)-(tert-butoxycarbonyl-amino)piperidine and/or replacing 3-cyanobenzaldehyde with the appropriate aldehydes, and replacing iodomethane with appropriate halides, the compounds listed in Tables 32 - 34 were prepared.




Table 32

Example	R1	R2	MS [M] <sup>+</sup>
222	3-hydroxyphenyl	n-propyl	617
223	3,4-methylenedioxyphenyl	n-propyl	645
224	3,4-dimethoxyphenyl	n-propyl	661
225	cyclopropyl	n-propyl	565
226	3-hydroxyphenyl	2-propen-1-yl	615
227	3,4-methylenedioxyphenyl	2-propen-1-yl	643
228	3,4-methoxyphenyl	2-propen-1-yl	659
229	cyclopropyl	2-propen-1-yl	563
230	cyclopropyl	cyclopropylmethyl	577
231	4-hydroxyphenyl	n-propyl	617

10




Table 33

Example	R1	R2	MS [M] <sup>+</sup>
232	3-hydroxyphenyl	n-propyl	616
233	3,4-methylenedioxyphenyl	n-propyl	644

234	3,4-methoxyphenyl	n-propyl	660
235	cyclopropyl	n-propyl	564
236	3-hydroxyphenyl	2-propen-1-yl	614
237	3,4-methylenedioxyphenyl	2-propen-1-yl	642
238	3,4-methoxyphenyl	2-propen-1-yl	658
239	cyclopropyl	2-propen-1-yl	562
240	cyclopropyl	cyclopropylmethyl	576

Table 34


Example	Compound	MS [M] <sup>+</sup>
241		602
242		603
243		599
244		599

#### Preparation 4

5

Resin-bound secondary amines **10** were treated with alkyl dihalides to give the corresponding resin-bound quaternary ammonium salts, which were then cleaved with 50% trifluoroacetic acid in 1,2-dichloroethane to afford targeted compounds **13** (Scheme 4).

Scheme 4



Conditions: a) alkyl dihalides, acetonitrile, 75 °C; b) 50% trifluoroacetic acid in  
 5 1,2-dichloroethane, rt.


### Example 245

#### Preparation of (2S)-2-[(N-[(4-[(1-methylethyl)oxy]carbonyl]phenyl) amino]carbonyl]-L-tyrosyl)amino]-6-azoniaspiro[5.6]dodecane trifluoroacetate

DMHB resin-bound 1-methylethyl 4-[(1S)-1-({4-[(1,1-dimethylethyl)oxy]phenyl}methyl)-2-oxo-2-[(3S)-3-piperidinylamino]ethyl)amino]carbonyl]amino]benzoate was prepared in the same way as described in example 134. To 80 mg (0.36mmol/g, 0.029 mmol) of this resin in acetonitrile (6.4 mL) was added (0.488mL, 3.2 mmol) of 1,6-dibromohexane. The mixture was shaken at 75 °C for overnight. After washing with methylene chloride (5x 2 mL), the resin was dried in vacuum oven at 35 °C for 24 h. The dry resin was treated with 2 mL of 50% trifluoroacetic acid in 1,2-dichloroethane at rt for 1 h. After the cleavage solution was collected, the resin was treated with another 2 mL of 50% trifluoroacetic acid in 1,2-dichloroethane at rt for 30 min. The combined cleavage solutions were concentrated *in vacuo*. The residue was purified using a Gilson semi-preparative HPLC system with a YMC ODS-A (C-18) column 50 mm by 20 mm ID, eluting with 10% B to 90% B in 3.2 min, hold for 1 min where A = H<sub>2</sub>O (0.1% trifluoroacetic acid) and B = CH<sub>3</sub>CN (0.1% trifluoroacetic acid) pumped at 25 mL/min, to produce (2S)-2-[(N-[(4-[(1-methylethyl)oxy]carbonyl]phenyl) amino]carbonyl]-L-tyrosyl)amino]-6-azoniaspiro[5.6]dodecane trifluoroacetate as a white powder (6.2 mg, 22% over 9 steps): MS (ESI) 551 [M]<sup>+</sup>.

Proceeding in a similar manner as described in example 245, the compound listed in Table 35 was prepared.

Table 35


Example	Compound	MS [M] <sup>+</sup>
246		550

5

### Preparation 5

Using the methodology described above, thiophene ester and amide antagonist compounds were prepared. 5-Nitro-2-thiophenecarboxylic acid was treated with oxalyl chloride to form acid chloride, which reacted with a series of cycloalkyl alcohols and amines to provide corresponding esters and amides **14**. The nitro group in **14** was converted to amine by hydrogenation via 10% palladium on carbon. The amines **15** were coupled with resin-bound intermediate **9** to afford the corresponding resin-bound ureas **16**. The ureas were subsequently treated with benzenethiolate to give the secondary amines, which underwent reductive amination with appropriate aldehydes to produce resin-bound tertiary amines **17**. Amines **17** were then treated with alkyl halides to form the corresponding quaternary ammonium salts. The resin was then cleaved by 50% trifluoroacetic acid in dichloromethane to afford targeted compounds **18** (Scheme 5).

Scheme 5



Conditions: a) oxalyl chloride, R<sub>1</sub>OH or R<sub>1</sub>NH<sub>2</sub>, rt b) 10% palladium on carbon, rt  
 c) 4-nitrobenzene chloroformate, diisopropylethylamine, N,N-dimethyl formamide,  
 5 dichloromethane, rt; d) K<sub>2</sub>CO<sub>3</sub>, PhSH, 1-methyl-2-pyrrolidinone, rt; e) R<sub>2</sub>CHO,  
 Na(OAc)<sub>3</sub>BH, 10% acetic acid in 1-methyl-2-pyrrolidinone, rt; f) R<sub>3</sub>Z, acetonitrile,  
 rt; g) 50% trifluoroacetic acid in dichloromethane, rt.

### Example 247

- 10 Preparation of *N*-[(3*S*)-1-[(3-hydroxyphenyl)methyl]-1-methyl-3-piperidiniumyl]-*N*-[({5-[(cyclohexyloxy)carbonyl]-2-thienyl}amino)carbonyl]-*L*-tyrosinamide trifluoroacetate  
GSK507470A WF205097-005A2



5-Nitro-2-thiophenecarboxylic acid (2.8 g, 16 mmol) was suspended in methylene chloride (50 mL). Oxalyl chloride in methylene chloride (2.0 M, 32.3 mL) was added at room temperature followed by one drop of dimethyl formamide (0.1 mL). The reaction mixture was stirred at RT for 1 hr and concentrated.

5 Methylene chloride (100 mL) was added, concentrated again and redissolved in methylene chloride (60 mL). N, N'-Dimethylaminopyridine (652 mg, 5.33 mmol), triethyl amine (4.47 mL, 32 mmol) and cyclohexanol (2.54 mL, 24 mmol) were added to reaction mixture and stirred at room temperature overnight. The reaction mixture was filtered through a pad of silica gel (250 g), eluting with methylene chloride. Cyclohexyl 5-nitro-2-thiophenecarboxylate was obtained after  
10 concentration. LCMS (ESI) 256 [M+H]<sup>+</sup>.

To cyclohexyl 5-nitro-2-thiophenecarboxylate in ethyl alcohol (50 mL) was added palladium on carbon (10%, 2 g). The reaction mixture was hydrogenated at 15 psi overnight. Cyclohexyl 5-amino-2-thiophenecarboxylate (4 g, 95%) was  
15 obtained after filtration and concentration. LCMS (ESI) 226.2 [M+H]<sup>+</sup>.

To a mixture of 70 mg (0.31 mmol) cyclohexyl 5-amino-2-thiophenecarboxylate in 5 mL of anhydrous dichloromethane was added 70 mg (0.35 mmol) 4-nitrobenzylchloroformate. The reaction mixture was stirred at room temperature for half an hour and concentrated. Diisopropylethylamine (0.2 mL, 1.14 mmol), DMHB resin bound O-(1,1-dimethylethyl)-N-[(3S)-1-[(2-nitrophenyl)sulfonyl]-3-pyrrolidinyl]-L-tyrosinamide **9** and dimethyl formamide (10 mL) were added to reaction mixture and shaken overnight. The resin was washed with CH<sub>2</sub>Cl<sub>2</sub> (3 x 1 mL), CH<sub>2</sub>Cl<sub>2</sub>/MeOH (1:1, 3 x 1 mL), MeOH (3 x 1 mL) and CH<sub>2</sub>Cl<sub>2</sub> (3 x 10 mL). The resulting resin was dried in vacuum oven at 35 °C for 24  
25 h. To a mixture of the above dry resin (0.04 mmol) in 1 mL of 1-methyl-2-pyrrolidinone was added 41.5 mg (0.3 mmol) of K<sub>2</sub>CO<sub>3</sub> and 15.4 µL (0.15 mmol) of PhSH. After the resulting mixture was shaken at rt for 2 h, the resin was washed with DMF (3 x 10 mL), H<sub>2</sub>O (3 x 10 mL), DMF (3 x 10 mL), CH<sub>2</sub>Cl<sub>2</sub>/MeOH (1:1, 3 x 10 mL) and MeOH (3 x 10 mL). The resulting resin was  
30 dried in vacuum oven at 35 °C for 24 h. An analytical amount of resin was

cleaved with 50% trifluoroacetic acid in dichloroethane for 2 h at rt. The resulting solution was concentrated *in vacuo*: MS (ESI) 515 [M+H-tBu]<sup>+</sup>.

To a mixture of the above dry resin (0.04 mmol) in 1 mL of 10% HOAc in anhydrous 1-methyl-2-pyrrolidinone solution was added 74 mg (0.6 mmol) of 3-hydroxybenzaldehyde and 127.2 mg (0.6 mmol) of sodium triacetoxyborohydride. After the resulting mixture was shaken at rt for 24 h, the resin was washed with DMF (3 x 10 mL), CH<sub>2</sub>Cl<sub>2</sub>/MeOH (1:1, 3 x 10 mL) and MeOH (3 x 10 mL). The resulting resin was dried in vacuum oven at 35 °C for 24 h. To a mixture of the above dry resin (0.04 mmol) in 1 mL of anhydrous acetonitrile was added 18.7 μL (0.3 mmol) of iodomethane. After the mixture was shaken at rt for 16 h, the resin was washed with DMF (3 x 10 mL), CH<sub>2</sub>Cl<sub>2</sub>/MeOH (1:1, 3 x 10 mL), MeOH (3 x 10 mL) and CH<sub>2</sub>Cl<sub>2</sub> (3x10mL). The resulting resin was dried in vacuum oven at 35 °C for 24 h. The dry resin was treated with 2 mL of 50% trifluoroacetic acid in dichloromethane at rt for 2h. After the cleavage solution was collected, the resin was treated with another 2 mL of 50% trifluoroacetic acid in dichloromethane at rt for 10min. The combined cleavage solutions were concentrated *in vacuo*. The residue was purified using a Gilson semi-preparative HPLC system with a YMC ODS-A (C-18) column 50 mm by 20 mm ID, eluting with 10% B to 90% B in 3.2 min, hold for 1 min where A = H<sub>2</sub>O (0.1% trifluoroacetic acid) and B = CH<sub>3</sub>CN (0.1% trifluoroacetic acid) pumped at 25 mL/min, to produce *N*-{(3*S*)-1-[(4-chlorophenyl)methyl]-1-methyl-3-piperidiniumyl}-*N*-[({5-[(cyclohexyloxy)carbonyl]-2-thienyl}amino)carbonyl]-L-tyrosinamide trifluoroacetate (white powder, 9 mg, 35% over 5 steps): MS (ESI) 635.8 [M]<sup>+</sup>.

Proceeding in a similar manner as described in example 247, but replacing cyclohexyl alcohol with the appropriate alkyl alcohols and amines, and/or replacing 3-hydroxybenzaldehyde with the appropriate aldehydes, the compounds listed in Tables 36- 51 were prepared.




Table 36

Example	R'	MS [M] <sup>+</sup>
247	3-hydroxyl	636
248	3-chloro	653
249	4-chloro	653




Table 37

Example	R'	MS [M] <sup>+</sup>
250	3-hydroxyl	621
251	3-chloro	639
252	4-chloro	639




Table 38

Example	R'	MS [M] <sup>+</sup>
253	3-hydroxyl	650
254	3-chloro	667





Table 39


Example	R'	MS [M] <sup>+</sup>
255	3-hydroxyl	635
256	3-chloro	653
257	4-chloro	653



5

Table 40


Example	R'	MS [M] <sup>+</sup>
258	3-hydroxyl	667
259	3-chloro	685
260	4-chloro	685



10

Table 41

Example	R'	MS [M] <sup>+</sup>
261	3-hydroxyl	582
262	3-chloro	599
263	4-chloro	599



5

Table 42

Example	R'	MS [M] <sup>+</sup>
264	3-hydroxyl	595
265	3-chloro	613
266	4-chloro	613




Table 43

Example	R'	MS [M] <sup>+</sup>
267	3-hydroxyl	607
268	3-chloro	625
269	4-chloro	625

10




Table 44

Example	R'	MS [M] <sup>+</sup>
270	3-hydroxyl	606




Table 45

Example	R'	MS [M] <sup>+</sup>
271	3-hydroxyl	649
272	3-chloro	667
273	4-chloro	667




Table 46

Example	R'	MS [M] <sup>+</sup>
274	3-hydroxyl	643
275	3-chloro	661
276	4-chloro	661




Table 47

Example	R'	MS [M] <sup>+</sup>
277	3-hydroxyl	595
278	3-chloro	613
279	4-chloro	613




Table 48

Example	R'	MS [M] <sup>+</sup>
280	3-hydroxyl	582




Table 49

Example	R'	MS [M] <sup>+</sup>
281	3-hydroxyl	620
282	3-chloro	638
283	4-chloro	638




Table 50

Example	R'	MS [M] <sup>+</sup>
284	3-hydroxyl	648
285	3-chloro	665
286	4-chloro	666

5




Table 51


Example	R'	MS [M] <sup>+</sup>
287	3-hydroxyl	648
288	3-chloro	666

10

### Preparation 6

Resin-bound tertiary amine **17** was treated with alkyl halides to give the corresponding symmetric resin-bound quaternary ammonium salts, which was then cleaved with 50% trifluoroacetic acid in dichloromethane to afford targeted compounds **19** (Scheme 6).





Scheme 6

- 5 Conditions: a) alkyl halides, acetonitrile, 50 °C; b) 50% trifluoroacetic acid in dichloromethane, rt.

### Example 289

#### Preparation of *N*-{[(3*S*)-1,1-bis[(3-chlorophenyl)methyl]-3-piperidiniumyl]-*N*-[(5-[(ethyloxy)carbonyl]-2-thienyl)amino]carbonyl]-L-tyrosinamide trifluoroacetate

DMHB resin-bound ethyl 5-[[[(1*S*)-2-[(3*S*)-1-[(3-chlorophenyl)methyl]-3-piperidiny]amino)-1-[(4-hydroxyphenyl)methyl]-2-oxoethyl]amino]carbonyl]amino)-2-thiophenecarboxylate was prepared in the same way as described in example 247. To 60 mg (0.048 mmol) of this resin in acetonitrile (6.4 mL) was added (656mg, 3.2 mmol) of 3-chlorobenzyl bromide. The mixture was shaken at 50 °C overnight. After washing with methylene chloride (5x 2 mL), the resin was dried in vacuum oven at 35 °C for 24 h. The dry resin was treated with 2 mL of 50% trifluoroacetic acid in dichloromethane at rt for 1 h. After the cleavage solution was collected, the resin was treated with another 2 mL of 50% trifluoroacetic acid in dichloromethane at rt for 30 min. The combined cleavage solutions were concentrated *in vacuo*. The residue was purified using a Gilson semi-preparative HPLC system with a YMC ODS-A (C-18) column 50 mm by 20 mm ID, eluting with

10% B to 90% B in 3.2 min, hold for 1 min where A = H<sub>2</sub>O (0.1% trifluoroacetic acid) and B = CH<sub>3</sub>CN (0.1% trifluoroacetic acid) pumped at 25 mL/min, to produce (2*S*)-2-[(*N*-{[(4-{[(1-methylethyl)oxy]carbonyl}phenyl) amino]carbonyl}-L-tyrosyl)amino]-6-azoniaspiro[5.6]dodecane trifluoroacetate as a white powder (5.7 mg, 17% over 9 steps): MS (ESI) 709 [M]<sup>+</sup>.




Table 52

Example	R'	MS [M] <sup>+</sup>
289	3-chloro	709

## BIOLOGICAL EXAMPLES

The inhibitory effects of compounds at the M<sub>3</sub> mAChR of the present invention are determined by the following *in vitro* and *in vivo* assays:

### Analysis of Inhibition of Receptor Activation by Calcium Mobilization:

### 1) 384-well FLIPR assay

A CHO (chinese hamster ovary) cell line stably expressing the human M3 muscarinic acetylcholine receptor is grown in DMEM plus 10% FBS, 2 mM Glutamine and 200 ug/ml G418. Cells are detached for maintenance and for plating in preparation for assays using either enzymatic or ion chelation methods. The day before the FLIPR (fluorometric imaging plate reader) assay, cells are detached, resuspended, counted, and plated to give 20,000 cells per 384 well in a

50 ul volume. The assay plates are black clear bottom plates, Becton Dickinson catalog number 35 3962. After overnight incubation of plated cells at 37 degrees C in a tissue culture incubator, the assay is run the next day. To run the assay, media are aspirated, and cells are washed with 1x assay buffer (145mM NaCl, 2.5mM KCl, 10mM glucose, 10mM HEPES, 1.2 mM MgCl<sub>2</sub>, 2.5mM CaCl<sub>2</sub>, 2.5mM probenecid (pH 7.4.) Cells are then incubated with 50ul of Fluo-3 dye (4uM in assay buffer) for 60 – 90 minutes at 37 degrees C. The calcium- sensitive dye allows cells to exhibit an increase in fluorescence upon response to ligand via release of calcium from intracellular calcium stores. Cells are washed with assay buffer, and then resuspended in 50ul assay buffer prior to use for experiments. Test compounds and antagonists are added in 25 ul volume, and plates are incubated at 37 degrees C for 5 -30 minutes. A second addition is then made to each well, this time with the agonist challenge, acetylcholine. It is added in 25 ul volume on the FLIPR instrument. Calcium responses are measured by changes in fluorescent units. To measure the activity of inhibitors / antagonists, acetylcholine ligand is added at an EC<sub>80</sub> concentration, and the antagonist IC<sub>50</sub> can then be determined using dose response dilution curves. The control antagonist used with M3 is atropine.

## 2) 96-well FLIPR assay

Stimulation of mAChRs expressed on CHO cells were analyzed by monitoring receptor-activated calcium mobilization as previously described . CHO cells stably expressing M<sub>3</sub> mAChRs were plated in 96 well black wall/clear bottom plates. After 18 to 24 hours, media was aspirated and replaced with 100 µl of load media (EMEM with Earl's salts, 0.1% RIA-grade BSA (Sigma, St. Louis MO), and 4 µM Fluo-3-acetoxymethyl ester fluorescent indicator dye (Fluo-3 AM, Molecular Probes, Eugene, OR) and incubated 1 hr at 37° C. The dye-containing media was then aspirated, replaced with fresh media (without Fluo-3 AM), and cells were incubated for 10 minutes at 37° C. Cells were then washed 3 times and incubated for 10 minutes at 37° C in 100 µl of assay buffer (0.1% gelatin (Sigma), 120 mM NaCl, 4.6 mM KCl, 1 mM KH<sub>2</sub> PO<sub>4</sub>, 25 mM NaH CO<sub>3</sub>, 1.0 mM CaCl<sub>2</sub>, 1.1 mM MgCl<sub>2</sub>, 11 mM glucose, 20mM HEPES (pH 7.4)). 50 µl of compound (1x10<sup>-11</sup> –

1x10<sup>-5</sup> M final in the assay) was added and the plates were incubated for 10 min. at 37° C. Plates were then placed into a fluorescent light intensity plate reader (FLIPR, Molecular Probes) where the dye loaded cells were exposed to excitation light (488 nm) from a 6 watt argon laser. Cells were activated by adding 50 µl of acetylcholine (0.1-10 nM final), prepared in buffer containing 0.1% BSA, at a rate of 50 µl/sec. Calcium mobilization, monitored as change in cytosolic calcium concentration, was measured as change in 566 nm emission intensity. The change in emission intensity is directly related to cytosolic calcium levels. The emitted fluorescence from all 96 wells is measured simultaneously using a cooled CCD camera. Data points are collected every second. This data was then plotting and analyzed using GraphPad PRISM software.

#### **Methacholine-induced bronchoconstriction**

Airway responsiveness to methacholine was determined in awake, unrestrained BalbC mice (*n* = 6 each group). Barometric plethysmography was used to measure enhanced pause (Penh), a unitless measure that has been shown to correlate with the changes in airway resistance that occur during bronchial challenge with methacholine. Mice were pretreated with 50 µl of compound (0.003-10 µg/mouse) in 50 µl of vehicle (10% DMSO) intranasally, and were then placed in the plethysmography chamber. Once in the chamber, the mice were allowed to equilibrate for 10 min before taking a baseline Penh measurement for 5 minutes. Mice were then challenged with an aerosol of methacholine (10 mg/ml) for 2 minutes. Penh was recorded continuously for 7 min starting at the inception of the methacholine aerosol, and continuing for 5 minutes afterward. Data for each mouse were analyzed and plotted by using GraphPad PRISM software.

The present compounds are useful for treating a variety of indications, including but not limited to respiratory-tract disorders such as chronic obstructive lung disease, chronic bronchitis, asthma, chronic respiratory obstruction, pulmonary fibrosis, pulmonary emphysema, and allergic rhinitis.

### **FORMULATION-ADMINISTRATION**

Accordingly, the present invention further provides a pharmaceutical formulation comprising a compound of formula (I), or a pharmaceutically acceptable salt, solvate, or physiologically functional derivative (e.g., salts and esters) thereof, and a pharmaceutically acceptable carrier or excipient, and optionally one or more other therapeutic ingredients.

Hereinafter, the term "active ingredient" means a compound of formula (I), or a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof.

Compounds of formula (I) will be administered via inhalation via the mouth or nose.

Dry powder compositions for topical delivery to the lung by inhalation may, for example, be presented in capsules and cartridges of for example gelatine, or blisters of for example laminated aluminium foil, for use in an inhaler or insufflator. Powder blend formulations generally contain a powder mix for inhalation of the compound of the invention and a suitable powder base (carrier/diluent/excipient substance) such as mono-, di- or poly-saccharides (e.g., lactose or starch), organic or inorganic salts (e.g., calcium chloride, calcium phosphate or sodium chloride), polyalcohols (e.g., mannitol), or mixtures thereof, alternatively with one or more additional materials, such additives included in the blend formulation to improve chemical and/or physical stability or performance of the formulation, as discussed below, or mixtures thereof. Use of lactose is preferred. Each capsule or cartridge may generally contain between 20µg-10mg of the compound of formula (I) optionally in combination with another therapeutically active ingredient. Alternatively, the compound of the invention may be presented without excipients, or may be formed into particles comprising the compound, optionally other therapeutically active materials, and excipient materials, such as by co-precipitation or coating.

Suitably, the medicament dispenser is of a type selected from the group consisting of a reservoir dry powder inhaler (RDPI), a multi-dose dry powder inhaler (MDPI), and a metered dose inhaler (MDI).

By reservoir dry powder inhaler (RDPI) it is meant as an inhaler having a reservoir form pack suitable for comprising multiple (un-metered doses) of medicament in dry powder form and including means for metering medicament dose from the reservoir to a delivery position. The metering means may for example comprise a metering cup or perforated plate, which is movable from a first position where the cup may be filled with medicament from the reservoir to a second position where the metered medicament dose is made available to the patient for inhalation.

By multi-dose dry powder inhaler (MDPI) is meant an inhaler suitable for dispensing medicament in dry powder form, wherein the medicament is comprised within a multi-dose pack containing (or otherwise carrying) multiple, defined doses (or parts thereof) of medicament. In a preferred aspect, the carrier has a blister pack form, but it could also, for example, comprise a capsule-based pack form or a carrier onto which medicament has been applied by any suitable process including printing, painting and vacuum occlusion.

The formulation can be pre-metered (eg as in Diskus, see GB 2242134 or Diskhaler, see GB 2178965, 2129691 and 2169265) or metered in use (eg as in Turbuhaler, see EP 69715). An example of a unit-dose device is Rotahaler (see GB 2064336). The Diskus inhalation device comprises an elongate strip formed from a base sheet having a plurality of recesses spaced along its length and a lid sheet hermetically but peelably sealed thereto to define a plurality of containers, each container having therein an inhalable formulation containing a compound of formula (I) preferably combined with lactose. Preferably, the strip is sufficiently flexible to be wound into a roll. The lid sheet and base sheet will preferably have leading end portions which are not sealed to one another and at least one of the said leading end portions is constructed to be attached to a winding means. Also, preferably the hermetic seal between the base and lid sheets extends over their whole width. The lid sheet may preferably be peeled from the base sheet in a longitudinal direction from a first end of the said base sheet.

In one aspect, the multi-dose pack is a blister pack comprising multiple blisters for containment of medicament in dry powder form. The blisters are typically arranged in regular fashion for ease of release of medicament therefrom.

In one aspect, the multi-dose blister pack comprises plural blisters arranged in generally circular fashion on a disk-form blister pack. In another aspect, the multi-dose blister pack is elongate in form, for example comprising a strip or a tape.

5 Preferably, the multi-dose blister pack is defined between two members peelably secured to one another. US Patents Nos. 5,860,419, 5,873,360 and 5,590,645 describe medicament packs of this general type. In this aspect, the device is usually provided with an opening station comprising peeling means for peeling the members apart to access each medicament dose. Suitably, the device  
10 is adapted for use where the peelable members are elongate sheets which define a plurality of medicament containers spaced along the length thereof, the device being provided with indexing means for indexing each container in turn. More preferably, the device is adapted for use where one of the sheets is a base sheet having a plurality of pockets therein, and the other of the sheets is a lid sheet,  
15 each pocket and the adjacent part of the lid sheet defining a respective one of the containers, the device comprising driving means for pulling the lid sheet and base sheet apart at the opening station.

By metered dose inhaler (MDI) it is meant a medicament dispenser suitable for dispensing medicament in aerosol form, wherein the medicament is comprised  
20 in an aerosol container suitable for containing a propellant-based aerosol medicament formulation. The aerosol container is typically provided with a metering valve, for example a slide valve, for release of the aerosol form medicament formulation to the patient. The aerosol container is generally designed to deliver a predetermined dose of medicament upon each actuation by  
25 means of the valve, which can be opened either by depressing the valve while the container is held stationary or by depressing the container while the valve is held stationary.

Spray compositions for topical delivery to the lung by inhalation may for example be formulated as aqueous solutions or suspensions or as aerosols  
30 delivered from pressurised packs, such as a metered dose inhaler, with the use of a suitable liquefied propellant. Aerosol compositions suitable for inhalation can be either a suspension or a solution and generally contain the compound of formula (I) optionally in combination with another therapeutically active ingredient and a

suitable propellant such as a fluorocarbon or hydrogen-containing chlorofluorocarbon or mixtures thereof, particularly hydrofluoroalkanes, e.g. dichlorodifluoromethane, trichlorofluoromethane, dichlorotetra-fluoroethane, especially 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3-heptafluoro-n-propane or a  
5 mixture thereof. Carbon dioxide or other suitable gas may also be used as propellant. The aerosol composition may be excipient free or may optionally contain additional formulation excipients well known in the art such as surfactants eg oleic acid or lecithin and cosolvents eg ethanol. Pressurized formulations will generally be retained in a canister (eg an aluminium canister) closed with a valve  
10 (eg a metering valve) and fitted into an actuator provided with a mouthpiece.

Medicaments for administration by inhalation desirably have a controlled particle size. The optimum aerodynamic particle size for inhalation into the bronchial system for localized delivery to the lung is usually 1-10 $\mu$ m, preferably 2-  
15 5 $\mu$ m. The optimum aerodynamic particle size for inhalation into the alveolar region for achieving systemic delivery to the lung is approximately .5-3  $\mu$ m, preferably 1-3  $\mu$ m. Particles having an aerodynamic size above 20 $\mu$ m are generally too large when inhaled to reach the small airways. Average aerodynamic particle size of a formulation may be measured by, for example cascade impaction. Average  
20 geometric particle size may be measured, for example by laser diffraction, optical means.

To achieve a desired particle size, the particles of the active ingredient as produced may be size reduced by conventional means eg by controlled crystallization, micronisation or nanomilling. The desired fraction may be  
25 separated out by air classification. Alternatively, particles of the desired size may be directly produced, for example by spray drying, controlling the spray drying parameters to generate particles of the desired size range. Preferably, the particles will be crystalline, although amorphous material may also be employed where desirable. When an excipient such as lactose is employed, generally, the  
30 particle size of the excipient will be much greater than the inhaled medicament within the present invention, such that the "coarse" carrier is non-respirable. When the excipient is lactose it will typically be present as milled lactose, wherein not



more than 85% of lactose particles will have a MMD of 60-90 $\mu$ m and not less than 15% will have a MMD of less than 15 $\mu$ m. Additive materials in a dry powder blend in addition to the carrier may be either respirable, i.e., aerodynamically less than 10 microns, or non-respirable, i.e., aerodynamically greater than 10 microns.

5            Suitable additive materials which may be employed include amino acids, such as leucine; water soluble or water insoluble, natural or synthetic surfactants, such as lecithin (e.g., soya lecithin) and solid state fatty acids (e.g., lauric, palmitic, and stearic acids) and derivatives thereof (such as salts and esters); phosphatidylcholines; sugar esters. Additive materials may also include colorants,  
10   taste masking agents (e.g., saccharine), anti-static-agents, lubricants (see, for example, Published PCT Patent Appl. No. WO 87/905213, the teachings of which are incorporated by reference herein), chemical stabilizers, buffers, preservatives, absorption enhancers, and other materials known to those of ordinary skill.

             Sustained release coating materials (e.g., stearic acid or polymers, e.g.  
15   polyvinyl pyrrolidone, polylactic acid) may also be employed on active material or active material containing particles (see, for example, Patent Nos. US 3,634,582, GB 1,230,087, GB 1,381,872, the teachings of which are incorporated by reference herein).

             Intranasal sprays may be formulated with aqueous or non-aqueous  
20   vehicles with the addition of agents such as thickening agents, buffer salts or acid or alkali to adjust the pH, isotonicity adjusting agents or anti-oxidants.

             Solutions for inhalation by nebulation may be formulated with an aqueous vehicle with the addition of agents such as acid or alkali, buffer salts, isotonicity adjusting agents or antimicrobials. They may be sterilised by filtration or heating  
25   in an autoclave, or presented as a non-sterile product.

             Preferred unit dosage formulations are those containing an effective dose, as herein before recited, or an appropriate fraction thereof, of the active ingredient.

30            All publications, including but not limited to patents and patent applications, cited in this specification are herein incorporated by reference as if each individual publication were specifically and individually indicated to be incorporated by reference herein as though fully set forth.


The above description fully discloses the invention including preferred embodiments thereof. Modifications and improvements of the embodiments specifically disclosed herein are within the scope of the following claims. Without further elaboration, it is believed that one skilled in the art can, using the

5 preceding description, utilize the present invention to its fullest extent. Therefore the Examples herein are to be construed as merely illustrative and not a limitation of the scope of the present invention in any way. The embodiments of the invention in which an exclusive property or privilege is claimed are defined as follows.

10

What is claimed is:

1. A compound according to Formula I herein below:



wherein

When X is carbon, n is 1, 2, or 3; m is 1, 2, or 3; p is 0, 1, or 2;

When X is oxygen, n is 1; m is 2; p is 1 or 2;

W is O, S, or NH;

10 U is NR3, O, or bond;

R3 is selected from the group consisting of hydrogen, C<sub>1</sub>-C<sub>8</sub> branched or unbranched alkyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl lower alkyl, unsubstituted or substituted phenyl, or unsubstituted or substituted phenyl C<sub>1</sub>-C<sub>3</sub> lower alkyl; wherein, when substituted, a group is substituted by one or more radicals selected from the group consisting of C<sub>1</sub>-C<sub>8</sub> alkoxy, halo, hydroxy, amino, cyano, trifluoromethyl, C<sub>1</sub>-C<sub>8</sub> branched or unbranched alkyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl and C<sub>3</sub>-C<sub>8</sub> cycloalkyl lower alkyl;

15

q is an integer from 0 to 7;

h is 0, 1, or 2;

20 g is 1, 2, or 3;

Z<sup>-</sup> is selected from the group consisting of I<sup>-</sup>, Br<sup>-</sup>, Cl<sup>-</sup>, F<sup>-</sup>, CF<sub>3</sub>COO<sup>-</sup>, mesylate, tosylate, and any other pharmaceutically acceptable counter ion;

V is selected from the group consisting of phenyl, thiophenyl, furanyl, pyridinyl, naphthyl, quinolinyl, indolyl, benzothiophenyl and benzofuranyl;

25 R4 is selected from the group consisting of hydrogen, hydroxy, amino, halo, cyano, trifluoromethyl, C<sub>1</sub>-C<sub>8</sub> alkoxy, C<sub>1</sub>-C<sub>8</sub> branched or unbranched alkyl, C<sub>3</sub>-C<sub>8</sub>

cycloalkyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl lower alkyl, phenyl, phenyl C1-C3 lower alkyl, COR<sub>6</sub>, COOR<sub>6</sub>, CONHR<sub>6</sub>, CON(R<sub>6</sub>)<sub>2</sub>, NHR<sub>6</sub>, N(R<sub>6</sub>)<sub>2</sub>, and G;

k is an integer from 0 to 5;

T is selected from the group consisting of an unsubstituted or substituted  
5 following group: phenyl, thiophenyl, furanyl, pyridinyl, naphthyl, quinolinyl, indolyl, benzothiophenyl, and benzofuranyl; wherein, when substituted, a group is substituted by one or more radicals selected from the group consisting of C<sub>1</sub>-C<sub>8</sub> alkoxy, halo, hydroxy, amino, trifluoromethyl, C<sub>1</sub>-C<sub>8</sub> branched or unbranched alkyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl lower alkyl, phenyl and phenyl C1-C3  
10 lower alkyl;

R<sub>5</sub> is selected from the group consisting of COOR<sub>6</sub>, CONHR<sub>6</sub>, COR<sub>6</sub>, CON(R<sub>6</sub>)<sub>2</sub>, COG, unsubstituted or substituted oxadiazolyl, unsubstituted or substituted oxazolyl, unsubstituted or substituted imidazolyl, unsubstituted or substituted phenoxy, or cyano; wherein, when substituted, a group is substituted  
15 by one or more radicals selected from the group consisting of C<sub>1</sub>-C<sub>8</sub> branched or unbranched alkyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl lower alkyl, phenyl and phenyl C1-C3 lower alkyl, C<sub>1</sub>-C<sub>8</sub> alkoxy, halo, hydroxy, amino, cyano and trifluoromethyl;

R<sub>6</sub> is selected from the group consisting of C<sub>1</sub>-C<sub>8</sub> branched or unbranched  
20 alkyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl lower alkyl, unsubstituted or substituted phenyl, unsubstituted or substituted phenyl C1-C3 lower alkyl, unsubstituted or substituted naphthyl, or unsubstituted or substituted naphthyl C1-C3 lower alkyl; wherein, when substituted, a group is substituted by one or more radicals selected from the group consisting of C<sub>1</sub>-C<sub>8</sub> alkoxy, halo, hydroxy, amino, cyano,  
25 trifluoromethyl, C<sub>1</sub>-C<sub>8</sub> branched or unbranched alkyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl lower alkyl, phenyl and phenyl C1-C3 lower alkyl;

G is selected from the group consisting of an unsubstituted or substituted following group: pyrrolidinyl, piperdinyl, dihydroindolyl, tetrahydroquinolinyl, morpholino, azetidiny, hexahydroazepinyl, or octahydroazocinyl; wherein, when  
30 substituted, a group is substituted by one or more radicals selected from the group consisting of C<sub>1</sub>-C<sub>8</sub> alkoxy, hydroxy, amino, C<sub>1</sub>-C<sub>8</sub> branched or unbranched alkyl,

C<sub>3</sub>-C<sub>8</sub> cycloalkyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl lower alkyl, phenyl and phenyl C<sub>1</sub>-C<sub>3</sub> lower alkyl;

R<sub>1</sub> is selected from the group consisting of an unsubstituted or substituted following group: phenyl, phenyl C<sub>1</sub>-C<sub>6</sub> lower alkyl, thiophenyl, thiophenyl C<sub>1</sub>-C<sub>6</sub> lower alkyl, furanyl, furanyl C<sub>1</sub>-C<sub>6</sub> lower alkyl, pyridinyl, pyridinyl C<sub>1</sub>-C<sub>6</sub> lower alkyl, imidazolyl, imidazolyl C<sub>1</sub>-C<sub>6</sub> lower alkyl, naphthyl, naphthyl C<sub>1</sub>-C<sub>6</sub> lower alkyl, quinolinyl, quinolinyl C<sub>1</sub>-C<sub>6</sub> lower alkyl, indolyl, indolyl C<sub>1</sub>-C<sub>6</sub> lower alkyl, benzothiophenyl, benzothiophenyl C<sub>1</sub>-C<sub>6</sub> lower alkyl, benzofuranyl, benzofuranyl C<sub>1</sub>-C<sub>6</sub> lower alkyl, benzoimidazolyl, benzoimidazolyl C<sub>1</sub>-C<sub>6</sub> lower alkyl, C<sub>1</sub>-C<sub>8</sub> branched or unbranched alkyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl C<sub>1</sub>-C<sub>6</sub> lower alkyl, or C<sub>3</sub>-C<sub>8</sub> alkenyl; wherein, when substituted, a group is substituted by one or more radicals selected from the group consisting of C<sub>1</sub>-C<sub>8</sub> alkoxy, phenoxy, phenyl C<sub>1</sub>-C<sub>3</sub> alkoxy, halo, hydroxy, amino, cyano, trifluoromethyl, methylenedioxy, ethylenedioxy, propylenedioxy, butylenedioxy, C<sub>1</sub>-C<sub>8</sub> branched or unbranched alkyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl lower alkyl, phenyl, phenyl C<sub>1</sub>-C<sub>3</sub> lower alkyl, thiophenyl, thiophenyl C<sub>1</sub>-C<sub>3</sub> lower alkyl, furanyl, furanyl C<sub>1</sub>-C<sub>3</sub> lower alkyl, pyridinyl, pyridinyl C<sub>1</sub>-C<sub>3</sub> lower alkyl, naphthyl, naphthyl C<sub>1</sub>-C<sub>3</sub> lower alkyl, quinolinyl, quinolinyl C<sub>1</sub>-C<sub>3</sub> lower alkyl, indolyl, indolyl C<sub>1</sub>-C<sub>3</sub> lower alkyl, benzothiophenyl, benzothiophenyl C<sub>1</sub>-C<sub>3</sub> lower alkyl, benzofuranyl, benzofuranyl C<sub>1</sub>-C<sub>3</sub> lower alkyl, COOH, COR<sub>6</sub>, COOR<sub>6</sub>, CONHR<sub>6</sub>, CON(R<sub>6</sub>)<sub>2</sub>, COG, NHR<sub>6</sub>, N(R<sub>6</sub>)<sub>2</sub>, G, OCOR<sub>6</sub>, OCONHR<sub>6</sub>, NHCOR<sub>6</sub>, N(R<sub>6</sub>)COR<sub>6</sub>, NHCOOR<sub>6</sub> and NHCONHR<sub>6</sub>;

R<sub>2</sub> is selected from the group consisting of C<sub>1</sub>-C<sub>8</sub> branched or unbranched alkyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl lower alkyl, C<sub>3</sub>-C<sub>8</sub> alkenyl, unsubstituted or substituted phenyl, or unsubstituted or substituted phenyl C<sub>1</sub>-C<sub>3</sub> lower alkyl; wherein, when substituted, a group is substituted by one or more radicals selected from the group consisting of C<sub>1</sub>-C<sub>8</sub> alkoxy, halo, hydroxy, amino, cyano, trifluoromethyl, C<sub>1</sub>-C<sub>8</sub> branched or unbranched alkyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl lower alkyl, phenyl and phenyl C<sub>1</sub>-C<sub>3</sub> lower alkyl;

or R<sub>1</sub> and R<sub>2</sub> together is an unsubstituted or substituted following group: –(CH<sub>2</sub>)<sub>j</sub>–, or –(CH<sub>2</sub>)<sub>i</sub>–Phenyl–(CH<sub>2</sub>)<sub>j</sub>–; wherein, j is an integer from 3 to 8; i is an

integer from 1 to 3; when substituted, a group is substituted by one or more radicals selected from the group consisting of C<sub>1</sub>-C<sub>8</sub> alkoxy, halo, hydroxy, amino, cyano, trifluoromethyl, C<sub>1</sub>-C<sub>8</sub> branched or unbranched alkyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl lower alkyl, phenyl and phenyl C<sub>1</sub>-C<sub>3</sub> lower alkyl;

5

2. A compound according to claim 1 wherein:

When X is carbon, n is 1, 2, or 3; m is 1, 2, or 3; p is 0, or 1;

When X is oxygen, n is 1; m is 2; p is 1;

W is O;

10

U is NR<sub>3</sub>;

R<sub>3</sub> is selected from the group consisting of hydrogen, C<sub>1</sub>-C<sub>8</sub> branched or unbranched alkyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl lower alkyl, and phenyl C<sub>1</sub>-C<sub>3</sub> lower alkyl;

q is 0;

15

h is 0;

g is 1;

Z<sup>-</sup> is selected from the group consisting of I<sup>-</sup>, Br<sup>-</sup>, Cl<sup>-</sup>, F<sup>-</sup>, CF<sub>3</sub>COO<sup>-</sup>, mesylate, tosylate, or any other pharmaceutically acceptable counter ion;

V is selected from the group consisting of phenyl, thiophenyl, furanyl, naphthyl, benzothiophenyl or benzofuranyl;

20

R<sub>4</sub> is selected from the group consisting of hydrogen, hydroxy, amino, halo, cyano, trifluoromethyl, C<sub>1</sub>-C<sub>8</sub> alkoxy, C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl lower alkyl, phenyl, phenyl C<sub>1</sub>-C<sub>3</sub> lower alkyl, phenylcarbonyl;

k is an integer from 1 to 5;

25

T is selected from the group consisting of an unsubstituted or substituted following group: phenyl, thiophenyl, furanyl, naphthyl, benzo- thiophenyl, and benzofuranyl; wherein, when substituted, a group is substituted by one or more radicals selected from the group consisting of C<sub>1</sub>-C<sub>8</sub> alkoxy, halo, hydroxy, amino, trifluoromethyl, C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl lower alkyl, phenyl and phenyl C<sub>1</sub>-C<sub>3</sub> lower alkyl;

30

R<sub>5</sub> is selected from the group consisting of COOR<sub>6</sub>, CONHR<sub>6</sub>, COR<sub>6</sub>, CON(R<sub>6</sub>)<sub>2</sub>, COG, unsubstituted or substituted oxadiazolyl, unsubstituted or

substituted phenoxy, or cyano; wherein, when substituted, a group is substituted by one or more radicals selected from the group consisting of C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl lower alkyl, phenyl, phenyl C<sub>1</sub>-C<sub>3</sub> lower alkyl and trifluoromethyl;

5 R<sub>6</sub> is selected from the group consisting of C<sub>1</sub>-C<sub>8</sub> branched or unbranched alkyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl lower alkyl, phenyl, phenyl C<sub>1</sub>-C<sub>3</sub> lower alkyl, naphthyl, or naphthyl C<sub>1</sub>-C<sub>3</sub> lower alkyl;

G is selected from the group consisting of pyrrolidinyl, piperdiny, dihydroindolyl, tetrahydroquinoliny, morpholino, azetidiny, hexahydroazepiny, and octahydroazociny;

10 R<sub>1</sub> is selected from the group consisting of an unsubstituted or substituted following group: phenyl C<sub>1</sub>-C<sub>6</sub> lower alkyl, thiophenyl C<sub>1</sub>-C<sub>6</sub> lower alkyl, furanyl C<sub>1</sub>-C<sub>6</sub> lower alkyl, pyridiny C<sub>1</sub>-C<sub>6</sub> lower alkyl, imidazolyl C<sub>1</sub>-C<sub>6</sub> lower alkyl, naphthyl C<sub>1</sub>-C<sub>6</sub> lower alkyl, quinoliny C<sub>1</sub>-C<sub>6</sub> lower alkyl, indolyl C<sub>1</sub>-C<sub>6</sub> lower  
 15 alkyl, benzothiophenyl C<sub>1</sub>-C<sub>6</sub> lower alkyl, benzofuranyl C<sub>1</sub>-C<sub>6</sub> lower alkyl, benzoimidazolyl C<sub>1</sub>-C<sub>6</sub> lower alkyl, C<sub>1</sub>-C<sub>8</sub> branched or unbranched alkyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl C<sub>1</sub>-C<sub>6</sub> lower alkyl, or C<sub>3</sub>-C<sub>8</sub> alkenyl; wherein, when substituted, a group is substituted by one or more radicals selected from the group consisting of C<sub>1</sub>-C<sub>8</sub> alkoxy, phenoxy, phenyl C<sub>1</sub>-C<sub>3</sub> alkoxy, halo, hydroxy, amino,  
 20 cyano, trifluoromethyl, methylenedioxy, ethylenedioxy, propylenedioxy, butylenedioxy, C<sub>1</sub>-C<sub>8</sub> branched or unbranched alkyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl lower alkyl, phenyl, phenyl C<sub>1</sub>-C<sub>3</sub> lower alkyl, thiophenyl, thiophenyl C<sub>1</sub>-C<sub>3</sub> lower alkyl, furanyl, furanyl C<sub>1</sub>-C<sub>3</sub> lower alkyl, pyridiny, pyridiny C<sub>1</sub>-C<sub>3</sub> lower alkyl, naphthyl, naphthyl C<sub>1</sub>-C<sub>3</sub> lower alkyl, quinoliny, quinoliny C<sub>1</sub>-C<sub>3</sub>  
 25 lower alkyl, indolyl, indolyl C<sub>1</sub>-C<sub>3</sub> lower alkyl, benzothiophenyl, benzothiophenyl C<sub>1</sub>-C<sub>3</sub> lower alkyl, benzofuranyl, benzofuranyl C<sub>1</sub>-C<sub>3</sub> lower alkyl, COOH, COR<sub>6</sub>, COOR<sub>6</sub>, CONHR<sub>6</sub>, CON(R<sub>6</sub>)<sub>2</sub>, COG, NHR<sub>6</sub>, N(R<sub>6</sub>)<sub>2</sub>, G, OCOR<sub>6</sub>, OCONHR<sub>6</sub>, NHCOR<sub>6</sub>, N(R<sub>6</sub>)COR<sub>6</sub>, NHCOOR<sub>6</sub> and NHCONHR<sub>6</sub>;

R<sub>2</sub> is selected from the group consisting of C<sub>1</sub>-C<sub>8</sub> branched or unbranched  
 30 alkyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl lower alkyl, C<sub>3</sub>-C<sub>8</sub> alkenyl, or unsubstituted or substituted phenyl C<sub>1</sub>-C<sub>3</sub> lower alkyl; wherein, when substituted,

a group is substituted by one or more radicals selected from the group consisting of C<sub>1</sub>-C<sub>8</sub> alkoxy, halo, hydroxy, amino, cyano, trifluoromethyl, C<sub>1</sub>-C<sub>8</sub> branched or unbranched alkyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl lower alkyl, phenyl and phenyl C<sub>1</sub>-C<sub>3</sub> lower alkyl;

5           or R<sub>1</sub> and R<sub>2</sub> together is  $-(CH_2)_j-$ , or  $-(CH_2)_i$ -Phenyl- $(CH_2)_j-$ ; wherein, j is an integer from 3 to 8; i is an integer from 1 to 3.

3.       A compound according to claim 2 wherein:

X is carbon;

10       n is 1, or 2;

m is 1, 2, or 3;

p is 0, or 1;

W is O;

U is NR<sub>3</sub>;

15       R<sub>3</sub> is hydrogen;

q is 0;

h is 0;

g is 1;

20       Z<sup>-</sup> is selected from the group consisting of I<sup>-</sup>, Br<sup>-</sup>, Cl<sup>-</sup>, F<sup>-</sup>, CF<sub>3</sub>COO<sup>-</sup>, mesylate, tosylate, and any other pharmaceutically acceptable counter ion;

V is selected from the group consisting of phenyl, or naphthyl;

R<sub>4</sub> is selected from the group consisting of hydroxy, amino, halo, cyano, trifluoromethyl, C<sub>1</sub>-C<sub>8</sub> alkoxy, C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl lower alkyl, phenyl, phenyl C<sub>1</sub>-C<sub>3</sub> lower alkyl, phenylcarbonyl;

25       k is an integer from 1 to 3;

30       T is selected from the group consisting of unsubstituted or substituted phenyl, and thiophenyl; wherein, when substituted, a group is substituted by one or more radicals selected from the group consisting of C<sub>1</sub>-C<sub>8</sub> alkoxy, halo, hydroxy, amino, trifluoromethyl, C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl lower alkyl, phenyl and phenyl C<sub>1</sub>-C<sub>3</sub> lower alkyl;

R<sub>5</sub> is selected from the group consisting of COOR<sub>6</sub>, CONHR<sub>6</sub>, COR<sub>6</sub>, CON(R<sub>6</sub>)<sub>2</sub>, COG, unsubstituted or substituted oxadiazolyl; wherein, when



substituted, a group is substituted by one or more radicals selected from the group consisting of C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl lower alkyl, phenyl and phenyl C<sub>1</sub>-C<sub>3</sub> lower alkyl;

R<sub>6</sub> is selected from the group consisting of C<sub>1</sub>-C<sub>8</sub> branched or unbranched alkyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl, and C<sub>3</sub>-C<sub>8</sub> cycloalkyl lower alkyl;

G is selected from the group consisting of pyrrolidinyl, piperidinyl, dihydroindolyl, tetrahydroquinolyl, morpholino, azetidyl, hexahydroazepinyl, and octahydroazocinyl;

R<sub>1</sub> is selected from the group consisting of an unsubstituted or substituted following group: phenyl C<sub>1</sub>-C<sub>6</sub> lower alkyl, thiophenyl C<sub>1</sub>-C<sub>6</sub> lower alkyl, furanyl C<sub>1</sub>-C<sub>6</sub> lower alkyl, pyridinyl C<sub>1</sub>-C<sub>6</sub> lower alkyl, imidazolyl C<sub>1</sub>-C<sub>6</sub> lower alkyl, naphthyl C<sub>1</sub>-C<sub>6</sub> lower alkyl, quinolyl C<sub>1</sub>-C<sub>6</sub> lower alkyl, indolyl C<sub>1</sub>-C<sub>6</sub> lower alkyl, benzothiophenyl C<sub>1</sub>-C<sub>6</sub> lower alkyl, benzofuranyl C<sub>1</sub>-C<sub>6</sub> lower alkyl, benzoimidazolyl C<sub>1</sub>-C<sub>6</sub> lower alkyl, C<sub>1</sub>-C<sub>8</sub> branched or unbranched alkyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl C<sub>1</sub>-C<sub>6</sub> lower alkyl, or C<sub>3</sub>-C<sub>8</sub> alkenyl; wherein, when substituted, a group is substituted by one or more radicals selected from the group consisting of C<sub>1</sub>-C<sub>8</sub> alkoxy, phenoxy, phenyl C<sub>1</sub>-C<sub>3</sub> alkoxy, halo, hydroxy, amino, cyano, trifluoromethyl, methylenedioxy, ethylenedioxy, propylenedioxy, butylenedioxy, C<sub>1</sub>-C<sub>8</sub> branched or unbranched alkyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl lower alkyl, phenyl, phenyl C<sub>1</sub>-C<sub>3</sub> lower alkyl, thiophenyl, thiophenyl C<sub>1</sub>-C<sub>3</sub> lower alkyl, furanyl, furanyl C<sub>1</sub>-C<sub>3</sub> lower alkyl, pyridinyl, pyridinyl C<sub>1</sub>-C<sub>3</sub> lower alkyl, naphthyl, naphthyl C<sub>1</sub>-C<sub>3</sub> lower alkyl, quinolyl, quinolyl C<sub>1</sub>-C<sub>3</sub> lower alkyl, indolyl, indolyl C<sub>1</sub>-C<sub>3</sub> lower alkyl, benzothiophenyl, benzothiophenyl C<sub>1</sub>-C<sub>3</sub> lower alkyl, benzofuranyl, benzofuranyl C<sub>1</sub>-C<sub>3</sub> lower alkyl, COOH, COR<sub>6</sub>, COOR<sub>6</sub>, CONHR<sub>6</sub>, CON(R<sub>6</sub>)<sub>2</sub>, COG, NHR<sub>6</sub>, N(R<sub>6</sub>)<sub>2</sub>, G, OCOR<sub>6</sub> and NHCOR<sub>6</sub>;

R<sub>2</sub> is C<sub>1</sub>-C<sub>8</sub> branched or unbranched alkyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl lower alkyl, or C<sub>3</sub>-C<sub>8</sub> alkenyl;

or R<sub>1</sub> and R<sub>2</sub> together is  $-(CH_2)_j-$ , or  $-(CH_2)_i$ -Phenyl- $(CH_2)_j-$ ; wherein, j is an integer from 3 to 7; i is an integer from 1 to 2.

4. A compound according to claim 1 selected from the group consisting of:

- N*-[({4-[(ethyloxy)carbonyl]phenyl}amino)carbonyl]-*N*-{1-[(4-hydroxyphenyl)methyl]-1-methyl-3-pyrrolidiniumyl}-*L*-tyrosinamide trifluoroacetate;
- N*-[1-(1,3-benzodioxol-5-ylmethyl)-1-methyl-3-pyrrolidiniumyl]-*N*-[({4-[(ethyloxy)carbonyl]phenyl}amino)carbonyl]-*L*-tyrosinamide trifluoroacetate;
- 5 *N*-[({4-[(ethyloxy)carbonyl]phenyl}amino)carbonyl]-*N*-{1-[(4-fluorophenyl)methyl]-1-methyl-3-pyrrolidiniumyl}-*L*-tyrosinamide trifluoroacetate;
- N*-[({4-[(ethyloxy)carbonyl]phenyl}amino)carbonyl]-*N*-{(3*S*)-1-[(4-hydroxyphenyl)methyl]-1-methyl-3-pyrrolidiniumyl}-*L*-tyrosinamide trifluoroacetate;
- N*-[({4-[(ethyloxy)carbonyl]phenyl}amino)carbonyl]-*N*-{(3*S*)-1-[(4-fluorophenyl)methyl]-1-methyl-3-pyrrolidiniumyl}-*L*-tyrosinamide trifluoroacetate;
- 10 *N*-[(3*S*)-1-(1,3-benzodioxol-5-ylmethyl)-1-methyl-3-pyrrolidiniumyl]-*N*-[({4-[(ethyloxy)carbonyl]phenyl}amino)carbonyl]-*L*-tyrosinamide trifluoroacetate;
- N*-[(3*S*)-1-(cyclopropylmethyl)-1-methyl-3-pyrrolidiniumyl]-*N*-[({4-[(ethyloxy)carbonyl]phenyl}amino)carbonyl]-*L*-tyrosinamide trifluoroacetate;
- 15 *N*-[(3*S*)-1-[[3,4-bis(methyloxy)phenyl]methyl]-1-methyl-3-pyrrolidiniumyl)-*N*-[({4-[(ethyloxy)carbonyl]phenyl}amino)carbonyl]-*L*-tyrosinamide trifluoroacetate;
- N*-[({4-[(ethyloxy)carbonyl]phenyl}amino)carbonyl]-*N*-{1-[(4-fluorophenyl)methyl]-1-methyl-3-piperidiniumyl}-*L*-tyrosinamide trifluoroacetate;
- N*-[1-(1,3-benzodioxol-5-ylmethyl)-1-methyl-3-piperidiniumyl]-*N*-[({4-[(ethyloxy)carbonyl]phenyl}amino)carbonyl]-*L*-tyrosinamide trifluoroacetate;
- 20 *N*-(1-[[3,4-bis(methyloxy)phenyl]methyl]-1-methyl-3-piperidiniumyl)-*N*-[({4-[(ethyloxy)carbonyl]phenyl}amino)carbonyl]-*L*-tyrosinamide trifluoroacetate;
- N*-[1-(cyclopropylmethyl)-1-methyl-3-piperidiniumyl]-*N*-[({4-[(ethyloxy)carbonyl]phenyl}amino)carbonyl]-*L*-tyrosinamide trifluoroacetate;
- 25 *N*-[[1-(cyclopropylmethyl)-1-methyl-4-piperidiniumyl]methyl]-*N*-[({4-[(ethyloxy)carbonyl]phenyl}amino)carbonyl]-*L*-tyrosinamide trifluoroacetate;
- N*-[({4-[(ethyloxy)carbonyl]phenyl}amino)carbonyl]-*N*-{(3*S*)-1-[(3-hydroxyphenyl)methyl]-1-methyl-3-pyrrolidiniumyl}-*L*-tyrosinamide trifluoroacetate;
- N*-[({4-[(ethyloxy)carbonyl]phenyl}amino)carbonyl]-*N*-{(3*S*)-1-[(3-fluorophenyl)methyl]-1-methyl-3-pyrrolidiniumyl}-*L*-tyrosinamide trifluoroacetate;
- 30 *N*-{(3*S*)-1-[(3-cyanophenyl)methyl]-1-methyl-3-pyrrolidiniumyl)-*N*-[({4-[(ethyloxy)carbonyl]phenyl}amino)carbonyl]-*L*-tyrosinamide trifluoroacetate;

- N*-[(3*S*)-1-[[4-(acetylamino)phenyl]methyl]-1-methyl-3-pyrrolidiniumyl]-*N*-[({4-[(ethyloxy)carbonyl]phenyl}amino)carbonyl]-L-tyrosinamide trifluoroacetate;  
*N*-[({4-[(ethyloxy)carbonyl]phenyl}amino)carbonyl]-*N*-[(1*R*,3*S*)-1-[(4-fluorophenyl)methyl]-1-methyl-3-pyrrolidiniumyl]-L-tyrosinamide trifluoroacetate;  
5 *N*-[({4-[(ethyloxy)carbonyl]phenyl}amino)carbonyl]-*N*-[(1*S*,3*S*)-1-[(4-fluorophenyl)methyl]-1-methyl-3-pyrrolidiniumyl]-L-tyrosinamide trifluoroacetate;  
*N*-[(1*R*,3*S*)-1-(1,3-benzodioxol-5-ylmethyl)-1-methyl-3-pyrrolidiniumyl]-*N*-[({4-[(ethyloxy)carbonyl]phenyl}amino)carbonyl]-L-tyrosinamide trifluoroacetate;  
*N*-[(1*S*,3*S*)-1-(1,3-benzodioxol-5-ylmethyl)-1-methyl-3-pyrrolidiniumyl]-*N*-[({4-[(ethyloxy)carbonyl]phenyl}amino)carbonyl]-L-tyrosinamide trifluoroacetate;  
10 *N*-[(3*S*)-1-(1,3-benzodioxol-5-ylmethyl)-1-methyl-3-pyrrolidiniumyl]-4-chloro-*N*-[({4-[(ethyloxy)carbonyl]phenyl}amino)carbonyl]-L-phenylalaninamide trifluoroacetate;  
(3*S*)-1-(1,3-benzodioxol-5-ylmethyl)-3-[[*N*-[({4-[(ethyloxy)carbonyl]phenyl}amino)carbonyl]-3-(2-naphthalenyl)-L-alanyl]amino]-1-methylpyrrolidinium trifluoroacetate;  
15 *N*-[(3*S*)-1-(1,3-benzodioxol-5-ylmethyl)-1-methyl-3-pyrrolidiniumyl]-*N*-[({4-[(ethyloxy)carbonyl]phenyl}amino)carbonyl]-4-(phenylcarbonyl)-L-phenylalaninamide trifluoroacetate;  
*N*-[(3*S*)-1-(1,3-benzodioxol-5-ylmethyl)-1-methyl-3-pyrrolidiniumyl]-*N*-[({4-[(ethyloxy)carbonyl]phenyl}amino)carbonyl]-4-fluoro-L-phenylalaninamide trifluoroacetate;  
20 (3*S*)-1-(1,3-benzodioxol-5-ylmethyl)-3-[(2*S*)-3-(4-biphenyl)-2-[[({4-[(ethyloxy)carbonyl]phenyl}amino)carbonyl]amino]propanoyl]amino]-1-methylpyrrolidinium trifluoroacetate;  
25 *N*-[(3*S*)-1-(1,3-benzodioxol-5-ylmethyl)-1-methyl-3-pyrrolidiniumyl]-*N*-[({4-[(ethyloxy)carbonyl]phenyl}amino)carbonyl]-4-methyl-L-phenylalaninamide trifluoroacetate;  
*N*-[(3*S*)-1-(1,3-benzodioxol-5-ylmethyl)-1-methyl-3-pyrrolidiniumyl]-4-bromo-*N*-[({4-[(ethyloxy)carbonyl]phenyl}amino)carbonyl]-L-phenylalaninamide trifluoroacetate;  
30 *N*-[(3*S*)-1-(1,3-benzodioxol-5-ylmethyl)-1-methyl-3-pyrrolidiniumyl]-3-chloro-*N*-[({4-[(ethyloxy)carbonyl]phenyl}amino)carbonyl]-L-phenylalaninamide trifluoroacetate;  
4-amino-*N*-[(3*S*)-1-(1,3-benzodioxol-5-ylmethyl)-1-methyl-3-pyrrolidiniumyl]-*N*-[({4-[(ethyloxy)carbonyl]phenyl}amino)carbonyl]-L-phenylalaninamide trifluoroacetate;

- N*-{(3*S*)-1-[(3-chlorophenyl)methyl]-1-methyl-3-pyrrolidiniumyl}-*N*-{[(4-[(1-methylethyl)amino]carbonyl]phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;
- 5 *N*-{(3*S*)-1-[(4-chlorophenyl)methyl]-1-methyl-3-pyrrolidiniumyl}-*N*-{[(4-[(1-methylethyl)amino]carbonyl]phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;
- N*-{(3*S*)-1-[[3,4-bis(methyloxy)phenyl]methyl]-1-methyl-3-pyrrolidiniumyl}-*N*-{[(4-[(1-methylethyl)amino]carbonyl]phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;
- 10 *N*-[(3*S*)-1-(1,3-benzodioxol-5-ylmethyl)-1-methyl-3-pyrrolidiniumyl]-*N*-{[(4-[(1-methylethyl)amino]carbonyl]phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;
- N*-{(3*S*)-1-[(4-fluorophenyl)methyl]-1-methyl-3-pyrrolidiniumyl}-*N*-{[(4-[(1-methylethyl)amino]carbonyl]phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;
- 15 *N*-{(3*S*)-1-[(4-chlorophenyl)methyl]-1-methyl-3-pyrrolidiniumyl}-*N*-{[(4-[(ethyloxy)carbonyl]phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;
- N*-{(3*S*)-1-[(3-chlorophenyl)methyl]-1-methyl-3-pyrrolidiniumyl}-*N*-{[(4-[(ethyloxy)carbonyl]phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;
- 20 (2*S*)-2-({*N*-[[(4-[(ethyloxy)carbonyl]phenyl)amino]carbonyl]-L-tyrosyl}amino)-5-azoniaspiro[4.5]decane trifluoroacetate;
- (3'*S*)-3'-({*N*-[[(4-[(ethyloxy)carbonyl]phenyl)amino]carbonyl]-L-tyrosyl}amino)-1,3-dihydrospiro[isindole-2,1'-pyrrolidine] trifluoroacetate;
- N*-{(3*S*)-1-[[3,4-bis(methyloxy)phenyl]methyl]-1-methyl-3-pyrrolidiniumyl}-*N*-{[(4-[(cyclopropylamino)carbonyl]phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;
- 25 *N*-{(3*S*)-1-ethyl-1-[(4-fluorophenyl)methyl]-3-pyrrolidiniumyl}-*N*-{[(4-[(ethyloxy)carbonyl]phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;
- N*-{[(4-[(ethyloxy)carbonyl]phenyl)amino]carbonyl}-*N*-{(3*S*)-1-[(4-fluorophenyl)methyl]-1-propyl-3-pyrrolidiniumyl}-L-tyrosinamide trifluoroacetate;
- 30 *N*-{[(4-[(ethyloxy)carbonyl]phenyl)amino]carbonyl}-*N*-[(3*S*)-1-[(4-fluorophenyl)methyl]-1-(2-propen-1-yl)-3-pyrrolidiniumyl]-L-tyrosinamide trifluoroacetate;

- N*-[(3*S*)-1-(1,3-benzodioxol-5-ylmethyl)-1-methyl-3-pyrrolidiniumyl]-*N*-{[(4-butanoylphenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;
- N*-[(2*S*)-5-azoniaspiro[4.4]non-2-yl]-*N*-{[(4-[(ethyloxy)carbonyl]phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;
- 5 (2*S*)-2-({*N*-{[(4-[(ethyloxy)carbonyl]phenyl)amino]carbonyl}-L-tyrosyl)amino)-5-azoniaspiro[4.6]undecane trifluoroacetate;
- N*-[(3*S*)-1-(1,3-benzodioxol-5-ylmethyl)-1-methyl-3-piperidiniumyl]-*N*-{[(4-[(1-methylethyl)amino]carbonyl]phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;
- 10 *N*-[(3*S*)-1-(1,3-benzodioxol-5-ylmethyl)-1-methyl-3-piperidiniumyl]-*N*-{[(4-[(methyloxy)carbonyl]phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;
- N*-[(3*S*)-1-(1,3-benzodioxol-5-ylmethyl)-1-methyl-3-piperidiniumyl]-*N*-{[(4-[(ethyloxy)carbonyl]phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;
- N*-[(3*S*)-1-(1,3-benzodioxol-5-ylmethyl)-1-methyl-3-piperidiniumyl]-*N*-{[(4-[(1-methylethyl)oxy]carbonyl]phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;
- 15 *N*-[(3*S*)-1-(1,3-benzodioxol-5-ylmethyl)-1-methyl-3-piperidiniumyl]-*N*-{[(4-[(propyloxy)carbonyl]phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;
- N*-[(3*S*)-1-(1,3-benzodioxol-5-ylmethyl)-1-methyl-3-piperidiniumyl]-*N*-{[(4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;
- 20 *N*-[(3*S*)-1-(1,3-benzodioxol-5-ylmethyl)-1-methyl-3-piperidiniumyl]-*N*-{[(4-(5-ethyl-1,2,4-oxadiazol-3-yl)phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;
- N*-[(3*S*)-1-(1,3-benzodioxol-5-ylmethyl)-1-methyl-3-piperidiniumyl]-*N*-{[(4-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;
- 25 *N*-{[(3*S*)-1-[(4-fluorophenyl)methyl]-1-methyl-3-piperidiniumyl]-*N*-{[(4-[(1-methylethyl)oxy]carbonyl]phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;
- N*-{[(3*S*)-1-[(4-hydroxyphenyl)methyl]-1-methyl-3-piperidiniumyl]-*N*-{[(4-[(1-methylethyl)oxy]carbonyl]phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;
- 30 *N*-{[(3*S*)-1-[(3-chlorophenyl)methyl]-1-methyl-3-piperidiniumyl]-*N*-{[(4-[(1-methylethyl)oxy]carbonyl]phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;

*N*-((3*S*)-1-[[3,4-bis(methyloxy)phenyl]methyl]-1-methyl-3-piperidiniumyl)-*N*-{[(4-{[(1-methylethyl)oxy]carbonyl}phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;

5 *N*-{[(3*S*)-1-[(3-hydroxyphenyl)methyl]-1-methyl-3-piperidiniumyl]-*N*-{[(4-{[(1-methylethyl)oxy]carbonyl}phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;

*N*-{[(3*S*)-1-[(4-chlorophenyl)methyl]-1-methyl-3-piperidiniumyl]-*N*-{[(4-{[(1-methylethyl)oxy]carbonyl}phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;

*N*-[(3*S*)-1-(cyclopropylmethyl)-1-methyl-3-piperidiniumyl]-*N*-{[(4-{[(1-methylethyl)oxy]carbonyl}phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;

10 *N*-{[(3*S*)-1-[(3-hydroxyphenyl)methyl]-1-methyl-3-piperidiniumyl]-*N*-{[(4-{[(1-methylethyl)amino]carbonyl}phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;

*N*-{[(3*S*)-1-[(3-hydroxyphenyl)methyl]-1-methyl-3-pyrrolidiniumyl]-*N*-{[(4-{[(1-methylethyl)oxy]carbonyl}phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;

15 *N*-[(3*S*)-1-(1,3-benzodioxol-5-ylmethyl)-1-methyl-3-pyrrolidiniumyl]-*N*-{[(4-{[(1-methylethyl)oxy]carbonyl}phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;

*N*-((3*S*)-1-[[3,4-bis(methyloxy)phenyl]methyl]-1-methyl-3-piperidiniumyl)-*N*-{[(4-{[(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]amino}carbonyl)-L-tyrosinamide trifluoroacetate;

20 *N*-((3*S*)-1-[[3,4-bis(methyloxy)phenyl]methyl]-1-methyl-3-piperidiniumyl)-*N*-{[(4-{[(5-ethyl-1,2,4-oxadiazol-3-yl)phenyl]amino}carbonyl)-L-tyrosinamide trifluoroacetate;

*N*-((3*S*)-1-[[3,4-bis(methyloxy)phenyl]methyl]-1-methyl-3-piperidiniumyl)-*N*-{[(4-{[(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]amino}carbonyl)-L-tyrosinamide trifluoroacetate;

25 *N*-{[(3*S*)-1-[(3-hydroxyphenyl)methyl]-1-methyl-3-piperidiniumyl]-*N*-{[(4-{[(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]amino}carbonyl)-L-tyrosinamide trifluoroacetate;

*N*-{[(3*S*)-1-[(3-hydroxyphenyl)methyl]-1-methyl-3-piperidiniumyl]-*N*-{[(4-{[(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]amino}carbonyl)-L-tyrosinamide trifluoroacetate;

30 *N*-{[(4-{[(5-ethyl-1,2,4-oxadiazol-3-yl)phenyl]amino}carbonyl)-*N*-{[(3*S*)-1-[(3-hydroxyphenyl)methyl]-1-methyl-3-piperidiniumyl]-L-tyrosinamide trifluoroacetate;

*N*-[(3*S*)-1,1-bis(cyclopropylmethyl)-3-piperidiniumyl]-*N*-{[(4-{[(1-methylethyl)oxy]carbonyl}phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;

*N*-[(3*S*)-1,1-bis(cyclopropylmethyl)-3-piperidiniumyl]-*N*-{[(4-{[(1-methylethyl)amino]carbonyl}phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;

(2*S*)-2-[(*N*-{[(4-{[(1-methylethyl)oxy]carbonyl}phenyl)amino]carbonyl}-L-

5 tyrosyl)amino]-6-azoniaspiro[5.6]dodecane trifluoroacetate;

*N*-{(3*S*)-1-[(3-hydroxyphenyl)methyl]-1-propyl-3-piperidiniumyl}-*N*-{[(4-{[(1-methylethyl)oxy]carbonyl}phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;

*N*-[(3*S*)-1-(1,3-benzodioxol-5-ylmethyl)-1-propyl-3-piperidiniumyl]-*N*-{[(4-{[(1-methylethyl)oxy]carbonyl}phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;

10 *N*-{(3*S*)-1-[[3,4-bis(methyloxy)phenyl]methyl]-1-propyl-3-piperidiniumyl}-*N*-{[(4-{[(1-methylethyl)oxy]carbonyl}phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;

*N*-{(3*S*)-1-[(3-hydroxyphenyl)methyl]-1-propyl-3-piperidiniumyl}-*N*-{[(4-{[(1-methylethyl)amino]carbonyl}phenyl)amino]carbonyl}-L-tyrosinamide

15 trifluoroacetate;

*N*-[(3*S*)-1-(1,3-benzodioxol-5-ylmethyl)-1-propyl-3-piperidiniumyl]-*N*-{[(4-{[(1-methylethyl)amino]carbonyl}phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;

*N*-{(3*S*)-1-[[3,4-bis(methyloxy)phenyl]methyl]-1-propyl-3-piperidiniumyl}-*N*-{[(4-{[(1-methylethyl)amino]carbonyl}phenyl)amino]carbonyl}-L-tyrosinamide

20 trifluoroacetate;

*N*-[(3*S*)-1-[(3-hydroxyphenyl)methyl]-1-(2-propen-1-yl)-3-piperidiniumyl]-*N*-{[(4-{[(1-methylethyl)oxy]carbonyl}phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;

25 *N*-[(3*S*)-1-(1,3-benzodioxol-5-ylmethyl)-1-(2-propen-1-yl)-3-piperidiniumyl]-*N*-{[(4-{[(1-methylethyl)oxy]carbonyl}phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;

*N*-[(3*S*)-1-[[3,4-bis(methyloxy)phenyl]methyl]-1-(2-propen-1-yl)-3-piperidiniumyl]-*N*-{[(4-{[(1-methylethyl)oxy]carbonyl}phenyl)amino]carbonyl}-L-tyrosinamide

30 trifluoroacetate;

*N*-[(3*S*)-1-[(3-hydroxyphenyl)methyl]-1-(2-propen-1-yl)-3-piperidiniumyl]-*N*-{[(4-{[(1-methylethyl)amino]carbonyl}phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;

*N*-{[(3*S*)-1-(1,3-benzodioxol-5-ylmethyl)-1-(2-propen-1-yl)-3-piperidiniumyl]-*N*-{[(4-  
 {[(1-methylethyl)amino]carbonyl}phenyl)amino]carbonyl}-L-tyrosinamide  
 trifluoroacetate;

*N*-{[(3*S*)-1-{[3,4-bis(methyloxy)phenyl]methyl}-1-(2-propen-1-yl)-3-piperidiniumyl]-

5 *N*-{[(4-{[(1-methylethyl)amino]carbonyl}phenyl)amino]carbonyl}-L-tyrosinamide  
 trifluoroacetate;

*N*-{(3*S*)-1-[(4-hydroxyphenyl)methyl]-1-propyl-3-piperidiniumyl)-*N*-{[(4-{[(1-  
 methylethyl)oxy]carbonyl}phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;

*N*-{(3*S*)-1-(cyclopropylmethyl)-1-(2-propen-1-yl)-3-piperidiniumyl)-*N*-{[(4-{[(1-  
 10 methylethyl)oxy]carbonyl}phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;  
*N*-{(3*S*)-1-(cyclopropylmethyl)-1-(2-propen-1-yl)-3-piperidiniumyl)-*N*-{[(4-{[(1-  
 methylethyl)amino]carbonyl}phenyl)amino]carbonyl}-L-tyrosinamide  
 trifluoroacetate;

*N*-{(3*S*)-1-(cyclopropylmethyl)-1-propyl-3-piperidiniumyl)-*N*-{[(4-{[(1-  
 15 methylethyl)amino]carbonyl}phenyl)amino]carbonyl}-L-tyrosinamide  
 trifluoroacetate;

*N*-{(3*S*)-1-(cyclopropylmethyl)-1-propyl-3-piperidiniumyl)-*N*-{[(4-{[(1-  
 methylethyl)oxy]carbonyl}phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;

*N*-{(3*S*)-1-{[3,4-bis(methyloxy)phenyl]methyl}-1-methyl-3-piperidiniumyl)-*N*-{[(4-  
 20 {[(1-methylethyl)amino]carbonyl}phenyl)amino]carbonyl}-L-tyrosinamide  
 trifluoroacetate;

*N*-{(3*S*)-1-[(3-chlorophenyl)methyl]-1-methyl-3-piperidiniumyl)-*N*-{[(4-{[(1-  
 methylethyl)amino]carbonyl}phenyl)amino]carbonyl}-L-tyrosinamide  
 trifluoroacetate;

25 *N*-{(3*S*)-1-[(4-hydroxyphenyl)methyl]-1-methyl-3-piperidiniumyl)-*N*-{[(4-{[(1-  
 methylethyl)amino]carbonyl}phenyl)amino]carbonyl}-L-tyrosinamide  
 trifluoroacetate;

*N*-{(3*S*)-1-[(4-fluorophenyl)methyl]-1-methyl-3-piperidiniumyl)-*N*-{[(4-{[(1-  
 methylethyl)amino]carbonyl}phenyl)amino]carbonyl}-L-tyrosinamide

30 trifluoroacetate;

*N*-{(3*S*)-1-(1,3-benzodioxol-5-ylmethyl)-1-methyl-3-pyrrolidiniumyl)-*N*-{[(4-(5-  
 methyl-1,2,4-oxadiazol-3-yl)phenyl)amino]carbonyl}-L-tyrosinamide  
 trifluoroacetate;



*N*-[(3*S*)-1-[(1,3-benzodioxol-5-yl)methyl]-1-methyl-3-pyrrolidiniumyl]-*N*-{[4-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]amino}carbonyl)-L-tyrosinamide trifluoroacetate;

*N*-{(3*S*)-1-[(3-hydroxyphenyl)methyl]-1-methyl-3-pyrrolidiniumyl)-*N*-{[4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]amino}carbonyl)-L-tyrosinamide trifluoroacetate;

*N*-{(3*S*)-1-[(3-hydroxyphenyl)methyl]-1-methyl-3-pyrrolidiniumyl)-*N*-{[4-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]amino}carbonyl)-L-tyrosinamide trifluoroacetate;

*N*-{[4-[(ethyloxy)carbonyl]phenyl]amino}carbonyl)-*N*-{(3*S*)-1-[(4-fluorophenyl)methyl]-1-methyl-3-piperidiniumyl)-L-tyrosinamide trifluoroacetate;

*N*-{(3*S*)-1-[(3-chlorophenyl)methyl]-1-methyl-3-piperidiniumyl)-*N*-{[4-[(ethyloxy)carbonyl]phenyl]amino}carbonyl)-L-tyrosinamide trifluoroacetate;

*N*-{(3*S*)-1-[[3,4-bis(methyloxy)phenyl]methyl]-1-methyl-3-piperidiniumyl)-*N*-{[4-[(ethyloxy)carbonyl]phenyl]amino}carbonyl)-L-tyrosinamide trifluoroacetate;

*N*-{[4-[(ethyloxy)carbonyl]phenyl]amino}carbonyl)-*N*-{(3*S*)-1-[(3-

hydroxyphenyl)methyl]-1-methyl-3-piperidiniumyl)-L-tyrosinamide trifluoroacetate;

*N*-{(3*S*)-1-(cyclopropylmethyl)-1-methyl-3-piperidiniumyl)-*N*-{[4-

[(ethyloxy)carbonyl]phenyl]amino}carbonyl)-L-tyrosinamide trifluoroacetate;

*N*-{[3,5-bis[(ethyloxy)carbonyl]-4-methyl-2-thienyl]amino}carbonyl)-*N*-{(3*S*)-1-[(3-hydroxyphenyl)methyl]-1-methyl-3-piperidiniumyl)-L-tyrosinamide trifluoroacetate;

*N*-{[3,5-bis[(ethyloxy)carbonyl]-4-methyl-2-thienyl]amino}carbonyl)-*N*-{(3*S*)-1-[(3-chlorophenyl)methyl]-1-methyl-3-piperidiniumyl)-L-tyrosinamide trifluoroacetate;

*N*-{[3,5-bis[(ethyloxy)carbonyl]-4-methyl-2-thienyl]amino}carbonyl)-*N*-{(3*S*)-1-[(4-chlorophenyl)methyl]-1-methyl-3-piperidiniumyl)-L-tyrosinamide trifluoroacetate;

*N*-{[5-[(ethyloxy)carbonyl]-2-thienyl]amino}carbonyl)-*N*-{(3*S*)-1-[(3-

hydroxyphenyl)methyl]-1-methyl-3-piperidiniumyl)-L-tyrosinamide trifluoroacetate;

*N*-{[5-[(ethyloxy)carbonyl]-2-thienyl]amino}carbonyl)-*N*-{(3*S*)-1-[(3-

chlorophenyl)methyl]-1-methyl-3-piperidiniumyl)-L-tyrosinamide trifluoroacetate;

*N*-{[5-[(ethyloxy)carbonyl]-2-thienyl]amino}carbonyl)-*N*-{(3*S*)-1-[(4-

chlorophenyl)methyl]-1-methyl-3-piperidiniumyl)-L-tyrosinamide trifluoroacetate;

*N*-{(3*S*)-1-[(3-hydroxyphenyl)methyl]-1-methyl-3-piperidiniumyl)-*N*-{[5-[(1-methylethyl)oxy]carbonyl]-2-thienyl]amino}carbonyl)-L-tyrosinamide

trifluoroacetate;

*N*-{[(3*S*)-1-[(3-chlorophenyl)methyl]-1-methyl-3-piperidiniumyl]-*N*-{[(5-[(1-methylethyl)oxy]carbonyl)-2-thienyl]amino]carbonyl}-L-tyrosinamide trifluoroacetate;

5 *N*-{[(3*S*)-1-[(4-chlorophenyl)methyl]-1-methyl-3-piperidiniumyl]-*N*-{[(5-[(1-methylethyl)oxy]carbonyl)-2-thienyl]amino]carbonyl}-L-tyrosinamide trifluoroacetate;

*N*-{[(5-[(cyclobutyloxy)carbonyl]-2-thienyl]amino)carbonyl]-*N*-{[(3*S*)-1-[(3-hydroxyphenyl)methyl]-1-methyl-3-piperidiniumyl]-L-tyrosinamide trifluoroacetate;

10 *N*-{[(5-[(cyclobutyloxy)carbonyl]-2-thienyl]amino)carbonyl]-*N*-{[(3*S*)-1-[(3-chlorophenyl)methyl]-1-methyl-3-piperidiniumyl]-L-tyrosinamide trifluoroacetate;

*N*-{[(5-[(cyclobutyloxy)carbonyl]-2-thienyl]amino)carbonyl]-*N*-{[(3*S*)-1-[(4-chlorophenyl)methyl]-1-methyl-3-piperidiniumyl]-L-tyrosinamide trifluoroacetate;

*N*-{[(5-[(cyclopropylmethyl)oxy]carbonyl)-2-thienyl]amino]carbonyl]-*N*-{[(3*S*)-1-[(3-hydroxyphenyl)methyl]-1-methyl-3-piperidiniumyl]-L-tyrosinamide trifluoroacetate;

15 *N*-{[(3*S*)-1-[(3-hydroxyphenyl)methyl]-1-methyl-3-piperidiniumyl]-*N*-{[(5-[(phenylmethyl)oxy]carbonyl)-2-thienyl]amino]carbonyl}-L-tyrosinamide trifluoroacetate;

*N*-{[(3*S*)-1-[(3-chlorophenyl)methyl]-1-methyl-3-piperidiniumyl]-*N*-{[(5-[(phenylmethyl)oxy]carbonyl)-2-thienyl]amino]carbonyl}-L-tyrosinamide trifluoroacetate;

20 *N*-{[(3*S*)-1-[(4-chlorophenyl)methyl]-1-methyl-3-piperidiniumyl]-*N*-{[(5-[(phenylmethyl)oxy]carbonyl)-2-thienyl]amino]carbonyl}-L-tyrosinamide trifluoroacetate;

*N*-{[(3*S*)-1-[(3-hydroxyphenyl)methyl]-1-methyl-3-piperidiniumyl]-*N*-{[(5-

25 [(propyloxy)carbonyl]-2-thienyl]amino)carbonyl]-L-tyrosinamide trifluoroacetate;

*N*-{[(3*S*)-1-[(3-chlorophenyl)methyl]-1-methyl-3-piperidiniumyl]-*N*-{[(5-[(propyloxy)carbonyl]-2-thienyl]amino)carbonyl]-L-tyrosinamide trifluoroacetate;

*N*-{[(3*S*)-1-[(4-chlorophenyl)methyl]-1-methyl-3-piperidiniumyl]-*N*-{[(5-[(propyloxy)carbonyl]-2-thienyl]amino)carbonyl]-L-tyrosinamide trifluoroacetate;

30 *N*-{[(5-[(cyclopentylamino)carbonyl]-2-thienyl]amino)carbonyl]-*N*-{[(3*S*)-1-[(3-hydroxyphenyl)methyl]-1-methyl-3-piperidiniumyl]-L-tyrosinamide trifluoroacetate;

*N*-{[(5-[(cyclopentylamino)carbonyl]-2-thienyl]amino)carbonyl]-*N*-{[(3*S*)-1-[(3-chlorophenyl)methyl]-1-methyl-3-piperidiniumyl]-L-tyrosinamide trifluoroacetate;

- N*-[({5-[(cyclopentylamino)carbonyl]-2-thienyl}amino)carbonyl]-*N*-{(3*S*)-1-[(4-chlorophenyl)methyl]-1-methyl-3-piperidiniumyl}-*L*-tyrosinamide trifluoroacetate;  
*N*-[({5-[(cycloheptylamino)carbonyl]-2-thienyl}amino)carbonyl]-*N*-{(3*S*)-1-[(3-hydroxyphenyl)methyl]-1-methyl-3-piperidiniumyl}-*L*-tyrosinamide trifluoroacetate;  
 5 *N*-[({5-[(cycloheptylamino)carbonyl]-2-thienyl}amino)carbonyl]-*N*-{(3*S*)-1-[(3-chlorophenyl)methyl]-1-methyl-3-piperidiniumyl}-*L*-tyrosinamide trifluoroacetate;  
*N*-[({5-[(cycloheptylamino)carbonyl]-2-thienyl}amino)carbonyl]-*N*-{(3*S*)-1-[(4-chlorophenyl)methyl]-1-methyl-3-piperidiniumyl}-*L*-tyrosinamide trifluoroacetate;  
*N*-[({5-[(cyclohexylmethyl)amino]carbonyl}-2-thienyl)amino]carbonyl]-*N*-{(3*S*)-1-  
 10 [(3-hydroxyphenyl)methyl]-1-methyl-3-piperidiniumyl}-*L*-tyrosinamide trifluoroacetate;  
*N*-[({5-[(cyclohexylmethyl)amino]carbonyl}-2-thienyl)amino]carbonyl]-*N*-{(3*S*)-1-[(3-chlorophenyl)methyl]-1-methyl-3-piperidiniumyl}-*L*-tyrosinamide trifluoroacetate;  
 15 *N*-{(3*S*)-1,1-bis[(3-chlorophenyl)methyl]-3-piperidiniumyl}-*N*-[({5-[(ethyloxy)carbonyl]-2-thienyl}amino)carbonyl]-*L*-tyrosinamide trifluoroacetate; and  
*N*-[({5-[(ethyloxy)carbonyl]-2-thienyl}amino)carbonyl]-*N*-{(3*S*)-1-[(3-hydroxyphenyl)methyl]-1-methyl-3-piperidiniumyl}-*L*-tyrosinamide trifluoroacetate  
 or any other pharmaceutically acceptable salt.

20

5. A compound according to claim 1 selected from the group consisting of:  
*N*-[(3*S*)-1-(1,3-benzodioxol-5-ylmethyl)-1-methyl-3-piperidiniumyl]-*N*-[({4-[(1-methylethyl)amino]carbonyl}phenyl)amino]carbonyl]-*L*-tyrosinamide trifluoroacetate;  
 25 *N*-[(3*S*)-1-(1,3-benzodioxol-5-ylmethyl)-1-methyl-3-piperidiniumyl]-*N*-[({4-[(ethyloxy)carbonyl]phenyl}amino)carbonyl]-*L*-tyrosinamide trifluoroacetate;  
*N*-[(3*S*)-1-(1,3-benzodioxol-5-ylmethyl)-1-methyl-3-piperidiniumyl]-*N*-[({4-[(1-methylethyl)oxy]carbonyl}phenyl)amino]carbonyl]-*L*-tyrosinamide trifluoroacetate;  
*N*-[(3*S*)-1-(1,3-benzodioxol-5-ylmethyl)-1-methyl-3-piperidiniumyl]-*N*-[({4-  
 30 [(propyloxy)carbonyl]phenyl)amino]carbonyl]-*L*-tyrosinamide trifluoroacetate;  
*N*-[(3*S*)-1-(1,3-benzodioxol-5-ylmethyl)-1-methyl-3-piperidiniumyl]-*N*-[({4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl}amino)carbonyl]-*L*-tyrosinamide trifluoroacetate;

*N*-[(3*S*)-1-(1,3-benzodioxol-5-ylmethyl)-1-methyl-3-piperidiniumyl]-*N*-{[4-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]amino}carbonyl)-L-tyrosinamide trifluoroacetate;

5 *N*-{(3*S*)-1-[(4-fluorophenyl)methyl]-1-methyl-3-piperidiniumyl}-*N*-{[4-[(1-methylethyl)oxy]carbonyl}phenyl)amino}carbonyl)-L-tyrosinamide trifluoroacetate;

*N*-{(3*S*)-1-[(4-hydroxyphenyl)methyl]-1-methyl-3-piperidiniumyl}-*N*-{[4-[(1-methylethyl)oxy]carbonyl}phenyl)amino}carbonyl)-L-tyrosinamide trifluoroacetate;

*N*-{(3*S*)-1-[(3-chlorophenyl)methyl]-1-methyl-3-piperidiniumyl}-*N*-{[4-[(1-methylethyl)oxy]carbonyl}phenyl)amino}carbonyl)-L-tyrosinamide trifluoroacetate;

10 *N*-{(3*S*)-1-[[3,4-bis(methyloxy)phenyl]methyl]-1-methyl-3-piperidiniumyl}-*N*-{[4-[(1-methylethyl)oxy]carbonyl}phenyl)amino}carbonyl)-L-tyrosinamide trifluoroacetate;

*N*-{(3*S*)-1-[(3-hydroxyphenyl)methyl]-1-methyl-3-piperidiniumyl}-*N*-{[4-[(1-methylethyl)oxy]carbonyl}phenyl)amino}carbonyl)-L-tyrosinamide trifluoroacetate;

15 *N*-{(3*S*)-1-[(4-chlorophenyl)methyl]-1-methyl-3-piperidiniumyl}-*N*-{[4-[(1-methylethyl)oxy]carbonyl}phenyl)amino}carbonyl)-L-tyrosinamide trifluoroacetate;

*N*-[(3*S*)-1-(cyclopropylmethyl)-1-methyl-3-piperidiniumyl]-*N*-{[4-[(1-methylethyl)oxy]carbonyl}phenyl)amino}carbonyl)-L-tyrosinamide trifluoroacetate;

20 *N*-{(3*S*)-1-[(3-hydroxyphenyl)methyl]-1-methyl-3-piperidiniumyl}-*N*-{[4-[(1-methylethyl)amino]carbonyl}phenyl)amino}carbonyl)-L-tyrosinamide trifluoroacetate;

*N*-{(3*S*)-1-[(3-hydroxyphenyl)methyl]-1-methyl-3-pyrrolidiniumyl}-*N*-{[4-[(1-methylethyl)oxy]carbonyl}phenyl)amino}carbonyl)-L-tyrosinamide trifluoroacetate;

25 *N*-[(3*S*)-1-(1,3-benzodioxol-5-ylmethyl)-1-methyl-3-pyrrolidiniumyl]-*N*-{[4-[(1-methylethyl)oxy]carbonyl}phenyl)amino}carbonyl)-L-tyrosinamide trifluoroacetate;

*N*-{(3*S*)-1-[[3,4-bis(methyloxy)phenyl]methyl]-1-methyl-3-piperidiniumyl}-*N*-{[4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]amino}carbonyl)-L-tyrosinamide trifluoroacetate;

30 *N*-{(3*S*)-1-[[3,4-bis(methyloxy)phenyl]methyl]-1-methyl-3-piperidiniumyl}-*N*-{[4-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]amino}carbonyl)-L-tyrosinamide trifluoroacetate;

*N*-{(3*S*)-1-[(3-hydroxyphenyl)methyl]-1-methyl-3-piperidiniumyl}-*N*-{[4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]amino}carbonyl)-L-tyrosinamide trifluoroacetate;

- N*-{(3*S*)-1-[(3-hydroxyphenyl)methyl]-1-methyl-3-piperidiniumyl}-*N*-{[4-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]amino}carbonyl}-L-tyrosinamide trifluoroacetate;  
*N*-{[4-(5-ethyl-1,2,4-oxadiazol-3-yl)phenyl]amino}carbonyl}-*N*-{(3*S*)-1-[(3-hydroxyphenyl)methyl]-1-methyl-3-piperidiniumyl}-L-tyrosinamide trifluoroacetate;
- 5 *N*-[(3*S*)-1,1-bis(cyclopropylmethyl)-3-piperidiniumyl]-*N*-{[4-[(1-methylethyl)oxy]carbonyl]phenyl]amino}carbonyl}-L-tyrosinamide trifluoroacetate;  
*N*-[(3*S*)-1,1-bis(cyclopropylmethyl)-3-piperidiniumyl]-*N*-{[4-[(1-methylethyl)amino]carbonyl]phenyl]amino}carbonyl}-L-tyrosinamide trifluoroacetate;
- 10 (2*S*)-2-[(*N*-{[4-[(1-methylethyl)oxy]carbonyl]phenyl]amino}carbonyl}-L-tyrosyl)amino]-6-azoniaspiro[5.6]dodecane trifluoroacetate;  
*N*-{(3*S*)-1-[(3-hydroxyphenyl)methyl]-1-propyl-3-piperidiniumyl}-*N*-{[4-[(1-methylethyl)oxy]carbonyl]phenyl]amino}carbonyl}-L-tyrosinamide trifluoroacetate;  
*N*-[(3*S*)-1-(1,3-benzodioxol-5-ylmethyl)-1-propyl-3-piperidiniumyl]-*N*-{[4-[(1-methylethyl)oxy]carbonyl]phenyl]amino}carbonyl}-L-tyrosinamide trifluoroacetate;
- 15 *N*-{(3*S*)-1-[[3,4-bis(methyloxy)phenyl]methyl]-1-propyl-3-piperidiniumyl}-*N*-{[4-[(1-methylethyl)oxy]carbonyl]phenyl]amino}carbonyl}-L-tyrosinamide trifluoroacetate;
- 20 *N*-{(3*S*)-1-[(3-hydroxyphenyl)methyl]-1-propyl-3-piperidiniumyl}-*N*-{[4-[(1-methylethyl)amino]carbonyl]phenyl]amino}carbonyl}-L-tyrosinamide trifluoroacetate;  
*N*-[(3*S*)-1-(1,3-benzodioxol-5-ylmethyl)-1-propyl-3-piperidiniumyl]-*N*-{[4-[(1-methylethyl)amino]carbonyl]phenyl]amino}carbonyl}-L-tyrosinamide trifluoroacetate;
- 25 *N*-{(3*S*)-1-[[3,4-bis(methyloxy)phenyl]methyl]-1-propyl-3-piperidiniumyl}-*N*-{[4-[(1-methylethyl)amino]carbonyl]phenyl]amino}carbonyl}-L-tyrosinamide trifluoroacetate;
- 30 *N*-[(3*S*)-1-[(3-hydroxyphenyl)methyl]-1-(2-propen-1-yl)-3-piperidiniumyl]-*N*-{[4-[(1-methylethyl)oxy]carbonyl]phenyl]amino}carbonyl}-L-tyrosinamide trifluoroacetate;
- N*-[(3*S*)-1-(1,3-benzodioxol-5-ylmethyl)-1-(2-propen-1-yl)-3-piperidiniumyl]-*N*-{[4-[(1-methylethyl)oxy]carbonyl]phenyl]amino}carbonyl}-L-tyrosinamide trifluoroacetate;

*N*-[(3*S*)-1-[[3,4-bis(methyloxy)phenyl]methyl]-1-(2-propen-1-yl)-3-piperidiniumyl]-*N*-[[4-[(1-methylethyl)oxy]carbonyl]phenyl)amino]carbonyl]-L-tyrosinamide trifluoroacetate;

5 *N*-[(3*S*)-1-[(3-hydroxyphenyl)methyl]-1-(2-propen-1-yl)-3-piperidiniumyl]-*N*-[[4-[(1-methylethyl)amino]carbonyl]phenyl)amino]carbonyl]-L-tyrosinamide trifluoroacetate;

*N*-[(3*S*)-1-(1,3-benzodioxol-5-ylmethyl)-1-(2-propen-1-yl)-3-piperidiniumyl]-*N*-[[4-[(1-methylethyl)amino]carbonyl]phenyl)amino]carbonyl]-L-tyrosinamide trifluoroacetate;

10 *N*-[(3*S*)-1-[[3,4-bis(methyloxy)phenyl]methyl]-1-(2-propen-1-yl)-3-piperidiniumyl]-*N*-[[4-[(1-methylethyl)amino]carbonyl]phenyl)amino]carbonyl]-L-tyrosinamide trifluoroacetate;

*N*-[(3*S*)-1-[(4-hydroxyphenyl)methyl]-1-propyl-3-piperidiniumyl]-*N*-[[4-[(1-methylethyl)oxy]carbonyl]phenyl)amino]carbonyl]-L-tyrosinamide trifluoroacetate;

15 *N*-[(3*S*)-1-[[3,4-bis(methyloxy)phenyl]methyl]-1-methyl-3-piperidiniumyl]-*N*-[[4-[(1-methylethyl)amino]carbonyl]phenyl)amino]carbonyl]-L-tyrosinamide trifluoroacetate;

*N*-[(3*S*)-1-[(3-chlorophenyl)methyl]-1-methyl-3-piperidiniumyl]-*N*-[[4-[(1-methylethyl)amino]carbonyl]phenyl)amino]carbonyl]-L-tyrosinamide

20 trifluoroacetate;

*N*-[(3*S*)-1-[(4-hydroxyphenyl)methyl]-1-methyl-3-piperidiniumyl]-*N*-[[4-[(1-methylethyl)amino]carbonyl]phenyl)amino]carbonyl]-L-tyrosinamide trifluoroacetate;

*N*-[(3*S*)-1-[(4-fluorophenyl)methyl]-1-methyl-3-piperidiniumyl]-*N*-[[4-[(1-methylethyl)amino]carbonyl]phenyl)amino]carbonyl]-L-tyrosinamide

25 trifluoroacetate;

*N*-[[4-[(ethyloxy)carbonyl]phenyl]amino]carbonyl]-*N*-[(3*S*)-1-[(4-fluorophenyl)methyl]-1-methyl-3-piperidiniumyl]-L-tyrosinamide trifluoroacetate;

*N*-[(3*S*)-1-[(3-chlorophenyl)methyl]-1-methyl-3-piperidiniumyl]-*N*-[[4-

30 [(ethyloxy)carbonyl]phenyl]amino]carbonyl]-L-tyrosinamide trifluoroacetate;

*N*-[(3*S*)-1-[[3,4-bis(methyloxy)phenyl]methyl]-1-methyl-3-piperidiniumyl]-*N*-[[4-[(ethyloxy)carbonyl]phenyl]amino]carbonyl]-L-tyrosinamide trifluoroacetate;

*N*-[({4-[(ethyloxy)carbonyl]phenyl}amino)carbonyl]-*N*-{(3*S*)-1-[(3-hydroxyphenyl)methyl]-1-methyl-3-piperidiniumyl}-*L*-tyrosinamide trifluoroacetate; and

*N*-{(3*S*)-1-(cyclopropylmethyl)-1-methyl-3-piperidiniumyl}-*N*-[({4-

5 [(ethyloxy)carbonyl]phenyl}amino)carbonyl]-*L*-tyrosinamide trifluoroacetate;

*N*-{(3*S*)-1-[(3-hydroxyphenyl)methyl]-1-methyl-3-piperidiniumyl}-*N*-[({5-[(cyclohexyloxy)carbonyl]-2-thienyl}amino)carbonyl]-*L*-tyrosinamide trifluoroacetate;

10 *N*-{(3*S*)-1-[(3-chlorophenyl)methyl]-1-methyl-3-piperidiniumyl}-*N*-[({5-[(cyclohexyloxy)carbonyl]-2-thienyl}amino)carbonyl]-*L*-tyrosinamide trifluoroacetate;

*N*-{(3*S*)-1-[(4-chlorophenyl)methyl]-1-methyl-3-piperidiniumyl}-*N*-[({5-[(cyclohexyloxy)carbonyl]-2-thienyl}amino)carbonyl]-*L*-tyrosinamide trifluoroacetate;

15 *N*-[({5-[(cyclopentyloxy)carbonyl]-2-thienyl}amino)carbonyl]-*N*-{(3*S*)-1-[(3-hydroxyphenyl)methyl]-1-methyl-3-piperidiniumyl}-*L*-tyrosinamide trifluoroacetate;

*N*-[({5-[(cyclopentyloxy)carbonyl]-2-thienyl}amino)carbonyl]-*N*-{(3*S*)-1-[(3-chlorophenyl)methyl]-1-methyl-3-piperidiniumyl}-*L*-tyrosinamide trifluoroacetate;

20 *N*-[({5-[(cyclopentyloxy)carbonyl]-2-thienyl}amino)carbonyl]-*N*-{(3*S*)-1-[(4-chlorophenyl)methyl]-1-methyl-3-piperidiniumyl}-*L*-tyrosinamide trifluoroacetate;

*N*-[({5-[(cyclohexylmethyl)oxy]carbonyl}-2-thienyl)amino]carbonyl]-*N*-{(3*S*)-1-[(3-hydroxyphenyl)methyl]-1-methyl-3-piperidiniumyl}-*L*-tyrosinamide }-*L*-tyrosinamide trifluoroacetate;

*N*-[({5-[(cycloheptyloxy)carbonyl]-2-thienyl}amino)carbonyl]-*N*-{(3*S*)-1-[(3-hydroxyphenyl)methyl]-1-methyl-3-piperidiniumyl}-*L*-tyrosinamide trifluoroacetate;

25 *N*-[({5-[(cycloheptyloxy)carbonyl]-2-thienyl}amino)carbonyl]-*N*-{(3*S*)-1-[(3-chlorophenyl)methyl]-1-methyl-3-piperidiniumyl}-*L*-tyrosinamide trifluoroacetate; and trifluoroacetate;

*N*-[({5-[(cyclohexylmethyl)oxy]carbonyl}-2-thienyl)amino]carbonyl]-*N*-{(3*S*)-1-[(3-chlorophenyl)methyl]-1-methyl-3-piperidiniumyl}-*L*-tyrosinamide trifluoroacetate;

30 *N*-[({5-[(cyclohexylmethyl)oxy]carbonyl}-2-thienyl)amino]carbonyl]-*N*-{(3*S*)-1-[(4-chlorophenyl)methyl]-1-methyl-3-piperidiniumyl}-*L*-tyrosinamide trifluoroacetate;

*N*-{[(5-{[(cyclopentylmethyl)oxy]carbonyl}-2-thienyl)amino]carbonyl}-*N*-{(3*S*)-1-[(3-hydroxyphenyl)methyl]-1-methyl-3-piperidiniumyl}-L-tyrosinamide trifluoroacetate;  
*N*-{[(5-{[(cyclopentylmethyl)oxy]carbonyl}-2-thienyl)amino]carbonyl}-*N*-{(3*S*)-1-[(3-chlorophenyl)methyl]-1-methyl-3-piperidiniumyl}-L-tyrosinamide trifluoroacetate;  
5 *N*-{[(5-{[(cyclopentylmethyl)oxy]carbonyl}-2-thienyl)amino]carbonyl}-*N*-{(3*S*)-1-[(4-chlorophenyl)methyl]-1-methyl-3-piperidiniumyl}-L-tyrosinamide trifluoroacetate;  
and

*N*-{[(5-{[(cycloheptyloxy)carbonyl]-2-thienyl)amino]carbonyl}-*N*-{(3*S*)-1-[(4-chlorophenyl)methyl]-1-methyl-3-piperidiniumyl}-L-tyrosinamide trifluoroacetate;

10 or any other pharmaceutically acceptable salt.

6. A pharmaceutical composition for the treatment of muscarinic acetylcholine receptor mediated diseases comprising a compound according to claim 1 and a pharmaceutically acceptable carrier thereof.

15

7. A method of inhibiting the binding of acetylcholine to its receptors in a mammal in need thereof comprising administering a safe and effective amount of a compound according to claim 1.

20 8. A method of treating a muscarinic acetylcholine receptor mediated disease, wherein acetylcholine binds to said receptor, comprising administering a safe and effective amount of a compound according to claim 1.

9. A method according to claim 8 wherein the disease is selected from the group consisting of chronic obstructive lung disease, chronic bronchitis, asthma, chronic respiratory obstruction, pulmonary fibrosis, pulmonary emphysema and allergic rhinitis.

25

10. A method according to claim 9 wherein administration is via inhalation via the mouth or nose.

30



11. A method according to claim 10 wherein administration is via a medicament dispenser selected from a reservoir dry powder inhaler, a multi-dose dry powder inhaler or a metered dose inhaler.

5 12. A method according to claim 11 wherein the compound is administered to a human and has a duration of action of 12 hours or more for a 1 mg dose.

13. A method according to claim 12 wherein the compound has a duration of action of 24 hours or more.

10

14. A method according to claim 13 wherein the compound has a duration of action of 36 hours or more.

# INTERNATIONAL SEARCH REPORT

International application No:

PCT/US05/26756

<b>A. CLASSIFICATION OF SUBJECT MATTER</b> IPC(7) : C07D 405/12; 207/50; A61K 31/40, 4025 US CL : 548/525, 557; 514/422, 426 According to International Patent Classification (IPC) or to both national classification and IPC		
<b>B. FIELDS SEARCHED</b> Minimum documentation searched (classification system followed by classification symbols) U.S. : 548/525, 557; 514/422, 426 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) STN Databases Online: FILE REGISTRY, FILE CAPLUS, structure searches		
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	U.S. 2005/0137230 A1 (DORSCH et al) 23 June 2005 (23.06.2005), see entire document.	4
<input type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.		
* Special categories of cited documents:		
"A"	document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"E"	earlier application or patent published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O"	document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family
"P"	document published prior to the international filing date but later than the priority date claimed	
Date of the actual completion of the international search 12 December 2005 (12.12.2005)		Date of mailing of the international search report 06 FEB 2006
Name and mailing address of the ISA/US Mail Stop PCT, Attn: ISA/US Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 Facsimile No. (571) 273-3201		Authorized officer Janet L. Coppins Telephone No. 703.308.1235

**INTERNATIONAL SEARCH REPORT**

International application No.

PCT/US05/26756

**Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)**

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☒ Claims Nos.: 1-3 and 5-14  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:  
Please See Continuation Sheet
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

**Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)**

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
  2. ☐ As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of any additional fees.
  3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
  4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
- Remark on Protest ☐ The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- ☐ The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- ☐ No protest accompanied the payment of additional search fees.

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US05/26756

Continuation of Box II Reason 2:

In these claims, the numerous variables (e.g. T, U, V, W, X, Y, R1-R6, etc), their voluminous complex meanings, their seemingly endless permutations and combinations make it virtually impossible to determine the full scope and complete meaning of the claimed subject matter. As presented, the claimed subject matter cannot be regarded as being a clear and concise description for which protection is sought and as such the listed claims do not comply with the requirements of PCT article 6. Thus it is impossible to carry out a meaningful search on the same. A search will be made on the first discernable invention in the claims, which is the first compound as recited in claim 4.